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ABSTRACT 
Thiamet-G inhibits the activity of N-acetyl-β-glucosaminidase, a glycoside 
hydrolase known as OGA.  A validated bioanalytical method has been developed to 
enable pharmacokinetic studies of Thiamet-G and its related analogues.  The bioanalysis 
was carried out using high performance liquid chromatography (HPLC) coupled to a 
tandem mass spectrometer (MS/MS). In the MS/MS, multiple reaction monitoring 
(MRM) was used to monitor the transition of analyte parent ions to diagnostic daughter 
ions.  The validated method utilized the Hypercarb SPE cartridge as the cleanup tool and 
the ZIC-HILIC column as the suitable stationary phase.  The method was validated for 
linearity, specificity, accuracy, precision, recovery, matrix effect, stability, and 
sensitivity.  Pharmacokinetic samples obtained from rats treated by oral gavage with 
Thiamet-G were subjected to analysis using the validated method.  Thiamet-G was found 
to be absorbed with a Cmax of 370 ± 20 ng / mL and showed a tmax of 2 h.   
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CHAPTER 1: INTRODUCTION 
1.1 Carbohydrates and the O-GlcNAc Modification 
 The central dogma of molecular biology was a theory originally established in 
1958.  It describes the transcription process, in which genetic information encoded in the 
chains of DNA are converted into messenger RNA.  Following transcription, the 
messenger RNA is translated into protein.  The resulting proteins are either used for 
various functions inside the cell or secreted out of the cell.  Many proteins interact with 
each other to enable functioning of a cell, which is the smallest dividing unit of all living 
things[1]. 
In addition to proteins and lipids, carbohydrates are important biomolecules that 
act as signalling molecules and structural components[1-3].  Carbohydrates also play a 
role as crucial intermediates in generating energy within cells[1].  Carbohydrates often 
exist on the surface of proteins as glycans, which are covalently linked sugar chains of 
varying structures and sizes[4].  These glycoproteins act to enable cells and their 
surroundings to interact and therefore enable construction of complex muticellular organs 
and organisms[1].   
The exact functions of glycans in vivo are difficult to define, but they have been 
found to be important for the development, growth, functioning, and survival of the 
organism that synthesizes them[1].  The biological roles of glycans can be separated into 
three main categories.  First, glycans function in the maintenance of cellular structure and 
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to modulate cell-cell interactions[2].  Second, glycans regulate the proper folding of the 
newly synthesized polypeptides in the endoplasmic reticulum (ER) and Golgi apparatus.  
Proper glycosylation within the secretory pathway helps to maintain protein stability and 
conformation.  If proteins are not properly glycosylated and / or they fail to fold properly, 
they are removed from the ER and subjected to proteolysis [2].  The other key biological 
function of glycans is their role as targets for recognition by other molecules[2], which 
can influence the localization of the glycans and glycoproteins. 
1.1.1 Monosaccharides, the Basic Components for all Carbohydrates 
The basic component for all carbohydrates is monosaccharides.  Monosaccharides 
contain multiple hydroxyl groups and exist predominantly as either a six- or five-
membered ring.  There are two classes of monosaccharides, aldoses and ketoses (Figure 
1.1).  An aldose has an aldehyde function whereas a ketose contains a ketone group[5].  
Many aldoses and ketoses exist in either an open chain form and a cyclic form[5].  The 
cyclic form of many 6-carbon and 5-carbon sugars is formed by the nucleophilic attack of 
the hydroxyl group, typically the stereogenic centre furthest from the carbonyl group, on 
the open chain sugar[5].  A pyranose, a 6-membered ring, or a furanose, a 5-membered 
ring are the most common cyclic species formed in carbohydrates[5].   
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Figure 1.1. Examples of an Aldose, Glucose (A), and a Ketose, Fructose (B).  
The structures on the left hand side are the open chain forms of the sugars shown in 
Fisher projection while the structures on the right hand side are in the ring forms 
illustrated in modern projection. 
One of the two anomers, α and β, can be generated during formation of the ring.  
The open chain forms of glucose and fructose are shown in the middle of Figure 1.2 (A) 
and (B) respectively.  Anomers for D-glucopyranose and D-fructofuranose are illustrated 
in Fischer projection on the left hand side (α-anomer) and the right hand side (β-anomer) 
of the figure.  In an α-anomer, the hydroxyl group attached to the anomeric carbon is on 
the same side of the carbon backbone, as drawn in Fischer projection, as is the oxygen 
atom attached to the highest numbered stereogenic centre.  On the other hand, when the 
two substituents are on opposite sides of the carbon background in the Fischer projection, 
the configuration is β[5]. 
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Figure 1.2. Formation of Two Different Anomers Resulting from the Cyclisation of 
Carbohydrates. 
(A) Glucose and (B) ketose are shown in the figure as examples of an aldose and 
ketose respectively.  All structures are illustrated in Fischer projection format.  The 
order of the structures from left to right in the figure are the α-anomer (left), the open 
chain forms (middle), and the β-anomer (right).  After the formation of the ring, when 
the nucleophilic oxygen is on the same side as the hydroxyl group attached to the 
anomeric carbon, the configuration is α  When the substituents are on the opposite side, 
the configuration is β. 
There are several forms of monosaccharides, some of the most commonly found 
forms in nature are hexoses and hexosamines.  A hexose is composed of six carbons and 
an example is glucose.  A hexosamine has the same structure as hexose, except that an 
amino group replaces a particular hydroxyl group substituent.  N-acetylglucosamine 
(GlcNAc) and N-acetylgalactosamine (GalNAc) are examples of hexosamines (Figure 
1.3) [1, 5]. 
  
5 
 
Figure 1.3. N-acetylglucosamine (GlcNAc) is Example of a Hexosamine with a 2-
Acetamido Group Replacing the 2-Hydroxyl Group of Glucose. 
In eukaryotic cells, proteins and lipids are commonly modified by glycosylation.  In order 
for chains of monosaccharides to become covalently linked or to become linked to 
another molecule (whether it be another saccharide, protein, or lipid), they need to be 
attached via glycosidic linkages, which are usually formed through the hydroxyl group of 
the anomeric centre.  The formation of a glycosidic bond is initiated by the nucleophilic 
attack of the oxygen of a hydroxyl group to the anomeric carbon.  In Figure 1.4, the 
nucleophilic oxygen is part of the hydroxyl group of R′OH while the anomeric carbon is 
carbon 1 of D-glucopyranose.  Each monosaccharide can form an α- or a β-glycosidic 
linkage when attached to another molecule[5].  Due to the fact that there are numerous 
possible positions on a monosaccharide which can attach to another molecule to form a 
glycosidic linkage, the study of glycobiology can be very challenging.  Luckily, the 
possible combinations of glycosidic linkages that exist in natural biological 
macromolecules are limited.  However, the diversity of different glycan structures in 
nature is still large because the hydroxyl groups can also be modified by phosphorylation, 
sulfation, methylation, O-acetylation, or fatty acid acylation[1, 5].  This thesis involves a 
particular type of O-linked glycosylation on proteins, the O-GlcNAc modification, which 
is the focus of further discussion. 
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Figure 1.4 The Reaction Mechanism for Acid Catalyzed Glycosidic Bond Formation. 
A hemiacetal has reacted with R′OH to yield an acetal group with a β-configured 
glycosidic bond. 
1.1.2 The O-GlcNAc Modification 
β-O-linked N-acetylglucosamine, abbreviated as O-GlcNAc, is produced by an 
enzymatic transfer of the monosaccharide N-acetyl glucosamine (GlcNAc) to the 
hydroxyl group of certain serine and threonine residues of eukaryotic proteins.  Different 
from other characterised glycosylations, this type of glycosylation happens in the nucleus 
and cytoplasm and consists of the addition of just a single GlcNAc unit[6].  The O-
GlcNAc modification was discovered more than two decades ago[7].  During studies of 
the O-GlcNAc modification in rat hepatocytes, it was found to dominantly occupy the 
nuclear envelope and the chromatin, especially at the nuclear pore complex[8].  
Researchers also discovered O-GlcNAc on many cytoplasmic proteins, including 
cytoskeletal proteins[9].  The O-GlcNAc modification is one of the most common post-
translational modifications found on proteins[10-12].  Approximately 500 proteins have 
been classified as O-GlcNAc modified proteins to date, and these proteins are involved in 
a number of roles[10, 12], including stress responses[13, 14], transcription[15-18], 
translation[19], and cellular signalling[20].  A number of O-GlcNAc modified proteins 
are part of the cytoskeleton, and regulate the assembly of microtubules and the bridging 
of actins[21-24].  Research has suggested that this modification of proteins is involved in 
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type II diabetes[25, 26], Alzheimer’s disease[25, 26], and cancer[17]; however, their 
exact roles are unclear and are contentious[27, 28]. 
The cycling of O-GlcNAc relies on two enzymes (Figure 1.5).  Uridine 
diphospho-N-acetylglucosamine:polypeptide β-N-acetylglucosaminyltransferase (OGT), 
a glycosyltransferase, transfers the sugar moiety from the donor sugar substrate, uridine 
diphosphate (UDP)-GlcNAc, onto target proteins[29, 30].  In the reverse process, β-N-
acetylglucosaminidase (OGA) removes the O-GlcNAc moiety from proteins[26, 31].  As 
a result, O-GlcNAc is a dynamic process in which the addition and removal of the moiety 
can happen numerous times during the lifespan of a protein[12]. 
 
Figure 1.5. The Cycling of the O-GlcNAc Modification.   
 OGT, a Glycosyltransferase, Transfers the Sugar Moiety from the Donor Sugar 
Substrate, UDP-GlcNAc, onto Target Proteins.  In the Reverse Process, OGA 
Removes the O-GlcNAc Moiety from Proteins. 
Researchers have found that disruption of the gene encoding for the OGT is lethal 
at the single cell level and is essential for mouse embryogenesis[32].  Furthermore, when 
the genes encoding for either the O-GlcNAc transferase or the hydrolase, OGA, were 
knocked out in Caenorhabditis elegans, defects were detected in dauer larvae formation 
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and in the regulation of macronutrient storage[33, 34].  To date, gene deletion of OGA 
has not been done in mammals, although evidence suggests that O-GlcNAc cycling is 
important for development[33, 34].   
Analogous to phosphorylation, the O-GlcNAc modification appears to play a key 
role in regulating the activity of target proteins[35].  The O-GlcNAc modification has 
some analogies to phosphorylation (Figure 1.6).  For the O-GlcNAc modification, a 
transferase, and for a phosphorylation, a kinase, is responsible for putting the moiety onto 
the hydroxyl group of certain serine and threonine residues of eukaryotic proteins[36].  
Similarly, for phosphorylation, a phosphatase, and for the O-GlcNAc modification, a 
hydrolase, removes the moiety from the modification site[37].   
 
Figure 1.6. Cycling of O-GlcNAc and O-phosphate on the Same Amino Acid Residue of a 
Protein Molecule. 
As illustrated in Figure 1.6, O-phosphate and O-GlcNAc can occur on the same or 
nearby residues[38, 39].  In the case of the C-terminal domain of RNA polymerase II, 
competitive cycling was observed for the O-GlcNAc modification and 
phosphorylation[40].  Studies of oestrogen receptor-β suggested that two types of 
modification at the same site might function in regulating the activity and the turn over of 
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the receptor[41].  There are some cases where the O-GlcNAc modification modulates a 
nearby phosphorylation site[35, 42].  Historical evidence suggests that the O-GlcNAc 
modification alters phosphorylation and protein expression in crucial signalling 
pathways[43]. 
1.1.3 Methods to Modulate Levels of O-GlcNAc 
Altering O-GlcNAc levels in cells either in vivo or in vitro helps to provide a 
better understanding of the functions of the post-translational modifications on proteins.  
Researchers have tried various techniques to modulate the levels of O-GlcNAc.  
Upregulation can be done by elevating the concentrations of UDP-GlcNAc[44, 45] and 
increasing the expression of OGT[46].   
One can elevate the concentration of UDP-GlcNAc by increasing the 
concentration of glucose or glucosamine, which are metabolic precursors[47].  However, 
when introducing glucosamine, various other effects at the cellular level are observed, 
which complicates the study of the upregulation of UDP-GlcNAc[48-50].  Aside from 
OGT, other enzymes also transfer UDP-GlcNAc to proteins or other molecules during 
other types of glycosylation processes[51, 52].  Thus, methods to elevate levels of UDP-
GlcNAc for purposes of defining the role of O-GlcNAc by feeding metabolic precursors 
to increase the levels of the modification is ambiguous because these other glycosylation 
pathways are also affected[53]. 
 Another common approach is to overexpress OGT in cultured cells[30] or in 
animals[54].  Consistent with OGT being a large multidomain macromolecule, it has 
been found to interact with many other proteins.  Slawson et al. found that 
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overexpression of OGT actually disturbs the progression of the cell cycle[55].  Although 
the non-catalytic roles of OGT have not been defined, these data suggest that OGT may 
have functions other than just cycling O-GlcNAc.  Overexpression of OGT can induce 
other unavoidable effects due to the non-catalytic activities or interactions of OGT with 
other proteins[56-58].  Furthermore, OGT overexpression usually only results in small 
increases in O-GlcNAc levels. 
Another method for increasing the levels of O-GlcNAc modified proteins is to use 
inhibitors to block the activity of the enzyme responsible for removing O-GlcNAc from 
target proteins.  Haltiwanger et al. first showed that the inhibition of OGA can 
significantly increase the levels of O-GlcNAc in cells[59].  In order to understand the 
background about inhibitors currently used for OGA, some general information regarding 
OGA will first be discussed in the following section. 
1.1.4 OGA 
Many glycosyltransferases and glycoside hydrolases found in nature are 
responsible for the post-translational modification of proteins with sugar units.  Enzymes 
that have been identified from gene sequencing are classified in the CAZy database[60] 
according to their amino acid sequence and structural information where available[61].  
OGA is a member of family 84 of glycoside hydrolases (GH84).   
Aside from OGA, there are other enzymes found in the lysosome that are also 
capable of cleaving terminal N-acetylglucosamine residues off from glycoconjugates[62].  
They are called β-hexosaminidase A (HexA) and B (HexB).  These enzymes are 
members of family 20 of glycoside hydrolases (GH20)[62].  The substrates of these 
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enzymes are mainly gangliosides such as ganglioside GM2 which is directed to the 
lysosome for degradation[63].  These enzymes share no apparent sequence similarity to 
OGA[62].  A good inhibitor for use in cells or in vivo should be highly specific for OGA 
over the functionally related HexA and HexB so as to avoid concomitant inhibition of all 
three enzymes. 
Human OGA is composed of two domains, a C-terminal domain, which was 
proposed to have an acetyltransferase[64] and an N-terminal domain which has the 
glycoside hydrolase activity[64].  Some bacterial enzymes share high sequence similarity 
to the N-terminal domain of eukaryotic OGAs, and have been grouped into GH84[65].  A 
close homolog of human OGAs from Bacteroides thetaiotaomicron (BtGH84) is able to 
cleave O-GlcNAc from proteins and uses the same catalytic mechanism[66].  The crystal 
structure of human OGA has never been solved but that of BtGH84 is known[66] as is the 
structure of two other bacterial homologues[67, 68].  These structures have provided a 
good model of the human OGA to enable studies of inhibitors of OGA[69]. 
The substrate-assisted catalytic mechanism used by human OGA is shown in 
Figure 1.7.  In this double replacement retaining mechanism, the 2-acetamido group of 
the substrate acts a nucleophile[62].  The catalytic residues, two aspartate residues, in the 
active site of the human OGAs are involved in catalysis.  One residue polarises the 2-
acetamido group, which increases its nucleophilicity and assists its attack at the anomeric 
centre.  It most likely acts as a general base in the first step of the reaction.  The second 
residue acts as a general acid during the first step of the reaction, aiding the departure of 
the leaving group and leading to formation of an oxazoline intermediate.  During the 
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second step, the first residue acts as a general acid and the second residue now acts as a 
general base, aiding the attack of a molecule of water at the anomeric centre. 
 
Figure 1.7. The Retaining Mechanism for OGA.   
Amino Acid Residues are Labelled Based on the Numbering of the Human OGA[62]. 
1.1.5 Small Molecule Inhibitors 
Small molecule inhibitors are crucial for understanding the functional roles of 
many enzymes.  Using a cell permeable small molecule inhibitor to increase the O-
GlcNAc levels in cells through inhibition of OGA is in many ways more advantageous 
than genetic methods or altering the nutrient flux[70].  Given that not all the cells are 
capable of undergoing transfection employing a cell permeable small molecule inhibitor 
is more convenient[71].  The level of dosing can be easily adjusted and if necessary, the 
inhibitor can be removed to observe the effect on the cells[70].  Furthermore, the levels 
of the proteins themselves are not directly perturbed.  Hence, inhibition of OGA is often 
performed in cultured cells[20, 27], and tissues both in vitro[72, 73] and in vivo[74, 75] 
for studying the effects of increasing levels of O-GlcNAc.  One drawback of using 
inhibitors is that they are not all able to penetrate into all tissues types, and some 
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inhibitors are not selective for OGA, which can lead to some unanticipated results[62].  
Several inhibitors for OGA are known and these are summarised briefly below. 
PUGNAc and Streptozotocin 
O-(2-Acetamido-2-deoxy-D-glucopyranosylidene)-amino-N-phenylcarbamate 
(PUGNAc) is both an inhibitor of mammalian OGA (KI = 52 nM) and the functionally 
related lysosomal β-hexosaminidase (KI = 52 nM)[76].  By treating cells with PUGNAc, 
some off-target effects were observed that resulted from inadvertant inhibition or 
alteration of enzymes or processes, other than OGA[28, 50, 77, 78].  Since PUGNAc 
inhibits the function of the lysosomal β-hexosaminidases, which are important for 
recycling glycosphingolipids, levels of the ganglioside GM2 in cultured neuron cells 
increase after PUGNAc treatment[77].  PUGNAc treatment, which causes an increase in 
O-GlcNAc levels, has been shown to cause insulin resistance.  But this effect could be 
due to an off-target activity and not solely by inhibition of OGA[28, 78].  An additional 
important factor which makes PUGNAc a poor candidate inhibitor is that it is not able to 
cross the blood brain barrier[75].  The structure of PUGNAc is shown in Figure 1.8 
Structure A. 
Streptozotocin (STZ) has poor potency towards OGAs (KI = 2 mM)[79, 80].  
Many disastrous effects, such as the death of β-cells that ultimately leads to an insulin-
dependent diabetic phenotype in rodents, were observed following treatment with 
STZ[81-83].  Two studies support that these complications do not arise from the 
inhibition of OGA by STZ, but instead from off-target effects[84, 85].  These 
complications indicate that both PUGNAc and STZ (Figure 1.8 Structure B) are poor 
tools for investigating the functional role of O-GlcNAc. 
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Figure 1.8. Structures of (A) PUGNAc and (B) Streptozotocin. 
NAG-thiazoline, NButGT and Thiamet-G 
1,2-Dideoxy-2′-methyl-α-D-glucopyranoso-[2,1-d]-∆ 2′-thiazoline (NAG-
thiazoline) was first synthesized by Knapp et al[86].  This compound has since been 
shown to be a good inhibitor of both OGA (KI = 0.07 µM) and lysosomal β-
hexosaminidases (KI = 0.07 µM) but shows no selectivity[62].  Figure 1.9 shows the 
structures of NAG-thiazoline (A) and its derivative that possesses a butyl chain, NButGT 
(B). 
 
Figure 1.9. Structures of (A) NAG-thiazoline, (B) NButGT and (C) Thiamet-G. 
 The active site on the structure of OGA (or a bacterial homologue) was not known 
when the structure of lysosomal HexB was crystallized[71].  The active site of HexB, an 
enzyme known to be similar in function to OGA, has been shown to bind the 2-acetamido 
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group of inhibitors[87].  However, since the pocket surrounding this group is very small, 
lengthening the 2-acetamido group by adding larger substituents should weaken the 
binding of the inhibitor towards HexB.  A series of NAG-thiazoline derivatives with 
extending chains at the 2-acetamido group were therefore synthesized[62].  One of the 
derivatives, NButGT, was identified to be highly selective (700-fold) for OGA (KI = 
0.230 µM) over HexB (KI = 340 µM) with good potency[62].  The crystal structure of 
NButGT which possesses a butyl chain, in complex with BtGH84 supported the proposal 
that there is indeed a deep pocket able to accommodate substituents where the 2-
acetamido group of substrates are bound to OGA and its homologues[69]. 
Research studies have shown that Asp174 (Asp242 in BtGH84) located in the active 
site of OGA is a crucial catalytic residue having a pKa of 5.2[88, 89], making it 
deprotonated and anionic at physiological pH.  It has been found that the protonated form 
of NButGT has a pKa of 3.4[74].  These findings suggest that the majority of NButGT in 
solution would not be protonated at a physiological pH of 7.4 and, therefore, a favourable 
ionic pair interaction with Asp174 cannot be formed[71].  
In the crystal structure of BtGH84 in complex with NAG-thiazoline[66] or 
NButGT[69] (Figure 1.10), the endocyclic nitrogen of the thiazoline is within hydrogen 
bonding distance of the side chain of Asp174.  In order to generate a favourable ionic pair 
with Asp174, a new series of compounds, Thiamet-G (Figure 1.8 Structure C) and its 
analogues, were made by increasing the basicity of the endocyclic nitrogen of the 
thiazoline ring of NButGT[74].  The first methylene unit of the alkyl chain was replaced 
with an amine[74].  This change makes Thiamet-G much more basic (pKa = 8).  As a 
result it shows selectivity for OGA over HexB (37,000-fold) and the binding potency to 
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OGA is increased by 30-fold (KI = 21 nM at pH 7.4)[74].  Thiamet-G was also shown to 
be able to increase the O-GlcNAc levels in both cultured cells and in vivo in the rat 
brain[74]. 
 
Figure 1.10. The Crystal Structures of BtGH84 Glycoside Hydrolase Active Centre in 
Complex with either, (A) NButGT or (B) Thiamet-G.   
Adapted from [74].  
1.2 Pharmacokinetics 
Pharmacokinetics (PK) is the study of the relationship between doses of 
administered drugs and the measurable drug concentration in the blood in a quantitative 
fashion[90].  PK investigates how a drug behaves in the body after administration 
whereas pharmacodynamics investigates the relationship between the concentration of a 
drug at the site of receptors and the corresponding efficacy of the drug[91].  The focus of 
this thesis will be on PK. 
The LADME (Liberation, Absorption, Distribution, Metabolism, Excretion) 
processes are illustrated in Figure 1.11.  The abbreviation L stands for liberation of the 
drug from its dosage form while A stands for absorption of the drug from the site of 
dosage into the blood circulation.  The letter D represents distribution of the drug by 
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diffusion or active transporters transferring from the intravascular space into the body 
tissues while M represents metabolism of the drug transforming into metabolite.  Finally, 
E symbolizes excretion of the unchanged drug and / or metabolites from the body[92]. 
 
Figure 1.11. LADME Processes that Take Place after Drug Administration 
Adapted from [93]. 
PK is the study of LADME processes of a drug by determining the drug 
concentration during a time course in body fluids[91].  LADME or pharmacokinetic 
processes rely on the physical and chemical properties as well as the amount of drug 
administered into the body[92].  The LADME processes are generally considered to 
happen simultaneously.  For example, the liberation process does not need to be 
completed in order to initiate the absorption process. 
 One important factor to consider while administering drugs into a body is the 
process which occurs to transfer drugs across cell membranes.  Cellular membranes are 
composed of phospholipid bilayers with apolar hydrocarbon chains facing inward and the 
polar head groups facing outward[94].  Proteins are located in between the membranes 
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and form small gaps or pores[95], which permit flow of polar substances or drugs into 
cells[94].  Non-polar drugs usually enter the cells by diffusion through the hydrocarbon 
barriers located between the phospholipid bilayers[96].  Many factors influence the 
transport of a drug across cell membranes including the size, shape, solubility, and the 
degree of ionisation of the drug[94].  Some drugs might strongly bind to plasma or tissues 
in the body[94].  Consequently, only the free form of the drug is able to pass through the 
membranes[94].  At the steady state, the concentration of the unbound drugs is the same 
on both sides of the membrane[94].  pH differences across membranes also play a role in 
drug transfer only if the compounds are ionisable under physiological conditions[94].  
For ionisable drugs, their transfer relies upon the pKa of the drug and the pH 
gradient[94]. 
1.2.1 Basic Understandings of the LADME System 
Liberation of the drug is important for all drug products administrated via routes 
other than the intravenous route[92].  The main reasons for formulating drugs inside 
tablets are to protect the perishable drugs from decomposition, to minimize odour, and to 
smoothen the progress of swallowing[97].  The drug is released from its formulation 
during liberation and this process determines the rates of absorption and the 
bioavailability of the drug, and it is governed by the properties of the drug within the 
tablet[97]. 
By definition, absorption is the act of taking the drug from the site of 
administration into the bloodstream of the body.  The absorption site depends on the 
route of administration and the most common forms are oral and intravenous.  Other 
factors that affect the rate of absorption are the physical state of the drug, concentration 
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of the drug, the circulation at the absorption site, and the area of the absorbing surface.  
Among the various routes of administration, intravenous administration inputs the drug 
directly into the venous bloodstream, thereby eliminating the process of absorption[94].  
After the drug is in the circulation system, the process of distribution takes place 
from the bloodstream into the body tissues, to the site of action.  The rate of the process is 
dependent on the blood flow and the diffusion of the drug across cell membranes of a 
variety of tissues and organs in the body.  Only the unbound fraction of the drug is 
available for transfer and the distribution of this fraction of drug is governed by the 
binding to proteins or uptaken by cells in the body.  When drugs tend to bind to protein in 
the plasma, the amount of drug reaching into tissues is limited.  Hence, the distribution of 
the drug depends on the physicochemical properties of the drug and several physiological 
factors[94].   
Metabolism, sometimes referred to as biotransformation, is the bio-chemical 
alteration of a drug in the body prior to elimination.  To avoid the build up of foreign 
substances, the body uses enzymes to chemically convert lipophilic compounds into more 
water-soluble metabolites.  The processes of biotransformation are divided into Phase I 
and Phase II reactions.  In the Phase I reaction, a polar group is added to the drug to 
increase its water solubility.  These reactions are generally either oxidative or hydrolytic.  
Phase II reactions involve formation of a covalent bond(s) with endogenous substances.  
The liver is known as the primary location of metabolism.  Processes of metabolism 
generally modify the drug into a substance which is inactive or less active than the parent 
compound[94]. 
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After the drug has undergone metabolism, it is ready to be eliminated from the 
body.  Among the various excretory organs, the most important organ is the kidney as the 
majority of drugs are excreted in the urine[92].  Substances in the feces are typically 
either unabsorbed drugs or compounds removed into the bile[94].  A portion of both non-
ionised and ionised drugs may be passively reabsorbed by the kidney[94]. 
The efficacy of a given drug is largely governed by the concentration of the drug 
in the body.  To measure efficacy, the ideal location for measuring the concentration of 
the drug is at the receptor, which is the site of action of the drug.  Practically, however, 
drug concentrations are usually measured in whole blood or other body fluids, such as 
plasma, saliva, urine, or cerebrospinal fluid.  The drug content in these fluids is believed 
to be in steady-state with the amount of drug at the receptor.  The measured drug 
concentration in these fluids is often referred to as the drug level, which is the free 
fraction of drug in equilibrium within the body[91]. 
1.2.2 Compartmental Modelling 
 For purposes of PK, a body consists of more than one compartment.  The input 
and output of drug from the body, and the transfer of the drug content between the 
compartments of the body are represented by rate constants.  PK models are often used to 
describe how a drug behaves in a biological system after administration.  The models that 
have been well classified are the one-compartment, two-compartment, and 
multicompartment models[98].   
 In a one-compartment model, all the tissues of the body are considered to be 
homogenous.  The drug is assumed to distribute instantly throughout the body upon 
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administration and hence the drug is instantaneously at steady state.  However, the drug 
concentration in plasma is not equal to the drug concentration in tissues.  In this model, 
the changes in the plasma concentration are proportional to the changes in the tissues.  As 
a result, a monophasic response or a monoexponential curve is observed when the drug 
concentration in plasma is plotted against time (Figure 1.12 A).  The plot of the log of 
concentration of drug in plasma versus time graph will show a linear relationship (Figure 
1.11 B) [98]. 
 
Figure 1.12. Plots that Exhibit a One-compartment Model.   
(A) Concentration of drug in plasma versus time plot, (B) the log of concentration of 
drug in plasma versus time plot.  In both plots, the data is for intravenous 
administration.   
 In a two-compartment model, the tissues of the body are not simply a 
homogenous unit.  In this model, the body is composed of a central compartment and a 
peripheral compartment.  The central compartment is considered to be the organs 
including the heart, lungs, kidneys, liver, and brain.  The peripheral compartment is 
mainly the muscle, fat, and skin of the body.  It is assumed that the central compartment 
has tissues that are highly perfused whereas the peripheral compartment is less perfused.  
In this model, when drug is administered into the central compartment, equilibration is 
not achieved instantly between the two compartments due to the differences in the rate of 
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drug distribution.  A biphasic response is demonstrated when the concentration of drug in 
plasma is plotted against time (Figure 1.13 A).  When one takes the log of the 
concentration of drug in plasma and plots it against time, a plot consisting of two distinct 
lines is obtained (Figure 1.13 B) [98]. 
 
Figure 1.13. Plots that Exhibit a Two-compartment Model.   
(A) Concentration of drug in plasma versus time plot, (B) the log of concentration of 
drug in plasma versus time plot.  In both plots, the data is for intravenous 
administration.   
The last model is called the multicompartment model.  As the name suggests, the 
model takes into account the presence of an additional compartment in the body system 
into which the drug will distribute.  In a plot of the concentration of drug in the plasma 
versus time, one would expect more than a single exponential decay.  Differences are also 
expected in the log of concentration of drug in the plasma versus time curve[98].  Consult 
Appendix A 1.1 for a description of the fundamental parameters for PK. 
1.3 Analytical Issues in PK 
1.3.1 Complexity of Biological Samples 
Biological samples are highly complex due to the influence of many endogenous 
substances.  Quantitation of administered drugs in biological fluids can also be a 
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challenge because of the low quantity of the target analytes.  In blood fluids, such as 
serum and plasma, there are often proteins and phospholipids present along with the 
target analytes.  Plasma is about 55 % of the total blood volume.  Roughly, 90 % of the 
plasma is water.  The other 10 % is comprised of many dissolved substances, such as 
fibrinogen, proteins, nutrients, hormones, and inorganic mineral salts.  Plasma serves an 
important role as a storage and transport medium for blood clotting factors[99]. 
The ideal analytical method to monitor the concentration of a compound in 
plasma would enable isolation of the analytes from the matrix in a fast, simple, 
inexpensive, and reproducible way, while yielding high recoveries and avoiding 
degradation of the analytes[100].   
1.3.2 Sample Preparation Processes 
1.3.2.1 Deproteinisation before LC-MS/MS Analysis 
After the collection of plasma from a body, the samples have to undergo some 
extraction and clean up processes before the instrumental analysis by LC-MS.  This step 
is essential to ensure that the mass spectrometer is not contaminated and that it remains 
operational.  One of the common processes is deproteinisation by protein precipitation.  
Sometimes protein precipitation is followed by some form of solid phase extraction to 
further clean up the extracts[101, 102].  In the protein precipitation method, the plasma 
extract is treated with a common organic solvent or low pH aqueous solution to denature 
the proteins.  After centrifugation, the analyte remains in the supernatant while the 
proteins present in the plasma will aggregate and be concentrated in the pellet[102].  
Another method uses ultrafilters to trap proteins present in the plasma extracts followed 
by HPLC using a configuration in which an ion exchange column is placed in front of the 
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analytical column enabling further online purification of the target analytes[103].  In 
2001, Chou and Cheng described a method involving deproteinisation with acetonitrile 
followed by extraction of the polar analytes from the supernatant using dichloromethane 
and water[104].  This procedure is a liquid-liquid extraction (LLE) that can remove 
various contaminants present in the supernatant after organic deproteinisation.   
1.3.2.2 Further Cleanup of Plasma Extracts before LC-MS/MS Analysis 
Plasma extracts contain abundant salts, lipids, proteins, and surfactants[105].  All 
of these compounds can be a cause of ion suppression during ESI–MS/MS bioanalysis, 
but it is generally thought that phospholipids are the major cause of ion suppression[105].  
Lipids can also build up on the analytical column over time and lead to analytical 
complications[105]. 
Using protein precipitation alone in the sample preparation process will lead to a 
significant amount of ion suppression and therefore the removal of lipids is also an 
important step for achieving reliable drug quantification.  Accordingly, further treatment 
of samples after deproteinisation enables the depletion of many of the remaining matrix 
ions, contributing to improved reproducibility of peak shapes in the chromatograms[105]. 
1.3.2.3 Common Sample Cleanup Techniques 
Among the various cleanup processes, solid phase extraction (SPE) is a common 
technique adopted for isolating analytes of interest from a wide variety of matrices 
including urine and blood[106]. SPE can be useful for removing matrix interference but it 
does require considerable method development and optimization.  Many different 
commercially available stationary phases can trap analytes and remove contaminants 
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from the matrices or vice versa.  Other than SPE, usage of an online trap column before 
the actual stationary phase can also help to remove matrix interference[107]. 
1.3.3 HPLC Chromatography for Separation of Polar Compounds  
1.3.3.1 Column Separation Challenges Encountered for the Thiamet-G analogues  
As commented by Li X. et al., “The physicochemical characteristics of a 
monosaccharide, such as low molecular weight and high hydrophilicity pose a significant 
analytical challenge[108].”   Due to the sugar-like structure of the compounds of interest, 
the analogues are very polar and highly soluble in water.  As a result of these hydrophilic 
properties, they cannot easily be retained using typical reverse stationary phases, 
including those which are silica-based and organic polymer-based[109].  The compounds 
are also hard to analyse due to their poor volatility and the fact that they have low UV 
absorption[110].   Although ion exchange chromatography is generally used for 
separation of polar compounds, it is also not a good choice when carrying out LC-
MS/MS bioanalysis since the use of high salt containing mobile phases is not compatible 
to the ion sources of mass spectrometers.  A normal phase column is more suitable for 
hydrophilic compounds, however, the solvents for normal phase, such as 
dichloromethane, hexane, toluene, and other hydrocarbons, are not suitable for ESI-
MS[111].  This incompatibility arises because ESI requires the use of a polar mobile 
phase for ionisation[111].  None of the traditional chromatography methods therefore are 
ideal for separating highly polar compounds. 
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1.3.3.2 Alternative Phases for HPLC Chromatography: HILIC Stationary Phase  
There are some techniques reported that can enable online separation of polar 
compounds coupled with ESI-MS.  In 1990, Alpert explained the mechanism of 
hydrophilic interaction liquid chromatography (HILIC), a variant form of normal-phase 
chromatography using aqueous solvent[112].  HILIC is compatible with polar organic 
mobile phase solvents despite the hydrophilic stationary phase[113].  The addition of 
small amounts of water in the mobile phase creates an aqueous layer on the surface of the 
stationary phase and this essentially leads to the generation within the column of a liquid-
liquid extraction system[113].  The analyte of interest then partitions between the mobile 
phase and the aqueous layer present on the stationary phase[113].  The polar functional 
groups of the analytes form hydrogen bonds with the polar groups of the stationary 
phase[113].  Lastly, the elution of analytes is governed by the polarity of the eluent as 
well as the solubility of the sample in the mobile phase[113]. 
1.3.3.3 Alternative Phases for HPLC Chromatography: PGC Phase 
Another attractive alternative for the analysis of carbohydrate-like molecules 
involves the use of a porous graphite carbon (PGC) column that can be coupled online to 
ESI-MS[114].  PGC columns enable the retention of very polar compounds using 
standard reversed phase chromatography eluents[114].  The retention of polar solutes 
onto this chemically stable and super-hydrophobic stationary phase is believed to be 
driven by hydrophobic interactions and the polarisability of the surface[114].  The PGC 
column is made up of flat sheets of hexagonally arranged carbon atoms, graphite[114].  
In 2002, Jackson and Carr were able to show that the presence of any functional group 
inducing polarization of a benzene ring, such as an electron-donor or electron-acceptor, 
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will lead to greater retention of the molecule[115].  The binding of the analyte is due to 
interactions between the hybridized orbitals of the carbon surface and analyte.  The result 
suggests that there are dipole-type and electron lone pair donor-acceptor interactions, and 
that graphite can donate as well as accept electrons[116].  Compared to other packing 
materials, a porous graphite column often offers better retention and selectivity of polar 
compounds[116].  The material can in some cases discriminate between compounds that 
differ only by a single methylene unit[116].  Möckel et al.[117] and Tanaka et al.[118] 
have both shown that graphite offers better separation of various analogues than either 
C18-silica or pyrenylethyl-silica. 
1.3.3.4 Mobile Phase Optimization 
There are a great variety of columns available for use, so selection and 
optimization of a column for separating analogues of interest is the crucial step for 
development of an appropriate HPLC method.  Other than column choice, the next most 
important factor is the optimization of the mobile phase which is important because both 
the polar sample and the solvent molecules may interact strongly with the column 
surface[119].  As commented by Strege, the use of buffered mobile phases is important 
for maintaining repeatability in the separation of charged species between 
chromatography runs because the electrostatic interactions between the analyte and the 
stationary phase are strongly influenced by the buffer[120]. Strege found that increased 
salt concentrations in the mobile phase reduced the retaining capacity of HILIC 
columns[120].  However, removal of buffer from the mobile phase resulted in the pH and 
ionic strength of the prepared samples having a strong influence on the results[120].  
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Accordingly, some balance between ionic strength and buffering capacity should be 
aimed for. 
1.4 Liquid Chromatography Coupled with Mass Spectrometry  
 In this thesis, liquid chromatography (LC) coupled with mass spectrometry was 
chosen as the platform to develop an analytical method.  The mass spectrometer (MS) is a 
tandem quadrupole-linear ion trap MS and electrospray ionisation (ESI) is the technique 
used for ion production. 
Analysis Using LC-MS 
In general, the LC method is started by pumping mobile phase from the solvent 
reservoirs.  Once the sample is injected into the sample loop of the autosampler, the 
solvent in the system pushes the sample from the injection port into the analytical column 
where chromatographic separation of the analyte takes place.  The analytical column 
outlet is connected to the ionisation source, where the ions are produced and then 
detected using the MS[121]. 
The mass spectrometer is composed of five components, an ion source, vacuum 
system, mass analyser, detector, and computer system for acquiring the digitalised data.  
For this thesis, the ion source is electrospray (ESI), the mass analyser is a tandem 
quadrupole / linear ion trap, and the detector is an electron multiplier.  Two pumps are 
responsible for creating the vacuum inside the mass spectrometer.  They are the rotatory 
vane and the turbomolecular pump.  In the following section, a brief introduction about 
the ion source, mass analyser, and the different scan modes is provided.  The positive ion 
mode is used throughout the project. 
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ESI 
The ionisation technique of ESI (Figure 1.13) occurs in three steps, droplet 
formation, shrinkage of the droplet, and formation of the gaseous ion[122].  The sample 
from the column outlet passes through the electrospray needle, which has a high positive 
voltage of 4 to 5 kV applied to it[121].  A downward electrical potential and pressure 
gradient is set from the electrospray needle towards the counter electrode at the entrance 
of the first mass analyser of the mass spectrometer[123].  The high electric field at the 
electrospray needle leads to partial separation of charges in the solution delivered to the 
end of the electrospray needle.  In the positive ion-mode, the cations present in the 
solution gather at the tip of the electrospray needle travelling towards the counter 
electrode whereas the anions inside the needle move away from the tip[124].  The mutual 
repulsion at the end of the needle tip increases due to the accumulation of charges[125].  
When the repulsion of the positive ions at the surface tension and the attraction of these 
ions toward the counter electrode overcomes the surface tension of the liquid, the liquid 
at the meniscus will deform into a cone, the Taylor cone, just outside the electrospray 
tip[124, 126, 127].  After the formation of the cone, a fine stream of liquid is 
instantaneously ejected out from the tip of the cone towards the counter electrode[124, 
128].  The liquid becomes unstable and breaks down into positively charged 
droplets[124].  The droplets reduce in diameter through evaporation of the solvent as they 
are drawn toward the counter electrode[123].  During the process, the charges inside the 
droplets remain the same[127].  As a result, the charge density on the surface of the 
droplets continuously rises[127].  The droplets become unstable when the charge density 
reaches the Rayleigh stability limit[127, 129].  When the electrostatic repulsion has 
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exceeded the surface tension, which is holding the droplets in place, the droplets 
disintegrates into smaller droplets[127].  Droplet-jet fission[127] splits the droplets into 
smaller and irregularly shaped droplets[130].  During the process, the microdroplets do 
not explode.  However, smaller microdroplets eject from the elongated end of the parent 
droplets[130].  Solvent evaporates continuously from the successive droplets that have 
been relieved from the coulombic stress through jet fission[127].  These droplets 
eventually reach the Rayleigh stability limit and undergo another jet fission[127]. 
There are two schools of thought regarding the formation of gas-phase ions from 
the small and highly charged droplets.  The charged residue model suggests that the 
smallest droplets will contain an analyte with one charge remaining.  When the remaining 
solvent is removed from the droplet by the process of evaporation, an ion is formed.  On 
the other hand, the ion evaporation model suggests that when the radii of the droplets 
decreases to a particular size, an ion can be directly ejected from the droplet.  In order for 
an ion to form, the mutual repulsive force experienced by the escaping ion has to exceed 
the attraction between the escaping ion and the droplet[127]. 
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Figure 1.14. Features of the ESI Interface of the Atmospheric Pressure Region. 
In the positive-ion mode, electrochemical oxidation takes place at the metal capillary 
while reduction occurs at the counter-electrode.  The imposed electric field causes 
accumulation of positive ions at the tip of the electrospray needle.  When the charge 
repulsion and electric field overcome the surface tension of the liquid at the tip, the 
liquid will expand into a Taylor cone.  The fine jet of liquid immediately ejects out 
from the tip of the cone.  The liquid becomes unstable and breaks down into 
positively charged droplets.  Through solvent evaporation and the process of 
droplet-jet fission, the droplets shrink in size and ultimately form gaseous ions.  TDC 
stands for total droplet current, I[124]. 
Once the ions are accelerated out of the ion source, they enter into the vacuum 
interface leading to the quadrupole mass analyser[121].  A quadrupole mass analyzer 
uses a stable trajectory in the oscillating electric field to separate ions according to their 
mass-charge-ratios[125].  It consists of four parallel rods arranged symmetrically in a 
square array, with opposite rods connected to each other electrically[121].  Separation of 
ions are achieved by applying a direct current (DC) and a time-dependent radio frequency 
(RF) potential on these rods[131].  Rods adjacent to each other have voltages of opposite 
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polarity applied to them[123].  Positive DC potential is applied to two opposite rods in 
the X-Z plane whereas negative DC potential is applied to the rods in the Y-Z plane[131].  
The superimposed RF potential, V cos wt, is also applied on both pairs of rods with V, w, 
and t representing the amplitude of the applied RF voltage, angular frequency, and time 
respectively[123].  The magnitude of the RF potential is the same for both pairs of rods, 
but the polarity is opposite from each other[131].  The RF potential rapidly changes back 
and forth from a positive charge to negative one in a cyclic manner[123].  The trajectory 
of the ions is affected by the total electric field made up of the applied potentials on the 
rods[123].  The forces cause the ions to oscillate between the four rods[123].  If the 
oscillation is unstable, the ion trajectory is unstable and the ion will strike a rod and 
therefore fail to reach the detector[123].  The rods applied with positive DC act as a high-
pass filter for the heavier ions while the rods with a negative DC act as the low-pass filter 
for the lighter ions[123].  Only ions with particular mass-to-charge ratios can pass 
through the quadrupole along the z-axis in between the four rods while other ions cannot 
reach the detector[123].  Consult Figure 1.15 for an expanded depiction of a quadrupole. 
Tandem mass spectrometers in space 
A tandem quadrupole mass spectrometer is composed of four quadrupoles.   
The second quadrupole (Q1) and fourth quadrupole (Q3) of the instrument are both 
operated with DC and RF voltages as discussed above.  The first quadrupole (Q0) and the 
third quadrupole (q2) are RF only.  Q0 is for focusing the ions before they enter Q1.  For 
q2, collision gas is introduced so that an ion entering the quadrupole will undergo one or 
more collisions.  Within the RF-quadrupole, when an ion collides with a neutral gas 
molecule, a fraction of the kinetic energy of the ion converts into internal energy[124].  
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This process can cause the ion to fragment in a process known as collisionally induced 
dissociation (CID).   
 The components of the tandem mass spectrometer are illustrated in Figure 1.14.  
As one can see, the potential energy gradually decreases from the counter electrode (1000 
V) to Q3 (-33V).  The electric field draws the ions across the z-axis from the entrance of 
the mass spectrometer towards the detector.  The Decluster potential (DP) is referred to 
as the voltage applied to the orifice relative to ground.  The orifice plate is located 
between the counter electrode and the skimmer.  The DP energy is applied on the ions at 
the orifice plate in order to eliminate the solvent cluster and reduce the chemical noise in 
the final spectrum.  The potential energy at q2 is more negative when compared to Q1.  
The purpose is to increase the kinetic energy of the ions significantly so that CID can take 
place[132]. 
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Figure 1.15. Schematic Cross-section View of the Mass Spectrometer Used for this Work. 
The mass spectrometer is composed of four quadrupoles (Q0, Q1, q2, and Q3) and 
a detector.  An electric field with decreasing potential draws the ions across the z-
axis towards the detector.  An expanded version of the Q1 quadrupole is illustrated 
in the circle.  (DP = declustering potential applied on the ions at the orifice plate, IQ1 
= Q1 entrance lens, IQ2 = collision cell entrance lens, IQ3 = Q3 entrance lens, EXB 
= exit lens for linear ion trap mode, DET = detector, DF = deflector)[132]. 
Several scan modes that are frequently used in tandem mass spectrometry are 
described below (Table 1.1). 
 Q1 scan: The first quadrupole is set to scan simultaneously.  All the ions within a 
preset range of m/z would pass through Q1 and be detected in the detector.  This scan 
mode is useful for identifying a wide range of components within a mixture. 
Product-ion scan: Ions with a particular mass-to-charge ratio are chosen in the 
first quadrupole.  In the RF-only quadrupole, these ions collide with gas molecules to 
undergo CID fragmentation.  Q3 is set to scan and analyse the entire set of fragments, 
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which are known as product ions  The product-ion scan mode is commonly used for 
structure elucidation of an analyte of interest[123]. 
Precursor-ion scan: The third analyser is set to detect only the product ion of 
interest.  At the same time, Q1 is scanning for a certain mass range to transmit only 
precursor ions that could yield the product ions of interest through CID fragmentation.  
Only precursor ions that generate the product ions of interest will be detected in the 
resulting mass spectrum.  This scan mode is useful for identifying classes of compounds 
having similar polarities and structures within a mixture[123]. 
Neutral-loss scan: Both Q1 and Q3 are set to scan simultaneously and at the same 
rate so that all the ions pass through Q1 but only those species that fragment to give a 
product ion with a fixed mass offset pass through both mass analysers and are detected.  
Similar to the precursor-ion scan, this scan mode is useful for identifying structurally 
related classes of compounds in a mixture[123]. 
Multiple-reaction monitoring (MRM): The MRM experiment is carried out by 
specifying the parent mass of the compound for fragmentation in the first quadrupole and 
then specifically monitoring for a particular product ion in the third quadrupole.  MRM is 
useful for quantitative measurements of analytes present in complex samples.  The name 
also indicates that under this scan mode, more than one reaction can be monitored 
simultaneously[123].  Also, the duty cycle, the time allocated to monitoring the ions, is 
much lower when performing a MRM experiment as compared to many other 
experiments. 
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Table 1.1. The Five Common Scan Modes for Tandem MS with Quadrupole Analysers. 
 Scan Mode# Operation of Q1 Operation of q2 Operation of Q3 
1 Q1 Scan desired range N / A N / A 
2 Product-ion, define m1 No scan, select m1 CID 
Scan up to m1 to 
collect its fragment 
3 Precursor-ion, define m2 
Scan from m2 
upwards to cover 
potential 
precursors 
CID No scan, select m2 
4 Neutral-loss, define ∆m 
Scan desired 
range CID 
Scan range shifted by 
∆m to low mass 
5 
Multiple-reaction 
Monitoring, 
define m1 and m2 
No scan, select m1 CID No scan, select m2 
Table was adapted from [124]. 
#Masses for reaction m1 = m2 +n, except for 1) Q1 scan. 
m1 and m2 are any mass of interest chosen by the user whereas n is equivalent to the difference 
between m1 and m2. 
1.5 Research Interest 
Both glycosylation with O-GlcNAc and phosphorylation, are post-translational 
modifications found on the microtubule-associated protein tau (MAPT).  The levels of 
these two post-translational modifications on tau have been found to vary reciprocally.  
This is thought to be due to the fact that they both occur on either the same or nearby 
hydroxyl groups of certain serine and threonine residues.  It has long been proposed that 
hyperphosphorylation of tau leads to its aggregation, which in turn generates paired 
helical filaments, and leads to the eventual formation of neurofibrillary tangles, a 
distinctive feature of Alzheimer’s disease.  Therefore, by increasing the level of O-
GlcNAc modification on tau, it may be possible to prevent or slow its 
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hyperphosphorylation, thus altering progression of disease in patients suffering from 
tauopathies, which include Alzheimer’s disease[74].   
Thiamet-G inhibits the activity of the glycoside hydrolase, OGA.  OGA is the 
enzyme responsible for removing the O-GlcNAc modification from tau.  When OGA 
function is impaired, the levels of O-GlcNAc will increase at all sites of modification but, 
most relevantly for tau, at sites that are either potential targets for phosphorylation or 
adjacent to such sites, thus helping to prevent the formation of neurofibrillary tangles.  
Thiamet-G is able to cross the blood brain barrier, and it has been demonstrated that this 
inhibitor can decrease the phosphorylation of tau in vivo.  An animal pharmacodynamic 
study, which reveals what the drug does to the body, has been recently carried out using 
Thiamet-G.  However, no pharmacokinetics for Thiamet-G have been described nor is 
there a published bioanalytical method for characterizing its pharmacokinetics 
behaviour[74].   
As discussed earlier, the PK of a molecule describes how it is liberated, absorbed, 
distributed, metabolized, and excreted from a body[133].  In an animal study, scientific 
investigation of how fast the drug is being distributed and eliminated from the body is of 
importance since this is a key factor in designing safe and effective therapeutics[133].  
After administration of a drug, one way to quantitate remaining drug in the body is by 
monitoring its concentration in plasma over time[133].  The development of a highly 
sensitive and reproducible bioanalytical method for quantifying and characterizing the 
drug present in the plasma of an animal is therefore a critical step in establishing its PK.
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Figure 1.16. Structures of Thiambu-G (R = NHBu), Thiampro-G (R = HNPr), Thiamet-G (R = 
NHEt), Thiamme-G (R = HNMe), and ThiamH-G (R = NH2). 
Five analogues shown in Figure 1.15, Thiambu-G (R = NHBu), Thiampro-G (R = 
HNPr), Thiamet-G (R = NHEt)[74], Thiamme-G (R = HNMe), and ThiamH-G (R = 
NH2), were developed in the Vocadlo laboratory.  Progress toward developing a 
bioanalytical method for use in PK studies of the analogues is described in Chapter 2 of 
this thesis.  The bioanalysis was carried out using high performance liquid 
chromatography (HPLC) coupled to a tandem mass spectrometer.  In the MS/MS, MRM 
was used to monitor the transition of parent ions of the compounds to diagnostic product 
ions, which are generated by collision induced dissociation.  A validated bioanalytical 
method was developed so that rat PK parameters from oral and intravenous 
administration of Thiamet-G, Thiampro-G, and Thiamme-G, can be determined and is 
described in Chapter 3.  Optimization of the bioanalytical method cycled among the 
following areas until a reliable and reproducible method was realized:  1) MS 
optimization, 2) HPLC separation of the analytes, and 3) sample cleanup of samples 
mimicking genuine PK samples.  With the PK data and an effective bioanalytical method, 
important parameters, such as the therapeutic effective concentration range of the 
compounds and the half-life of these molecules in vivo can be determined. 
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CHAPTER 2: METHOD DEVELOPMENT 
2.1 Scope of Work 
The work was directed toward devising a sensitive and reproducible bioanalytical 
method optimized in three areas: 1) MS analysis, 2) HPLC separation of the analogues, 
and 3) sample cleanup.  The process of method development cycled among these three 
areas until a well polished method had evolved. 
2.2 Optimization of MS for Quantitation 
The system used was a Dionex Ultimate 3000 HPLC system coupled to an 
Applied Biosystems Sciex 4000 QTRAP quadrupole linear ion trap tandem mass 
spectrometer equipped with a turbo ion spray ion source.  Analyst 1.4.2 software was 
used for data acquisition and processing.  A less sensitive mass spectrometer, the AB 
Sciex API 2000 triple quadrupole tandem mass spectrometer was also employed in 
various studies.  The API 2000 was coupled to a PerkinElmer Series 200 HPLC system.  
Unless mentioned specifically, the work presented was performed using the API 4000 
QTRAP. 
2.2.1 Establishment of the MRM Transitions for the Analytes 
The first step in developing the LC-MS/MS method was to determine the polarity 
of ionisation to be used for detection of Thiamet-G, Thiampro-G, Thiamme-G, and 
Thiambu-G[134].  The type of ionisation used was based on which mode gave a higher 
ion count.  Simultaneously, the ESI operating parameters were optimized during the 
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infusion of a standard of mixed analogues, Thiamet-G, Thiampro-G, Thiamme-G, and 
Thiambu-G.  Parameters were optimized to give high signal intensity of both molecular 
and fragments ions.  This allowed the parameters for the MRM scan analysis to be 
determined concurrently for all four analogues.  
2.2.1.1 Polarity of Ionisation 
A mixture of the compounds was infused directly into the MS with an external 
pump for the Q1 scan analysis.  The total ion chromatogram (TIC) that was generated is a 
type of Q1 chromatogram that depicts the signal intensity over the entire range of all m/z 
plotted against time.  The extracted ion chromatogram (XIC) for each corresponding 
compound was generated by extracting the ion of interest from the TIC.  The XIC is the 
chromatogram with the signal of just one single ion plotted against time.  Determination 
of the fragmentation pattern of the compounds was elucidated after consolidating the 
preferred instrumental parameters for ionizing the ions.  See Method 1 for the 
experimental details (Section 2.5.1). 
Results 
All the analytes were observed when positive ionisation was chosen in the 
acquisition method during the Q1 scan analysis.  The positive ions characterized in the 
chromatograms are shown in Table 2.1, and the spectra obtained for Q1 scan analysis is 
shown in Figure 2.1 (I).  The consistent signal in the XIC supported the fact that the 
compounds were constantly infused into the MS and could readily be detected 
simultaneously.  An attempt was made to detect the compounds using negative ionisation, 
but no predicted negative ions for the corresponding compounds were observed.   Table 
2.1 also shows the predicted molecular ions that were expected if negative ionisation was 
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chosen in the acquisition method of the MS.  The XIC for these ions was extracted 
independently as shown in Figure 2.1 (II), but lack of signal suggested that these 
compounds did not ionise to yield the predicted negative ions. 
Table 2.1. Determination of the Ionisation Polarity of the Analogues. 
Analogue Ion (m/z) Acquired 
with Positive Polarity 
Ion (m/z) Expected to 
be Observed with 
Negative Polarity 
Thiamet-G 249 247 
Thiambu-G 277 275 
Thiampro-G 263 261 
Thiamme-G 235 233 
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Figure 2.1. Q1 scans in Positive and Negative Ionisation Modes for Thiamet-G and its 
Analogues. 
A mixture of the analogues was infused directly into the MS using an external pump 
after the acquisition was started.  (I) Positive ionisation mode: (A) The TIC for all the 
expected molecular ions (B – E) and the XIC for each analogue; (B) Thiamet-G, (C) 
Thiambu-G, (D) Thiampro-G, and (E) Thiamme-G.  The consistent signal in the XIC 
indicates the compounds were constantly infused into the MS and are being 
detected simultaneously.  Repeat (II) Negative ionisation mode: In all the XIC 
collected (B – E), the signal intensity of the negative ions was much lower than the 
signal intensity of the TIC (A).  This suggests that the predicted negative molecular 
ions were not detected. 
2.2.1.2 Fragmentation Pattern of the Analogues 
Product-ion scans have to be determined individually for each compound in order 
to determine the most representative or intense product ion that results after fragmenting 
the analogue precursor ion.  The specificity of the analytical method can be vastly 
increased by monitoring a distinct fragmentation process for each compound in order to 
realize absolute quantitation.  The MRM scan mode has been adopted for this purpose in 
this thesis.  
Thiamet-G and its analogues were infused into the MS for the product-ion scan 
analysis.  The precursor ion of each compound was selected for fragmentation with the 
optimized collision energy (CE) to generate a series of MS/MS chromatograms, which 
are plots of the signal intensity against the m/z of the remaining precursor ions and the 
resulting daughter ions.  See Method 2 for the experimental details (Section 2.5.2). 
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Results 
The precursor ion for each compound as reported in Table 2.1 was independently 
selected for product-ion scan analysis.  The MS/MS spectra of these analogues are shown 
in Figure 2.2.   
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Figure 2.2. MS/MS Spectra for Thiamet-G and its Analogues. 
Collision-induced dissociation mass spectra of each compound were generated by 
using the product-ion scan mode with positive ionisation chosen as the acquisition 
method.  A mixture of the analogues was infused into the MS.  The MS/MS 
chromatograms are (A) Thiamet-G, (B) Thiambu-G, (C) Thiampro-G, and (D) 
Thiamme-G. 
 As shown in the MS/MS spectra, fragmentation of the precursor ion of each 
compound generated two daughter ions both having high intensities.  For each analogue, 
one of the two daughter ions was chosen for the MRM analysis.  The pair of ions, 
precursor ion, and the selected daughter ion for all the analogues are tabulated in Table 
2.2.   
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Table 2.2. The MRM transitions of the Analytes using Positive Polarity. 
Analogue Precursor Ion (m/z) 
Daughter Ion with 
the Highest 
Intensity (m/z) 
Thiamet-G 249.00 171.00 
Thiambu-G 277.00 199.00 
Thiampro-G 263.00 185.00 
Thiamme-G 235.00 157.00 
2.2.2 Optimization of the MS Parameters for each Analytical Column 
The ideal method for use with each analytical column studied was optimized by 
using a mixing tee with two inlet ports and one outlet port, which connects to the turbo 
ion spray ion source on the MS.  Optimization of each column method was achieved by 
infusing the mixture of standards into one inlet port by using an external pump (at a flow 
rate of 10 µL / min) and, at the same time, pumping the mobile phase into the other inlet 
port using the HPLC pump at the flow rate that was going to be used during the 
subsequent experiments.  Consult Figure 2.3 for an illustration of the configuration. 
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Figure 2.3. The Setup of the MS Using a Mixing T for Optimization of the System 
Parameters for Column.   
The delivery rate of the mobile phase from the HPLC is set to 300 µL / min as an 
example.  A column does not have to be incorporated in the configuration. 
Results 
MS parameters for two analytical columns, TSKgel and ZIC-HILIC, were subject 
to optimization. The optimized methods are summarised in Method 3 and Method 4 for 
TSKgel (Section 2.5.3) and ZIC–HILIC (Section 2.5.4) respectively. 
2.3 Column Phase Selection for HPLC Separation 
A stationary phase is compatible with the MS when solvent passed through it 
produces a low background signal in the MRM chromatogram since this indicates that the 
column is not bleeding materials into the MS.  The column of choice should separate 
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analytes of interest with high resolution and enable their sensitive detection.  Therefore, 
when comparing different stationary phases, sharp and tall peaks for the target analytes in 
the resulting chromatograms are preferred.   
Reverse phase columns have been reported to be suitable for compounds with a 
variety of properties.  The first column investigated was a reverse phase column.  Two 
other types of columns, hydrophilic interaction (HILIC) and porous graphite carbon 
(PGC) were also tested.  Table 2.3 summarises the properties of the different stationary 
phases. 
Table 2.3. Properties of the Tested Stationary Phases. 
 
2.3.1 Ranking the Stationary Phases 
A mixture containing the analogues was injected into each of the different 
columns and the performance of each column was evaluated by examining the resulting 
MRM chromatograms.  The protocols used for each column were initially based on those 
established in the literature. 
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Table 2.4. Literature Methods for Columns of Interest. 
Column Reference 
Synergi Fusion-RP 
C18 reverse phase - alternated with hydrophobic and polar 
embedded groups on a silica surface 
[135, 136] 
Agilent Zorbax Eclipse XDB 
C18 reverse phase – alkyl chains on a silica surface 
[137] 
TSKgel Amide-80 
HILIC - carbamoyl group covalently linked to a silica gel matrix 
[120, 138-
140] 
ZIC-HILIC 
HILIC - zwitterionic functional groups covalently attached on a 
porous silica surface 
[134, 141, 
142] 
Hypercarb 
PGC – flat sheets of hexagonally arranged carbon atoms, porous 
[114, 116] 
The performance of each column was evaluated based on: 1) its ability to retain 
the polar compounds on the stationary phase, 2) the level of background in the 
chromatogram, 3) the peak shapes of the analytes, and 4) integration of the signal 
corresponding to each analyte. 
2.3.2 Optimization of Retention and Analyte Resolution of the Column(s) 
Optimum conditions were established to enable a column to adequately retain all 
the analytes.  The ideal capacity factor for the analytes (also called the retention factor) is 
greater than 0.5 and less than 10[143].  Optimization of various compositions of mobile 
phase was carried out to improve the resolution of the peaks.  The aim was to identify a 
mixture of ACN / H2O where the compounds were retained on the stationary phase yet 
elution did not take overly long.  Adjustment of the pH and the addition of ion pairing 
reagents also affected the retention time of the analytes.  Since there were multiple 
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analytes in the matrix, separating the analytes from each other and also from the matrix 
was desirable. 
2.3.2.1 Results Obtained by Separating the Analytes with Different Types of 
Stationary Phases 
A mixture of the analogues was injected into the LC-MS system for MRM 
analysis using the MRM transitions tabulated in Table 2.2.  Chromatographic separation 
was carried out using the different columns so that separation and retention of the 
compounds can be evaluated for each stationary phase.  Only the data obtained using the 
HILIC columns are shown in this chapter.  The data obtained using other columns are 
shown in Appendix A 3.1 and A 3.2. 
HILIC Columns 
2.3.3.1 TOSOH Bioscience TSKgel Amide-80, 3 µm (TSKgel column) 
TSKgel was the first HILIC column tested.  The stationary phase has a carbamoyl 
group covalently linked to a silica gel matrix.  This group is non-ionic (Figure 2.4).   
 
Figure 2.4. Functional Group on the TSKgel column. 
Figure 2.5 shows the MRM chromatogram of the analogues and reveals that all 
the ion peaks afford a Gaussian peak shape.  The column volume of the empty TSKgel 
column (CVempty) was 503 µL.  In general, the void volume (V0) is assumed to be 60-70 
  
50 
% of the empty column, and 30-40% is assumed to be the space taken up by the packing 
material[144]. 
V0 = 0.65 x CVempty (1) 
T0 = V0 / flow rate (2) 
The void time (T0) was calculated to be 1.63 min.  It is recommended that analytes of 
interest are eluted with at least 1.5 void volumes in order to provide sufficient time for 
the analytes to interact with the stationary phase[111].  Hence, the time recommended for 
eluting the least retained analogue (Trecommended) is 2.45 min.   
 
Figure 2.5. Separation of the Four Analytes Using the TSKgel column.   
Concentration of the mixture of analytes was 210 ng / mL.  (Column: 2.0 mm x 15 
cm; guard: 2.0 mm x 1.0 cm, flow rate: 200 µL / min, elution with: 0.1 % FA + 80 % 
ACN / H2O)  
The TSKgel column provided retention as well as separation of the compounds.  
In contrast to the reverse phase column, the least polar compound, Thiambu-G, eluted 
first while the most polar compound, Thiamme-G, was retained on the stationary phase 
for the longest time.  Thiambu-G eluted at about 5.0 min, hence analytes were retained 
sufficiently on this column.  In this thesis, the term background is defined as chemical 
noise which arises from the signals corresponding to species other than the analytes 
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present in the analytical system[145].  The term noise refers to electronic signal produced 
by the analytical instrumentation[146] and is defined as the change in detector response 
over a specified time period without the introduction of solvent or samples[145].  
Notably, the documented maximum S / N of the instrument used in this thesis is less than 
20.  As a result, the instrument noise is insignificant when compared to the background 
noise. 
The level of background noise in the chromatogram of Figure 2.4 was generally 
lower than 200 cps.  Compared to the intensity of the analogues, the background level 
was a thousand times lower.  In Table 2.5, the minimum S / B measured is reported in 
Table 2.5 and is greater than 6000.  Thus, the column provides suitable sensitivity. 
Table 2.5. S / B Ratios for the Separation and Detection of Thiamet-G and its Analogues 
on a TSKgel Column. 
Analyte S / B 
Intensity of 
Analyte 
(cps) 
Maximum Levels of 
Background (cps) 
Thiamet-G 1.1 x 104 1.8 x 106 2.8 x 102 
Thiambu-G 2.8 x 104 2.7 x 106 1.6 x 102 
Thiampro-G 2.7 x 104 2.4 x 106 1.7 x 102 
Thiamme-G 6.2 x 103 1.2 x 106 3.1 x 102 
Levels of background were measured from 0 to 0.5 min. 
Separation as shown in Figure 2.5. 
As shown in Table 2.6, the retention factors, k′, for all the analytes ranged from 
1.92 to 3.26 and were within the range (0.5-15) suggested by the literature[143].  The 
peaks were separated as shown in Figure 2.5.  The measured resolution values confirm 
that there is an excellent separation between the peaks. 
  
52 
Table 2.6. Calculation of the k' Values and the Chromatographic Resolution of the 
TSKgel Column. 
Analyte RT (min) k'A Selectivity Half Peak Width (min) Nt Resolution 
Thiambu-G 4.90 2.01  0.14 3.0 x 103  
Thiampro-G 5.88 2.61 1.30 0.15 4.3 x 103 3.0 
Thiamet-G 7.19 3.41 1.31 0.17 5.7 x 103 3.8 
Thiamme-G 9.00 4.52 1.33 0.22 6.5 x 103 4.5 
Separation as shown in Figure 2.5. 
Stability of the TSKgel Column 
A standard solution containing the four analytes at a concentration of 210 ng / mL 
each was analysed using the TSKgel column at the beginning and at the end of each set 
of analyses.  In between analyses of these two sets of standard solutions, samples 
containing plasma were separated using the column and analysed by MRM using the 
MS/MS.  Table 2.7 tabulates the peak area counts and retention times of the standard 
solutions.  Within a group of samples containing 62 individual samples (about 11 h of 
analysis time), the drifting of the retention time for the analytes was less than 4%.  The 
peak area counts of the two standard samples were very similar with less than 5 % 
difference in all cases.  The data demonstrates that the TSKgel column is stable based on 
the reported retention times and peak area counts. 
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Table 2.7. Comparison of the Peak Area Counts of the Samples Analysed over the 
Course of 11 h. 
Analyte 
Standard 
(Sample 
3) 
(min) 
Standard 
(Sample 
63) 
(min) 
% 
Change 
in RT 
Peak Area 
of 
Standard 
(Sample 3) 
(cps) 
Peak Area 
of 
Standard 
(Sample 
63) 
(cps) 
% 
Change 
in Peak 
Area 
Thiamet-G 5.87 5.64 3.92 6.39 x 106 6.61 x 106 3.44 
Thiambu-G 4.13 3.99 3.39 7.85e x 106 8.33 x 106 6.11 
Thiampro-G 4.88 4.71 3.48 7.30e x 106 7.68 x 106 5.21 
Thiamme-G 7.29 7.05 3.29 5.12e x 106 5.25 x 106 2.54 
% shift in X (peak area or RT) = (|X of Sample 3 - X of Sample 63| / X of Sample 3) x 100 %. 
2.3.3.2 Merck SeQuant ZIC-HILIC, 5 µm 200Å PEEK with PEEK frits (ZIC-HILIC column) 
ZIC-HILIC is another type of HILIC column that is similar to the TSKgel 
column.  It has a stationary phase covalently bonded with zwitterionic functional groups 
on the surface (Figure 2.6).  Due to the overall neutral charge state of the functional 
group, a charged analyte will have weak electrostatic interactions with the stationary 
phase.   
 
Figure 2.6. Functional Group on the ZIC-HILIC Column. 
All analytes showed Gaussian peak shapes in the chromatogram.  Based on the 
column volume, the minimum time required to elute the least retained analyte is 1.35 
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min.  The least polar compound, Thiambu-G, took 3.45 min to elute.  The chromatogram 
is reported in Figure 2.7. 
 
Figure 2.7. Separation of the Four Analytes Using the ZIC-HILIC Column. 
Concentration of the mixture of analytes was 210 ng / mL.  (Column: 2.1 x 100 mm; 
guard: 2.1 x 20 mm, flow rate: 300 µL / min; elution with: 0.1 % FA + 85 % ACN / 
H2O) 
The levels of background in the chromatogram were generally lower than 200 
cps.  The numerical data shown in Table 2.8 demonstrates the signal of the analytes was 
well above the background noise. 
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Table 2.8. S / B Ratios for the Separation of Thiamet-G and its Analogues Using a ZIC-
HILIC Column. 
Analyte S / B 
Intensity of 
Analyte 
(cps) 
 
Maximum Levels of 
Background (cps) 
Thiamet-G 3.80 x 103 3.20 x 105 9.50 x 101 
Thiambu-G 4.51 x 103 4.30 x 105 1.10 x 102 
Thiampro-G 6.60 x 103 4.30 x 105 7.00 x 101 
Thiamme-G 1.17 x 103 1.80 x 105 2.60 x 102 
Levels of background were measured from 0.5 to 1 min. 
Separation as shown in Figure 2.7. 
Based on equation 1, T0 was determined to be 0.90 min.  As shown in Table 2.9, 
the retention factors, k′, for all the analytes were within the range (0.5-15) as suggested 
by the article, “HPLC Method Development and Validation for Pharmaceutical 
Analysis”[143].  The peaks were greater than 2.5 as shown in Figure 2.7.  The suitable 
resolution confirmed that there was an excellent separation between the peaks. 
Table 2.9. Calculation of the k′ Values and the Chromatographic Resolution of the ZIC-
HILIC Column. 
Analyte RT (min) k'A Selectivity 
Half Peak 
Width (min) Nt Resolution 
Thiambu-G 3.44 2.82  0.21 7.8 x 102  
Thiampro-G 4.57 4.08 1.44 0.26 1.14 x 103 2.4 
Thiamet-G 6.41 6.12 1.50 0.33 1.52 x 103 3.3 
Thiamme-G 9.46 9.51 1.55 0.46 1.96 x 103 4.3 
Separation as shown in Figure 2.7. 
A standard solution, containing the four analytes at a concentration of 210 ng / 
mL, was analysed on the ZIC-HILIC column at the beginning and at the end of analysis.  
Plasma samples were analysed during the period in between collecting data on these two 
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sets of standards.  Table 2.10 tabulates the peak area counts and retention times of the 
samples.  An increase in peak area response was observed for sample 63.  The apparent 
increase in concentration might be due to evaporation of the ACN in the sample vial 
although this effect was not observed when using the TSKgel column.  With a time gap 
of more than 11h, the shifting of the retention time for the analytes was significant; the 
smallest shift in retention time for the analogues was found to be over 20 %.  A possible 
reason that could account for this effect is that left over matrix ions present inside the 
column may not be completely washed out prior to the injection of the next sample.  The 
matrix ions might adhere onto the stationary phase and thereby alter the properties of the 
column.  Consult the experimental data in Appendix A4.3.4 for further investigations 
regarding the stability of the ZIC-HLIC column.   
Table 2.10. Stability of the ZIC-HILIC Column. 
Analyte 
Standard 
(Sample 
3) 
(min) 
Standard 
(Sample 
63) 
(min) 
% 
Change 
In RT 
Peak Area of 
Standard 
(Sample 3) 
(cps) 
Peak Area of 
Standard 
(Sample 63) 
(cps) 
% 
Change 
in Peak 
Area 
Thiamet-G 3.45 4.32 25.2 5.25 x 106 5.88 x 106 12.0 
Thiambu-G 2.16 2.61 20.8 6.11 x 106 6.92 x 106 13.3 
Thiampro-G 2.64 3.28 24.2 5.69 x 106 6.21 x 106 9.14 
Thiamme-G 4.81 6.10 26.8 4.58 x 106 5.18 x 106 13.1 
% shift in X (peak area or RT) = (|X of Sample 3 - X of Sample 63| / X of Sample 3) x 100 %. 
Discussion 
As discussed in Section 2.3.1, a suitable stationary phase was chosen for the 
analytical method based on its ability to retain the polar analogues, the level of 
background signal in the chromatogram, the peak shapes of the analytes, and the intensity 
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of the signal corresponding to each analyte.  Both the TSKgel and ZIC-HILIC columns 
show an ability to fulfill the above criteria.  Although for both columns, there were 
difference in peak area responses among the compounds, the relative peak area responses 
for the compounds were consistent among all the chromatograms.  These two columns 
were therefore considered as possible candidates for future use.  Further optimization of 
the sample cleanup procedure is discussed below. 
2.4 Sample Cleanup of Model Samples 
As described in Section 1.3.2, samples containing a biological matrix, such as rat 
plasma, have to undergo some kind of cleanup process before being injected into an 
analytical system for analysis.  The higher the extent of interference from the matrix, the 
lower the efficiency of the ionisation of the analytes.  Thus, the removal of matrix 
interference required optimization of sample cleanup procedures. 
Various types of samples were prepared to mimic PK samples and these contained 
a known concentration of a mixture of the analogues.  These samples were used to assess 
each of the sample cleanup processes tested.  The blank rat plasma was purchased from a 
commercial supplier with sodium heparin as the anticoagulant. 
Sample preparation: types of samples. 
1. Standard: Thiamet-G and its analogues diluted from stock solution into ACN / 
H2O mixture (composition dependent on experimental setup). 
2. Control sample (positive control): Thiamet-G and its analogues were spiked in 
water. 
3. Blank sample (negative control): plasma spiked in water. 
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4. Plasma sample: Thiamet-G and its analogues were spiked into plasma diluted 
with water. 
All the samples went through the sample cleanup processes except for the standard. 
2.4.1 Assessment of each Sample Preparation Process During Method 
Development 
a) % Recovery = (sample peak area / standard peak area) x 100 % 
The comparison of peak area response between the sample and the standard 
yielded the percent ratio of the recovery of the analytes.  This value provides an estimate 
of the loss of analytes during the sample cleanup process.  The desired % recovery is 
above 80 %. 
b) % Matrix suppression = (plasma sample peak area / control sample peak 
area) x 100 % 
Suppression of the analogue ions is caused by matrix ions coeluting with the 
target analytes.  The percent ratio of matrix suppression reflects the influence of matrix 
ions present in the rat plasma on the analyte signal intensity.  A percent ratio of less than 
100 % indicates that matrix present in the sample is suppressing ionisation and detection 
of the analyte.  A percent ratio of over 100 % could be caused by an ionisation 
enhancement effect, in which analyte is lost in the absence of matrix during 
analysis[147]. 
c) % RSD = (standard deviation of x / average of x) x 100 %  
 x = either the peak area response or retention time of the analytes 
The percent ratio of relative standard deviation (RSD) measures the repeatability of 
the peak area or retention time (RT) during repeated sample runs of the analytes within 
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the same batch.  The desired % RSD for the peak area is less than 10 % and the desired % 
RSD for the RT is less than 2 %. 
d) Q1 scan (Scanning with the second quadrupole) 
Comparison of the Q1 scan of the control sample and plasma sample reveals the 
matrix ions present in the plasma sample. 
2.4.2 Results with Different Sample Preparation Procedures 
 Several sample cleanup procedures were attempted in order to remove proteins 
and other matrix components that were present in the model samples so that these 
samples could be ionised efficiently for the MS analysis.  Through the comparison of the 
chromatograms between the control and plasma samples, ion suppression was observed 
for Thiamet-G and Thiamme-G, in particular, in the absence of sample clean up.  This is 
evident from the high % matrix suppression and the distortion of peak shapes of the 
analytes in the chromatograms of the plasma sample (Appendix Section A 4).  As 
discussed in Appendix Section A4.3.2, one set of samples was prepared using procedure 
4 and was analysed using the ZIC-HILIC column.  Although ion suppression was not 
observed for the analytes, using this sample preparation procedure yielded poor % 
recovery for both the control and plasma samples.  All the detailed experimental results 
are summarised in Table 2.11 and are reported in greater detail in Appendix A4. 
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Table 2.11. Preliminary Methods for Sample Preparation and other Types of Method 
Development. 
 Sample 
Cleanup 
Procedure 
Description Result 
1 Protein 
Precipitation 
Experimented with 
different organic 
solvents for 
precipitating the 
protein from plasma 
extracts. 
 
Phospholipids and salts remained and caused ion 
suppression. 
2 Different 
eluents as 
mobile 
phase 
 
1. Combination of 
ACN / H2O + 0.1 % 
FA. 
2. Combination of 
MeOH / H2O + 0.1 
% FA. 
2: The compounds were not retained on the 
stationary phase likely due to interactions between 
the compounds and the eluent.  
3 Ultrafiltration Obtained the filtrate 
using an ultra 
filtration device 
while removing the 
proteins in the 
filtrand. 
Salts and other components remained and caused 
ion suppression. 
Phospholipids were removed. 
4 Ultrafiltration 
+ LLE 
 
Extracted out the 
non polar matrix 
ions present in the 
filtrate that can 
interfere with 
analysis. 
Salts were present resulting in ion suppression. 
Phospholipids were removed. 
 
See Appendix A4 for full details. 
In Table 2.12, results obtained from sample cleanup procedures involving solid phase 
extraction devices have been summarised.  None of the procedures yielded good results 
except for the Hypercarb offline 1 mL SPE cartridge.  In the following section the results 
obtained from using this particular cartridge are discussed in more detail.  The detailed 
results for procedures 1, 3, 4 are reported in Appendix A5.  Since Thiamme-G and 
Thiampro-G were not retained on the Supelclean ENVI-Carb SPE tube when washing the 
cartridge with 100 % water, procedure 2 was not pursued further.  All these experiments 
were performed using a ZIC-HILIC column because only minor suppression was 
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observed for the analytes when using this column.  In contrast, when using the TSKgel 
column, detection of the analytes suffered from severe matrix suppression.   
Table 2.12. Sample Preparation Using Solid Phase Extraction Devices. 
 Sample 
cleanup 
procedure 
Description Result 
1 Ultrafiltration + 
ZiptipC18 
Filtrate collected from the 
ultrafilter was further cleaned 
up by the C18 cartridge in the 
ziptip. 
Analytes were lost in the 
ZiptipC18. 
2 Supelclean 
ENVI-Carb 1 
mL SPE tube 
Nonporous graphite cartridge 
(NPGC) used after 
ultrafiltration. 
Compounds eluted out at 
100% water limiting 
usefulness. 
3 Sigma Hybrid 
SPE 1 mL 
Lipid remover was used after 
protein precipitation. 
Lipids were removed but 
salts were still present. 
4 Captiva NDlipid Lipid remover was used after 
protein precipitation. 
Lipids were present in the 
final samples.  The 
cartridge was not 
compatible with solvent 
composed of high organic 
composition. 
5 Hypercarb 
offline 1 mL 
SPE cartridge 
Porous graphite cartridge 
(PGC). 
Analogues were obtained 
with low carryover of 
matrix. 
See Appendix A5 for full details. 
Hypercarb SPE Cartridge 
Figure 2.8 shows the analyses of the samples using the ZIC-HILIC column after 
they have undergone the sample cleanup process using the Hypercarb SPE cartridges.  As 
shown in Figure 2.8, Gaussian shapes were observed for the analytes.  The plasma 
sample was analysed followed by nine samples, standards, and other plasma samples, 
before analysis of the control sample.  The peak area counts of the analytes from both 
chromatograms were very similar. 
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Figure 2.8. Use of Hypercarb SPE Cartridge for Sample Cleanup on Plasma Samples 
Containing Thiamet-G and its Analogues. 
Chromatogram (A) and (B) were the control and the plasma samples respectively.  
These samples were separated using a ZIC-HILIC column after sample cleanup.  
Separation conditions: Step 1) 0 - 10 min, 300 µL / mL, 84 % B, Step 2) 10.5 – 13 
min, 600 µL / mL, 30 % B, Step 3) 13.5 – 16 min, 600 µL / mL, 84 % B, Step 4) 16.5 
- 18 min, 300 µL / mL, 84 % B (A = 0.5 % FA + 5 % ACN + H2O, B = 0.1 % FA + 
ACN). 
To evaluate the % matrix suppression following sample clean up, analogues were 
added into both the control and plasma samples prior to the sample cleanup process.  The 
% matrix suppression was calculated based on the chromatographic separation as shown 
in Figure 2.8.  The percent ratio close to 100 % demonstrated that no matrix suppression 
occurred for any of the analytes when contained in the plasma sample and cleaned up by 
Hypercarb SPE (Table 2.13).  As indicated in the chromatograms, any changes in 
retention time were small.   
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Table 2.13. Comparison of the Peak Area Counts of Thiamet-G and its Analogues 
Prepared in Water versus Plasma. 
Analyte 
Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
Suppression 
Thiambu-G 2.08 x 105 2.31 x 105 111 
Thiamet-G 2.24 x 105 2.36 x 105 105% 
Thiampro-G 2.40 x 105 2.60 x 105 108% 
Thiamme-G 1.86 x 105 1.96 x 105 105% 
% Matrix suppression = peak area counts of (plasma /control) x 100 %. 
Separation as shown in Figure 2.8. 
A % recovery experiment was carried out, and the results are reported in Table 
2.14.  The peak area counts were compared between the plasma sample and a blank 
sample that was spiked with the compounds at the same concentration as the plasma 
sample that had undergone the sample cleanup process.  The purpose of this comparison 
was to test the efficiency of the sample extraction process.  As shown in Table 2.14, the 
% recovery ranged from 93.4 to 98.0 %.  A % recovery of close to 100 % suggests that 
the extraction process was efficient.   
 
 
 
 
  
64 
Table 2.14. % Recovery of the Analogues. 
Analyte 
Plasma 
Sample (cps) 
Plasma 
Spike (cps) 
% Recovery 
Thiambu-G 2.31 x 10
5
 2.39 x 105 96.6 % 
Thiamet-G 2.36 x 10
5
 2.53 x 105 93.4 % 
Thiampro-G 2.60 x 10
5
 2.66 x 105 97.6 % 
Thiamme-G 1.96 x 10
5
 2.00 x 105 98.0 % 
Separation as shown in Figure 2.8. 
Stability of the ZIC-HILIC Column 
In Figure 2.8, the elution time of Thiamme-G in chromatogram (A) was different 
when compared to chromatogram (B).  The retention times for the other three compound 
ions in both chromatograms were similar.  From experience in using the ZIC-HILIC 
column, changing in retention times of analytes were observed throughout the time it 
took to analyse one batch of samples.  However, the deviation of the retention time for 
Thiamme-G was often the greatest.  A possible explanation is that some matrix ions were 
still present in the column even though a wash cycle was incorporated in the run.  As a 
result, the elution time of the analytes, particularly Thiamme-G, might be affected by the 
co-eluted matrix ions.  Another possible reason was that the stationary phase might 
become more polar due to frequent exposure to the polar matrix ions.  As described in 
Section A4.1.2, a similar observation was seen for other experiments carried out using a 
ZIC-HILIC column. 
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During method development, it was not known whether the samples needed to 
undergo deproteinisation prior to loading onto the cartridge or not.  Analytes present in 
the samples that were directly applied onto the Hypercarb SPE cartridges were better 
retained on the bulk material and did not elute out during washing with 100 % water (data 
not shown).  When proteins were first removed from the samples by protein precipitation, 
elution of Thiamme-G occurred when the cartridge was washed with water using 6.5 
times of the bulk material volume.  Thiamet-G also eluted out when the cartridge was 
washed with water using 8.5 times the bulk material volume.  When the samples were 
first passed through an ultrafilter, elution of Thiamme-G occurred when the cartridge was 
washed with 8.5 times of the bulk material of 100 % water.  Interestingly, when directly 
applied to the column, the analytes were still able to bind on the cartridge when washing 
with 100 % water using 20 times of the bulk material volume.  Nevertheless, in Q1 scan 
analysis, the same matrix ions co-eluting with the analytes were observed regardless of 
which of the three sample cleanup processes (protein precipitation, ultrafiltration, direct 
application to cartridge) was employed.  Based on these data it was decided to use 
Hypercarb SPE alone for sample clean up since this was rapid and enabled a good 
balance between retention of the analytes and ease of elution from the cartridge.  Further, 
this approach to clean up, along with use of the ZIC-HILIC column, showed little matrix 
suppression and demonstrated good run to run reproducibility.   
2.4.3 The Optimized Method 
An optimized analytical method was developed.  The optimized method used 
Hypercarb SPE cartridges as the cleanup tool and a ZIC-HILIC column as a compatible 
stationary phase.  The analytical system for LC–MS/MS analysis consisted of a Dionex 
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Ultimate 3000 HPLC system coupled with an AB Sciex 4000 QTRAP quadrupole linear 
ion trap tandem mass spectrometer equipped with a turbo ion spray ion source. 
2.5 Method Section 
2.5.1 Method 1: Generic Method for the 2000 QTRAP LC/MS system 
Chemicals and reagents.  HPLC grade acetonitrile and HPLC grade or LC-MS 
grade water were purchased from Caledon Laboratories Ltd. (Georgetown, Canada) and 
Mallinckrodt Baker, Inc. (Phillipsburg, USA) respectively while reagent grade formic 
acid was purchased from Fluka, Sigma-Aldrich Canada Ltd. (Oakville, Canada).  The 
compounds, Thiamet-G (batch JJ-37)[74], Thiambu-G (batch JJ-1-28), Thiampro-G 
(batch JJ-1-47), and Thiamme-G (batch JJ-1-42) were synthesized previously in the 
Vocadlo lab (Simon Fraser University, Burnaby, BC). 
 Instrumentation.  The 2000 QTRAP LC/MS system consisted of the 2000 
QTRAP mass spectrometer (Applied Biosystems, Life Technologies Corporation, Foster 
City, USA) interfaced with a Perkin Elmer Series 200 high performance liquid 
chromatography (HPLC) system (Perkin Elmer Inc, Massachusetts, USA).  The control 
software for data acquisition was Analyst version 1.4.2 (Applied Biosystems).  The LC 
system was composed of a binary LC pump, a vacuum degasser, controlled autosampler, 
and a column compartment without temperature control.  No analytical column was 
installed in the system.  The mobile phase, 0.1% FA + 85% ACN + H2O, was pumped at 
a flow rate of 300 µL / min. 
Preparation of Standards.  7.00 mg of each analogue was weighed out 
individually with a five decimal place analytical balance (Fisher Scientific Company, 
  
67 
Ottawa, Canada) for preparation of stock solutions.  Stock solutions (conc. = 70000 ng / 
mL) consisting of Thiamet-G, Thiambu-G, Thiampro-G, and Thiamme-G, were prepared 
by dissolving the compounds in water and making the volume to 100 mL using glass 
volumetric flasks.  These stock solutions were stored at 4 oC in an amber glass bottle.  
Mixed compound standard solution A (conc. = 1400 ng / mL) was prepared by adding 
200 µL from each stock solution to 8.5 mL ACN and making the volume to 10 mL with 
water using a glass volumetric flask.  This solution, standard solution A1, was stored at 4 
oC in a HPLC vial until analysis. 
Analytical Procedure.  Standard solution A was analysed using the MS in both 
positive ion and negative ionisation modes by continuously infusing the standard using a 
Harvard syringe pump at a flow rate of 10 µL / min into the turbo ion spray ion source of 
the MS.  Through a mixing tee, 300 µL / min of the mobile phase was concurrently 
delivered into the turbo ion spray ion source using the HPLC pump.  Q1 scan analysis 
was the selected acquisition method.  The scanning range of the mass range was set from 
230.00 amu to 280.00 amu, and the dwell time was set to 0.500 sec.  The resolution of Q1 
was set to be 1 unit mass resolution.  In positive ionisation mode set, the set parameters 
were CUR (25.00 psi), IS (4500.00 V), TEM (100.00 °C), GS1 (55.00 psi), GS2 (40.00 
psi), DP (42.50 V) FP (200.00 V), and EP (7.00 V).  In negative ionisation mode set in 
the acquisition method, the set parameters were CUR (25.00 psi), ISP (- 4500.00 V), 
TEM (100.00 °C), GS1 (55.00 psi), GS2 (40.00 psi), DP (- 42.50 V), FP (- 200.00 V) and 
EP (- 7.00 V). 
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2.5.2 Method 2: Generic Method for the 4000 QTRAP LC/MS system 
Chemicals and reagents.  See Method 1 (Section 2.5.1). 
Instrumentation.  The 4000 QTRAP LC-MS/MS system consisted of the 4000 
QTRAP mass spectrometer (Applied Biosystems) and the Ultimate 3000 HPLC system 
(Dionex Corporation, Bannockburn, USA).  The LC system was composed of a binary 
LC pump, a vacuum degasser, a temperature controlled autosampler, and a thermostated 
column compartment set at 40 oC.  The control software for data acquisition was Analyst 
version 1.4.2, Dionex Chromatography Mass Spectrometry Link software version 
2.0.0.2315, and Chromeleon version 6.80 SP2 (Dionex Corporation).  The mobile phase, 
0.1% FA + 85% ACN + H2O, was pumped at a flow rate of 300 µL / min. 
Preparation of Standards.  7.00 mg of compounds were weighed out separately 
with a five decimal place analytical balance for preparation of stock solutions.  Stock 
solutions (conc. = 70000 ng / mL) containing Thiamet-G, Thiambu-G, Thiampro-G, and 
Thiamme-G were prepared by dissolving the compounds in water and making the volume 
up to 100 mL using volumetric flasks.  These stock solutions were stored at 4 oC.  Mixed 
compound standard solution B (conc. = 1400 ng / mL) was prepared by adding 200 µL 
from each of the stock solutions into a 10 mL glass volumetric flask and making the 
volume up with water.  Standard solution B was stored at 4 oC in a glass vial.  Mixed 
compound standard solution C (conc. = 10 ng / mL) was prepared by transferring 10 µL 
of solution B into a HPLC vial.  To this vial, 980 µL of ACN and 410 µL H2O were 
added to yield solution C with a final composition of 70 % ACN / H2O.  Standard 
solution C was stored at 4 oC in a HPLC vial prior to analysis. 
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Analytical Procedure.  10 µL of standard solution C was injected by the 
autosampler of the HPLC system.  Using the HPLC pump to provide the mobile phase, 
sample was delivered into the turbo ions pray ion source.  The software began the 
acquisition prior to the injection of the sample.  The same solution was repeatedly 
injected into the autosampler for the product-ion scan analysis of all the compounds.  Q1 
scan analysis was selected in the acquisition method.  The scanning range of the mass 
spectrum was from 100.00 amu to 500.00 amu.  The dwell time was 4.00 sec.  The 
resolution of Q1 was unit and Q3 was low.  In positive ionisation mode set in the 
acquisition method, the other parameters were CUR (30.00 psi), ISP (4500.00 V), TEM 
(200.00 oC), GS1 (20.00 psi), GS2 (20.00 psi), DP (65.00 V), CAD (7.00 psi), EP (8.00 
V), and CXP (10.00 V).  The settings for CE were 32, 33, 30, and 32 eV for Thiamet-G, 
Thiambu-G, Thiampro-G, and Thiamme-G respectively.  
2.5.3 Method 3: Generic method for TSKgel-MS-Analysis 
The method was similar to the generic method for the 4000 QTRAP LC/MS 
system (See Section 2.5.2) with the following changes:   
Instrumentation.  The analytical column for the analysis, TOSOH Bioscience 
TSKgel Amide-80 (South San Francisco, USA) (3 µm, 2.0 x 150 mm ID), was protected 
by a guard column (3 µm, 2.0 x 10 mm ID).  The mobile phase, 0.1 % FA + 80 % ACN / 
H2O, was pumped at a flow rate of 200 µL / min.  The operating pressure of the column 
was approximately 47 bar. 
Preparation of Standards.  Mixed compound standard solution F (conc. = 1400 
ng / mL) was prepared by adding 200 µL of the analogue stock solutions, prepared in 
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Method 2 (Section 2.5.2), into a 10 mL glass volumetric flask containing 7 mL of ACN 
and making the volume up with water.  The standard solution F vial was stored at 4 oC in 
a HPLC vial prior to analysis.   
Analytical Procedure.  2 µL of standard solution F was injected by the 
autosampler of the LC / MS system.  Using the HPLC pump to provide the mobile phase, 
2 µL of the sample was delivered to the turbo ion spray ion source.  The MRM transitions 
were set according to Table 2.2, and the dwell time was set as 200.00 µsec.  The 
resolution of Q1 and Q3 was set to be 1 mass unit resolution.  In the positive ionisation 
mode, the other parameters were CUR (30.00 psi), ISP (4500.00 V), TEM (200.00 oC), 
GS1 (20.00 psi), GS2 (20.00 psi), DP (56.00 V), CAD (7.00 psi), EP (9.00 V), CE (31.00 
eV), and CXP (10.00 V). 
2.5.4 Method 4: Generic Method for ZIC-HILIC-MS-Analysis 
The method was similar to the generic method for the 4000 QTRAP LC-MS/MS 
system (See Section 2.5.2) with the following changes:   
Instrumentation.  The analytical column used for the analyses, Merck SeQuant 
ZIC-HILIC column (Umeå, Sweden) (5 µm, 2.1 x 100 mm ID), was protected by a guard 
column (5 µm, 2.1 x 20 mm ID).  The mobile phase, 0.1 % FA + 85 % ACN / H2O, was 
pumped at a flow rate of 300 µL / min. 
Preparation of Standards.  Mixed compound standard solution G (conc. = 210 
ng / mL) was prepared by adding 30 µL of the stock solutions of the analogues, prepared 
as in Method 2 (See Section 2.5.2), into a 10 mL glass volumetric flask containing 7 mL 
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of ACN and making the volume up with water.  The standard solution G was stored at 4 
oC in a HPLC vial prior to analysis.   
Analytical Procedure.  5 µL of solution G was injected by the autosampler of 
the LC-MS/MS system.  Using the HPLC pump to provide the mobile phase, the sample 
was delivered to the turbo ion spray ion source.  The MRM transitions were set according 
to Table 2.2 and the dwell time was set as 200.00 µsec.  The resolution of Q1 and Q3 was 
set to be 1 unit mass resolution.  In the positive ionisation mode, the other parameters 
were CUR (30.00 psi), ISP (4500.00 V), TEM (200.00 oC), GS1 (20.00 psi), GS2 (20.00 
psi), DP (56.00 V), CAD (7.00 psi), EP (8.00 V), CE (31.00 eV), and CXP (10.00 V). 
2.5.5 Method 5: Generic Method for Hypercarb SPE Cleanup and LC-MS/MS 
Analysis 
The method was similar to the method for validation (See Section 3.7) with the 
following changes:   
Preparation of Samples: One stock solution containing Thiamet-G, Thiampro-
G, and Thiamme-G (conc. = 10000 ng / mL) was prepared by dissolving 1.0 ± 0.1 mg of 
each standard in water and making up the volume in a 100 mL volumetric flask.  A mixed 
standard containing 100 ng / mL of each compound was prepared by serial dilution.  A 
separate 100 ng / mL internal standard was prepared the same way by preparing a stock 
solution containing only Thiambu-G (conc. = 10000 ng / mL).   
To generate the plasma sample 11 µL of the 100 ng / mL mixed standard and 11 
µL of the 100 ng / mL internal standard were transferred into a centrifuge tube.  In 
addition, two portions of 11 µL of the control rat plasma and 110 µL of water were added 
into the tube to give a total final volume of 154 µL.  After the tube was capped and 
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vortexed for 30 sec, it was centrifuged at 10000 rpm for 1 min at room temperature.  The 
control sample was prepared the same way except that the rat plasma was replaced with 
water.  A blank sample was also prepared using the same sample preparation procedure 
as the plasma sample except that the mixed standard was replaced with water.  To a blank 
sample, after undergoing the sample cleanup process, was added 11 µL of the 100 ng / 
mL mixed standard and 11 µL of the 100 ng / mL internal standard.  This sample was 
called the plasma spike sample.  These samples were cleaned up using the Hypercarb 
SPE cartridge following the procedure described in the validation method (See Section 
3.7).  The peak area counts of the analytes reported in Table 2.14 were corrected using 
equation 3 to make the peak area counts equivalent to what should be observed for a 
blank sample spiked with 10 µL of the standards. 
Analytical Procedure.  4 µL of the plasma sample was injected by the 
autosampler of the LC-MS/MS system after analysis of the control sample (injection 
volume = 4 µL) had finished.  Nine samples were analysed in the time between the 
control and the plasma sample analyses.  The plasma spike, 4 µL injection volume, was 
then analysed after the plasma samples. 
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CHAPTER 3: METHOD VALIDATION 
 A highly selective, sensitive, and reproducible method is needed for quantifying 
potential therapeutics and their metabolites within biological samples for 
biopharmaceutical studies.  The main objective of validating the current method is to 
demonstrate a bioanalytical method suitable for quantifying Thiamet-G and its analogues 
in rat plasma.  From this quantification, a PK curve can be generated for each of the 
compounds that were dosed into rats by either oral administration or intravenous 
administration.  According to the industrial guidance for bioanalytical method validation, 
the fundamental parameters for validation consist of linearity, ,specificity, accuracy, 
precision, recovery, matrix effect, stability, and sensitivity [148].  Limit of detection 
(LOD) and limit of quantitation (LOQ) are critical factors that need to be 
determined[148].  The method created here (See 2.5.5 Method 5) was tested to ensure 
that it met these general criteria. 
Specific samples were prepared for validation purposes.  The same amount of internal 
standard (10 µL of 100 ng / mL), Thiambu-G, was spiked into all three types of solutions. 
1) Control standard solution (CSS): Thiamet-G, Thiampro-G, and Thiamme-G were 
spiked into neat solvent (70 % ACN / H2O).  This solution did not go through the 
sample extraction process and serves as a positive control. 
2) Blank plasma solution:  Plasma (diluted with water) that has undergone the 
sample extraction process.  This solution serves as a negative control. 
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3) Working calibration standard solution (WCSS): Thiamet-G, Thiampro-G, and 
Thiamme-G were spiked into plasma diluted with water.  The solution went 
through the sample clean up process. 
3.1 Selectivity/Specificity, General Considerations 
 A method is selective when it can be used to quantify the analyte in the sample in 
the presence of other components[148].  It is important to maintain selectivity at the 
lower limit of the quantification (LLOQ)[148].  Specificity is crucial for identifying the 
correct analytes.  For this project, compounds of closely related structures were present in 
certain mixtures.  The method being developed and used should enable monitoring the 
response of one analyte and its specific detection over other analytes, providing that 
representative chromatograms are available for each analyte.  Bioanalytical validation 
practices recommend that analyses of blank samples collected from biological matrices 
should be obtained from at least six sources[148].  However, other sources state that a 
single source of matrix may be used when the bioanalytical method is able to maintain its 
selectivity[147].  A single matrix source was used here since the method was being 
developed for plasma. 
3.1.1 Results 
As discussed earlier, a QTRAP tandem mass spectrometer was the chosen 
analytical technique for analysis of Thiamet-G and its analogues.  The use of a tandem 
mass spectrometer (MS/MS) enables the use of MRM.  The analytical method was 
readily able to discriminate between compounds of closely related structures by using the 
MRM scan mode.  Chromatograms (A), (B), and (C) in Figure 3.1 were obtained using 
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LC-MS/MS analysis of the following solutions, the CSS, the blank, and the WCSS.  The 
blank sample was used to determine any interference present in the blank plasma 
solution.  Supporting data shows a positive peak response when a mixture of compounds 
was separated (chromatogram A), and no response when analysing samples that did not 
contain the analytes (chromatogram B).  The spectra demonstrated the specificity of the 
analytical method in the presence of the matrix ions present within the samples 
(chromatogram C). 
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Figure 3.1. Thiamet-G, Thiampro-G, and Thiamme-G were Easily Separated in the 
Presence of the Matrix Plasma.   
 Chromatogram (A) was obtained using the CSS sample.  Chromatogram (B) and (C) 
were blank samples containing the internal standard (Thiambu-G) and the WCSS 
sample, respectively.  A1, B1, and C1 are the expanded version of the 
corresponding chromatograms.  In all cases, the large off scale peak is Thiambu-G 
which was used as an internal standard. 
3.2 Linearity 
The linearity of the method is the ability of the procedure to relate the signal 
responses obtained during analysis directly to the concentration of analytes in the samples 
in a proportional manner within a specified range.  A calibration curve relates the 
detector response with a series of known concentrations of the analyte of interest.  A 
calibration curve is constructed from a blank sample lacking the internal standard, a zero 
sample containing the internal standard, and at least six standards covering the analyte of 
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concentration range expected to be present in the experiments to be analysed.  All 
standards used for the calibration curve should be prepared in the same biological matrix 
as the actual samples.  The concentrations of the working calibration standards are based 
on the concentration ranges used in the actual study. 
Linearity is assessed by visual inspection of a plot of signal response against the 
concentration of analytes and more quantitatively by taking the data from the regression 
line and determining the degree of linearity[148].  The Pearson product moment 
correlation coefficient, r, is often used during linear regression analysis to relate a 
dependent variable to an independent variable[149].  For a set of data points, linear 
regression generates a formula for the trend line that most closely matches those points.  
It also gives an r value to demonstrate how much of the variability of the dependent 
variable is explained by the independent variable.  A r value close to 1 indicates the 
signals are well correlated with the actual concentration of the analytes[149].  The 
acceptable r value for this method is above 0.99. 
3.2.1 Results 
Calibration standard solutions (CSSs), composed of Thiamet-G, Thiampro-G, and 
Thiamme-G, were diluted from a stock solution, stockmixed, by serial dilution.  A set of 
WCSS samples with a final concentration of 0.5, 1, 10, 100, 500, and 1000 ng / mL of the 
analytes were prepared using the CSSs.  As mentioned earlier, WCSS samples were 
spiked into blank rat plasma using a constant amount of the internal standard in order to 
offset the variation of instrumental responses due to the instability of the system. 
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Out of the various possible weighting factors commonly used, 1/y2 yielded the 
best fitting WCSS curves and this weighting was used for all analytes.  The plots below 
show the peak area ratio versus concentration plot, the working curve, for each 
compound.   
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Figure 3.2. Working Curves.  Plots of Peak Area Ratios versus Concentration of the 
WCSS Samples for (A) Thiamet-G, (B) Thiampro-G, and (C) Thiamme-G. 
The r value was greater than 0.99 in all cases.  The data suggested that the 
recorded signals can be well correlated with the actual concentration of the analogues, 
and one can directly predict the concentration of the analytes from the curve over a 
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concentration range of the analyte ranging from 0.5 to 1000 ng / mL. 
One observation in the working curves is that there appears to be curvature at the 
higher end (Figure 3.2), which results in systematic underestimation of the concentration 
at the higher concentrations.  The sample at 1000 ng / mL noticeably deviates from the 
line and it is possible that the response from the MS detector is becoming saturated at 
higher concentrations.  Since data for QC
 
at high concentrations (QCH = 800 ng / mL) are 
accurate (Section 3.4.1) and precise (Section 3.4.2), the results suggest that the working 
curves are still maintaining linearity at around 800 ng / mL.  Further, the expected range 
of analytes should be less than 800 ng / mL.  Therefore, we felt that these working curves 
were adequate for our analyses. 
3.3 Limits of the Method 
3.3.1 Lower Limit of Detection (LOD) 
LOD is the minimum concentration of analyte that is detectable using the 
analytical system being employed.  However, at the LOD, the signal does not have to be 
quantifiable.  In equation 4, Cm is the concentration at the detection limit[146].  ¯ Sbl is 
the mean background signal obtained by averaging the peak height of a blank sample in 
multiple mass spectra.  Sbl is the calculated standard deviation of the peak height 
responses recorded in the mass spectra.  Sm in equation 4 is the minimum distinguishable 
analytical signal and the m in equation 5 is the slope of the calibration curve. 
Sm = ¯ Sbl + (k x sbl), where k = variation of blank due to random errors (4) 
Cm = (Sm - ¯ Sbl) / m (5) 
By substituting equation 4 into equation 5, one obtains: 
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Cm = (k x sbl) / m, where k = 3.3 [146]  (6) 
Confirmation of the LOD can be done by using statistical techniques along with 
the signal-to-background ratio (S / B) [150].  Equation 7 shows the relationship that one 
can practically draw between % RSD (introduced in Section 2.4.1) and S / B.  The 
commonly accepted S / B ratio for the LOD is between 2 to 3[151].   
% RSD = 50 / (S / B) (7) 
By inputting the numerical value 3 for S / B in equation 7, the % RSD is about 17 
%.  This means that by injecting six replicates of a sample at the LOD, if the calculated % 
RSD for peak height is around 17 %, then the samples prepared were approximately at 
the LOD[150]. 
3.3.2 Limit of Quantification (LOQ) 
LOQ is the minimum concentration of analyte that is quantifiable.  In principle, 
the theoretical value of LOQ can be calculated with equation 8[150]. 
LOQ = (10 x sbl) / m (8) 
The signal response at the LOQ should be at least five times higher than a blank 
response[148].  Analyses of replicates at this concentration level should yield quantifiable 
results with precision and accuracy[148].  In practice however, the commonly accepted S 
/ B ratio for the LOQ is 10-20[151].  By inputting the numerical value 10 for S / B in 
equation 6, the % RSD obtained is about 5 %.  In other words, the % RSD of six injected 
replicates should be less than 5 % at the LOQ.   
LOD and LOQ are illustrated in Figure 3.3.  Bioanalytical validation 
recommendations and the actual data for LOQ are discussed in the Result sections of 
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accuracy and precision (See Section 3.4.1.1 and 3.4.2.1).  According to the guidance, % 
accuracy for LOQ should not deviate from the nominal concentration by more than 20 % 
and the precision data for LOQ should be within 20 %[148]. 
 
Figure 3.3. Limit of Detection and Limit of Quantitation Expressed in Signal-to-
Background Ratios. 
Adapted from [151]. 
LOQ is also the lowest working calibration standard for constructing the 
calibration curve[148].  For this project, the desired LOQ in the plasma is less than or 
equal to 2.5 ng / mL, since this is the lowest concentration at which most therapeutics are 
useful.  The lowest calibration standard for constructing the working calibration curve is 
0.5 ng / mL.  The concentration is equivalent to 1.25 ng / mL in the undiluted rat plasma. 
3.3.2.1 Result 
The background level (¯ Sbl) measured from the blank mass spectra was 1 x 101 
cps while the standard deviation of the background levels (sbl) was 1 x 101 cps.  The 
calculated LOD and LOQ are summarised in Table 3.1.  The LOD from the experimental 
result is found to be 0.05 ng / mL for all three compounds.  The working curves used to 
quantify the respective analytes are shown in Figure 3.2. 
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Table 3.1. The Calculated LOD and LOQ. 
Analyte LOD (ng / mL) LOQ (ng / mL) 
Thiamet-G 0.0210 0.0700 
Thiampro-G 0.0175 0.0585 
Thiamme-G 0.0307 0.1025 
3.4 Accuracy, Precision, Recovery, and Range 
The accuracy, precision, recovery, and the range of the method are determined 
based on the quality control (QC) samples.  A minimum of five replicates of QC samples 
(n = 5 for 3 different concentrations) are recommended to be included in each batch of 
runs[152].  A group of samples that are analysed within the same run is called a batch.  
Each sample is analysed one after the other with no machine idle time in between.   
During validation, the QC samples were prepared as follows:  The lowest 
concentration level of QC samples (QCL, conc. = 1 ng / mL) was prepared at a 
concentration level close to the LOQ.  The medium concentration level (QCM, conc. = 
400 ng / mL) was at the midrange of the calibration curve.  Lastly, the high QC sample 
(QCH, conc. = 800 ng / mL) was at a concentration close to the upper level of 
quantification (ULOQ).  During validation, six replicates of QC samples were run 
throughout the batch along with a freshly prepared WCSS.  The concentrations of the QC 
samples were determined by interpolating from the working curves.  The QC samples and 
the WCSS samples were freshly prepared for each batch analysed. 
3.4.1 Quantification of QC Samples 
Four batches of samples were analysed.  Tables 3.2 through 3.5 summarise the 
resulting data after quantifying the QC samples for each batch of analysis.  The reported 
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information are the nominal concentration of the analytes, the mean concentration of the 
replicates, and the SD of the concentration of the replicates.  The nominal concentration 
was the theoretical concentration of the QC samples, which was determined by the 
weight of the analyte added to the stock solution and the dilution factors.  The mean 
concentrations of the analytes at three different levels were determined to be close to the 
nominal concentration in all four batches of samples.  Some QC samples were not 
included the calculations due to verifiable injection failures. 
Table 3.2. Mean Concentration and SD of QC Samples for Thiamet-G and its Analogues 
in Sample Batch #1. 
 
QC samples were cleaned up using Hypercarb SPE cartridges.  These samples were then 
analysed using a LC equipped with a ZIC-HILIC column coupled with the MS.  Separation 
conditions: Step 1) 0 - 10 min, 300 µL / mL, 84 % B, Step 2) 10.5 – 13 min, 600 µL / mL, 30 % B, 
Step 3) 13.5 – 16 min, 600 µL / mL, 84 % B, Step 4) 16.5 - 18 min, 300 µL / mL, 84 % B (A = 0.5 
% FA + 5 % ACN + H2O, B = 0.1 % FA + ACN).  See the Methods for Validation (Section 3.7) for 
details. 
Table 3.3. Mean Concentration and SD of QC Samples for Thiamet-G and its Analogues 
in Sample Batch #2. 
 
Same conditions as described for sample batch #1 above. 
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Table 3.4. Mean Concentration and SD of QC Samples for Thiamet-G and its Analogues 
in Sample Batch #3. 
 
Same conditions as described for sample batch #1 above. 
Table 3.5. Mean Concentration and SD of QC Samples for Thiamet-G and its Analogues 
in Sample Batch #4. 
 
Same conditions as described for sample batch #1 above. 
3.4.1 Accuracy 
The accuracy of a method describes the deviation of the mean test results from the 
true concentration of the analyte[148].  Using a calibration curve constructed with freshly 
prepared standards, one can determine the measured concentrations of the QC samples (n 
= 6).  The mean measured concentrations of the QC samples were compared to the 
nominal concentrations to determine the % accuracy.   
% accuracy = (mean measured conc. of the replicates / nominal conc.) x 100 %
 (9) 
3.4.1.1 Results 
Four batches of samples were analysed.  Six replicates of QC samples for three 
concentration levels, 1, 400, and 800 ng / mL were acquired for each batch.  Each batch 
of samples was freshly prepared prior to analysis.  The accuracy data for Thiamet-G (Et), 
Thiampro-G (Pro), and Thiamme-G (Me) that were obtained from the four batches of QC 
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samples ranged from 86.5 % to 113 % (Table 3.6). 
Table 3.6. Accuracy Data for QC Samples of Thiamet-G and its Analogues. 
 
According to the FDA guidance, % accuracy for all the concentration levels is 
suggested to be within 15 % of the nominal concentration, and the LOQ is suggested to 
not deviate from the nominal concentration by more than 20 %[148].  As shown in Table 
3.6, the analytical method developed here provides an accurate means of quantifying 
Thiamet-G and its analogues that is consistent with FDA guidances. 
During the collection of data for the second batch of samples, the run was 
interrupted due to a setup error.  The run was resumed by acquiring data for six aliquots 
of system suitability (SS) samples to ensure the instrument was stable, and the data that 
were obtained after the analyses of the SS samples were labelled SS2.  SS1 were obtained 
in the same way as SS2, but they were collected at the beginning of the run prior to 
interruption.  SS was a solution composed of all the analogues including the internal 
standard with the same solvent compositions as the QC samples (70 % ACN / H2O), 
except that SS was not treated with plasma.  The main purpose of analysing SS samples 
is to monitor the stability of the instrumentation within a run.  The data for SS2 were 
compared with the data of SS1 as shown in Table 3.7.  The precision data for both sets of 
CV are less than 2 %.  The average signal response data for SS1 and SS2 also are very 
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similar.  The percent ratio tabulated in the last column shows that the average peak area 
responses for each compound deviates by no more than 7 % between the two sets of data.  
As a result, the instrument was shown to be stable throughout the entire period spanning 
the interruption.  Furthermore, no outlier was detected for the replicates of the QC 
samples as evaluated by performing the Grubbs' Outlier Test.   
Table 3.7. Comparison of the Data of SS1 and SS2 for QC Samples of Thiamet-G and its 
Analogues. 
Analyte 
Average 
Peak Area 
(cps) 
SD CV  
% (Peak Area of SS1/ 
Peak Area of SS2) 
SS1 Thiamet-G 2.35 x 105 0.03 x 105 1 % 94.2% 
Thiampro-G 1.99 x 105 0.04 x 105 2% 93.4% 
Thiamme-G 2.04 x 105 0.04 x 105 2% 94.1% 
Thiambu-G 
(IS) 2.26 x 10
5
 0.04 x 105 2% 93.9% 
     
SS2 Thiamet-G 2.50 x 105 0.03 x 105 1%  
Thiampro-G 2.13 x 105 0.03 x 105 1%  
Thiamme-G 2.16 x 105 0.02 x 105 1%  
Thiambu-G 
(IS) 2.41 x 10
5
 0.02 x 105 1%  
3.4.2 Precision 
The precision of a method demonstrates the deviation in measurements of the 
analyte when it is at a known constant concentration[148].  Precision is expressed as the 
percentage of relative standard deviation, % RSD, or coefficient of variation, CV. 
CV = (SD of measured conc. / mean measured conc.) x 100 % (10) 
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Validation of precision can be further classified as intra-batch (within-run) and inter-
batch (between-run). 
The intra-batch analysis involves the measurement of a group of samples under 
the same operating conditions for a short period of time, or samples within the same 
batch.  The QC samples being analysed are prepared separately for each run.  The 
purpose of the intra-batch analysis is to determine the repeatability of the sample 
preparation procedure through comparison of the precision of the QC samples within 
batches.  The inter-batch analysis involves varying the analytical method while assessing 
the precision of the QC samples during the run.  Differences in the analysts, equipment, 
and day of analysis all contribute to variation[148].  A minimum of three batches of 
samples are recommended for carrying out the inter-batch analyses[152]. 
3.4.2.1 Results 
Precision for a Single Run 
A total of four batches of samples were run.  In each batch run, QC samples (n = 6) 
at three different concentration levels were analysed.  Since these QC samples were 
extracted individually, the precision measurement took into account possible human 
errors and any sources of deviations that could arise during the sample preparation 
procedures.   
The resulting precision data are shown in Table 3.8.  According to the guidances, 
the % RSD for all the concentration levels should be within 15 % and the LOQ should be 
within 20 %[148].  A low percentage indicates the deviation among the QC replicates 
was low.  In the data, all CV values are below 10 %.  The data suggests that by following 
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the sample preparation procedure, the analytical method was able to reliably produce 
precise data that is consistent with the FDA guidances. 
Table 3.8. Precision Data for QC Samples of Thiamet-G and its Analogues. 
 
Intermediate Precision 
Two types of analyses were performed to validate for intermediate precision.  One 
was called the day-to-day analysis, and the other one was called the column-to-column 
analysis. 
Day-to-day Analysis 
The numerical data that were obtained on different days of analysis are reported 
in Table 3.9.  For each day of the analysis, samples were freshly prepared and analysed 
using the LC-MS/MS as an individual batch.  Since these batches of samples were all 
analysed with column # 1 installed in the system, the parameter that was monitored was 
the repeatability of the sample preparation process.  The mean accuracy data, calculated 
by averaging the % accuracy of the QC samples from the four batches of analyses, are 
close to 100 %.  The results for the QC samples are similar for all three compounds at 
three different concentration levels.  The precision data show a CV below 10 %.  These 
results demonstrate the sample extraction process was highly reproducible over different 
days. 
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Table 3.9. Precision Data for QC Samples of Thiamet-G and its Analogues in Different 
Batches of Samples over Different Days. 
% Accy 
QC Samples 
Batch 
# 1 
Batch 
# 2 
Batch 
# 3 
Batch 
# 4 
Mean 
% Accy 
(%) 
SD CV 
QCL(Thiamet-G) 113% 96.7% 101% 102% 103% 0.07 7% 
QCL(Thiampro-G) 107% 108% 104% 107% 107% 0.02 2% 
QCL(Thiamme-G) 112% 93.9% 104% 98.0% 102% 0.08 8% 
    
QCM(Thiamet-G) 97.6% 99.6% 100% 97.2% 98.7% 0.02 2% 
QCM(Thiampro-G) 94.5% 108% 95.6% 97.6% 98.8% 0.06 6% 
QCM(Thiamme-G) 96.6% 95.6% 105% 99.1% 99.1% 0.04 4% 
    
QCH(Thiamet-G) 93.8% 96.8% 93.0% 94.9% 94.6% 0.02 2% 
QCH(Thiampro-G) 91.8% 102% 86.8% 92.4% 93.2% 0.06 7% 
QCH(Thiamme-G) 94.5% 93.6% 99.4% 97.4% 96.2% 0.03 3% 
Column–to–column Analysis  
In the column–to–column analysis, the same batch of QC samples were analysed 
with different lots of the same stationary phase.  Each sample in batch #4 was divided 
into two HPLC vials before the LC-MS/MS analysis.  One set of samples were analysed 
using column # 1 (column # SB80414) installed on the analytical system and interfaced 
with the MS/MS.  After the completion of the analysis, the other set of samples were 
analysed in the same way but using column # 2 (column # SB81229) installed on the 
analytical system.  The purpose of this experiment was to see whether the analyses of the 
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same samples using different lots of the same stationary phase would lead to differences 
in accuracy and precision.  The data are reported in Table 3.10.  On both days of 
analyses, the accuracy data were close to 100 %.  The CV values for all concentration 
levels of the analytes were within 10 %.  The recorded data therefore suggests that using 
different lots of columns did not produce differences in the data. 
Table 3.10. Precision Data for QC Samples of Thiamet-G and its Analogues with Different 
Lots of Stationary Phase. 
% Accy 
QC Samples 
Column 
#1 
Column 
#2 
Mean % Accy SD CV 
QCL(Thiamet-G) 102% 107% 105% 0.04 4 x 100 % 
QCL(Thiampro-G) 107% 112% 110% 0.03 3 x 100 % 
QCL(Thiamme-G) 98.0% 111% 105% 0.09 9 x 100 % 
      
QCM(Thiamet-G) 97.3% 106% 102% 0.06 6 x 100 % 
QCM(Thiampro-G) 97.6% 102% 99.9% 0.03 3 x 100 % 
QCM(Thiamme-G) 99.1% 111% 105% 0.08 8 x 100 % 
      
QCH(Thiamet-G) 94.9% 110% 102% 0.1 1 x 101 % 
QCH(Thiampro-G) 92.4% 99.7% 96.0% 0.05 5 x 100 % 
QCH(Thiamme-G) 97.4% 111% 104% 0.09 9 x 100 % 
Stability of the ZIC-HILIC Column 
 20 SS samples were injected into the analytical system using a newly installed 
ZIC-HILIC column (Column #2).  The peak area responses and retention times of these 
analogues are summarised in Table 3.11.  Although the CV values for the peak area ratios 
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for Thiamet-G and Thiampro-G were low, suggesting that the system was reproducible, 
for Thiamme-G, the CV value was somewhat high.  This indicates that the behaviour of 
Thiamme-G on this column is to some extent less stable.  The retention time ratio for all 
three compounds had a small CV value indicating the retention times were constant when 
no plasma was present in the sample. 
Table 3.11. Consistency of Peak Area and RT Ratio of Thiamet-G and its Analogues over 
19 h of Analysis Time. 
Peak Area Ratio RT Ratio 
Analyte 
Average SD CV Average SD CV 
Thiamet-G 0.94 0.04 4% 1.8 0.005 0.3% 
Thiampro-G 0.88 0.02 2% 1.3 0.005 0.4% 
Thiamme-G 0.72 0.06 8% 2.6 0.009 0.3% 
A separate experiment was carried out to demonstrate the behaviour of a new 
ZIC-HILIC column (column # 2) when it was first exposed to WCSS samples.  Five QC 
samples were prepared in triplicate in plasma at 0.5, 1, 10, 100, and 1000 ng / mL.  When 
these QC samples were first exposed to the new column, the elution times of all three 
compound ions changed.  The trend of the elution time could not be tracked during these 
experiments.  This same batch of samples were also analysed using column # 1, and the 
results indicated all three analytes had stable retention times on column # 1.  It was found 
that after analysing at least two batches of samples on column #2, the precision and 
accuracy improved to acceptable levels, suggesting that the column requires a period of 
conditioning of approximately 70 QC samples before reproducible results are obtained. 
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3.4.3 Recovery 
Recovery describes the comparison of the detector response for analytes added to 
and then extracted from the biological matrix to the detector response for samples of 
authentic analytes of known concentration.  The recovery of analytes and the internal 
standard should be both consistent and reproducible[148].   
An experimental design was proposed by Chambers et al[153].  Recovery was 
expressed in % recovery.   
% Recovery = (signal response of sample spiked before extraction / signal 
response of sample spiked after extraction) x 100 %  
 (11) 
The FDA guidances suggest that % recovery does not need to be 100%, but the 
ability of the method to maintain consistency, precision, and reproducibility is the main 
objective[148].  For this analytical method, the expected range for % recovery was 80 to 
120 %.   
3.4.3.1 Results 
Samples at two different concentration levels (low and high) were measured.  The 
obtained data for the WCSS samples were compared with blank samples that were spiked 
with the same amount of analytes as the plasma samples.  The recovery data are reported 
in Table 3.12.  The results are within the expected range.  We are able to demonstrate the 
sample extraction process is efficient as only minimal sample is lost during the process.  
Consequently, the method yields good recovery. 
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Table 3.12. Recovery Data for QC Samples of Thiamet-G and its Analogues. 
Analyte QCL QCH 
Thiamet-G 83.8% 97.4% 
Thiampro-G 85.1% 83.4% 
Thiamme-G 86.3% 100% 
Thiambu-G (IS) 95.0% 105% 
3.4.4 Range 
The range of a method is the concentration of the analytes that can be detected 
with a suitable level of precision, accuracy, and linearity.  The range of a method is 
defined as the region between the upper and lower concentration levels[151].  The 
minimum specified ranges for assaying drug product is from 80 to 120 % of the test 
concentration[154].   
3.4.4.1 Results 
In the concentration range of 0.5 to 1000 ng / mL for Thiamet-G and its 
analogues, all the fundamental parameters for validation, such as precision, accuracy, and 
linearity, are expected to meet the guidance suggestions given the levels of analytes 
dosed to animals.  In the analysis of the actual PK samples for Thiamet-G (Section 3.8), 
most of the concentrations ranged from 50 to 420 ng / mL.  The lowest concentration 
detected was 2.8 ng / mL.  80 and 120 % of 2.8 ng / mL are 2.24 and 3.36 ng / mL 
respectively.  As a result, the linear dynamic range, 0.5 to 1000 ng / mL, is acceptable for 
detecting the concentrations of the actual PK samples.  
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3.5 Matrix Effect 
This experiment assesses the ionization efficiency of the analytes in MS-based 
analysis.  One generic observation for MS-based analysis is that ions are either 
suppressed or enhanced with the presence of matrix components in the biological 
samples[147].   
An experimental design was proposed by Chambers et al. 
% Matrix effect = (signal response of sample spiked in plasma /  
signal response of sample spiked in 70 % ACN / H2O) x 100 %  
 (12) 
A percent ratio of 100 % suggest that there is no effects.  When the value is low, there is 
signal suppression; when the value is high, there is ionization enhancement. 
For this analytical method, we expected the % matrix effect to be within the range of 70 
to 110 %[153]. 
3.5.1 Results 
Samples at two different concentration levels (low and high) were measured.  The 
obtained data for the WCSS samples were compared with the CSS samples that were 
spiked with the same amount of analytes as the plasma samples.  Data for the internal 
standard-normalized matrix effect are reported in Table 3.13.  The results are close to the 
preset range.  The data suggest that there were matrix ions suppressing the ionization of 
the analytes but the level of suppression was minor.  As a result, the method is not 
affected by the matrix to any extent causing complications. 
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Table 3.13. Matrix Effect Data for QC Samples of Thiamet-G and its Analogues. 
Analyte QCL QCH 
Thiamet-G 84.0% 79.6% 
Thiampro-G 85.3% 92.3% 
Thiamme-G 77.9% 77.9% 
3.6 Stability 
Short and long-term compound stability experiments can also be carried out.  
Short-term stability tests should include 3 freeze / thaw cycles, bench top, and 
refrigerated stability.  Short-term stability measurements are best carried out during 
method validation.  Long-term measurements are started prior to validation and should be 
completed after validation[155].  The stability of analytes is dependent on the storage 
conditions, chemical properties of the analytes, the biological matrix, and the container 
used.  In this work the following stability studies were carried out: stock solution, freeze-
thaw, bench top, refrigerated stability, and the stability of the samples at the -20 oC prior 
to reconstitution.  Some of the actual PK samples were stored at – 80 oC.  Under different 
storage conditions, it is generally accepted that the sample matrix will have variable 
stability.  Therefore, determination of the stability of the compounds in plasma at – 80 oC 
was also carried out[155]. 
3.6.1 Stock Solution Stability 
The stability of both the analyte and internal standard in the stock solutions is 
required for evaluation at room temperature for at least 6 h.  Stock solutions of analytes 
for the stability evaluation should be prepared in an appropriate solvent at known 
concentrations.  Fresh stock solutions are prepared from the reference material for 
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determination of the stability of the compounds in the stock solution and the stock 
solutions that were refrigerated[152]. 
3.6.1.1 Results 
For this method, the stock solutions were prepared in water.  One fresh stock 
solution, Stockmixed, was prepared for Thiamet-G, Thiampro-G, and Thiamme-G.  The 
other stock solution, StockIS, was prepared for the internal standard, Thiambu-G.  These 
fresh stock solutions were prepared from reference material to determine both the 
stability of analytes and the stability of the older stock solution (4 months old).   
The response of a fresh stock solution at time zero, T0, was compared with the 
response of the same stock solution that has been sitting at room temperature in the 
autosampler for 6 h, T6hrs.  The analysis of the stock stability was carried out individually 
for StockIS and Stockmixed.  A percent ratio can be obtained by the following formula 
where Tn stands for any time point: 
% Ratio = (Peak Area Response of Tn / Peak Area Response of T0) x 100 % 
 (13) 
In first row of Table 3.14, the percent ratios are tabulated for the analytes in 
Stockmixed.  With deviations of less than 5%, the compounds were shown to be stable 
within a time frame of 6 h at room temperature.  In the second row of the table, the 
percent ratios for comparing the signal response of an older Stockmixed with the signal 
response of the T0 sample are tabulated.  The response of the older stock solution should 
be within 5 to 7 % of the response of the fresh stock solution[152].  The data indicates the 
compounds are stable for 4 months when stored at 4 oC. 
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Table 3.14. Stability Test for Stockmixed. 
% Peak Area Thiamet-G Thiampro-G Thiamme-G 
%(T6hrs / T0) 105% 105% 103% 
%(T4 months old / T0) 99.0% 100% 95.5% 
 A similar experiment was performed using Thiambu-G in StockIS.  In Table 3.15, 
Thiambu-G was shown to be stable within a time frame of 6 h because the recorded 
percent ratio in the first row is close to 100 %.  The recorded percent ratios in the second 
and the last rows are similar, except that in the last row, the recorded signal response at 
each time point is divided by the measured weight of Thiambu-G.  A 17 % deviation is 
observed in the second percent ratio in the table.  The reason was that the nominal 
concentration of the T4 months old sample was slightly higher than T0.  Nominal 
concentration is determined by the weight of the analyte and the volume of the stock 
solution.  Therefore, a 10 % deviation is seen after the correction is made.  For the 
purpose of this project, a 10 % deviation is acceptable. 
Table 3.15. Stability Test for StockIS. 
% Peak Area Response Thiambu-G 
%(T6hrs / T0) 102% 
%(T4 months old / T0)1 110% 
1These samples have been corrected for the differences in their nominal concentrations. 
% Peak Area Response calculated based on equation 11. 
Three sets of system suitability (SS) samples were run at the beginning, in the 
middle, and at the end of the batch analysis of the stability samples.  The precision data 
of the three sets of SS are reported in Table 3.16.  The precision data are less than 5 %, 
and this indicates that the system was stable during the analysis. 
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Table 3.16. Stability of the Analytical System Determined by System Suitability Samples. 
Peak Area Relative RT 
 Average 
(cps) SD CV 
Average 
(min) SD % RSD 
SSThiamet-G 1.83 x 105 0.07 x 105 4% 4.82 0.05 1 
SSThiampro-G 1.55 x 105 0.07 x 105 5% 3.53 0.04 1 
SSThiamme-G 1.63 x 105 0.06 x 105 4% 7.03 0.09 1 
SSIS 1.88 x 105 0.09 x 105 5% 2.76 0.02 1 
For the rest of the stability experiments including freeze-thaw, bench top, 
refrigerated stability, and the stability of the samples at -20 oC prior to reconstitution, a 
set of samples freshly prepared from the stock solution of analytes in an appropriate 
analyte-free, interference-free biological matrix were used.  The replicate aliquots of 
stability samples were analysed along with a set of freshly prepared working calibration 
standard solutions (WCSS).  Two concentration levels of QC samples, QCL and QCH, are 
recommended to be used in the stability experiments and we followed this 
guideline[155]. 
3.6.2 Long-term Stability Experiment 
For long-term stability studies, the storage time of the QC samples should be long 
enough to account for the storage time of the sample analytes.  At least three aliquots of 
QC samples were stored at the storage conditions used for the eventual sample analyses.  
The volumes of the stability samples are large enough such that there is adequate sample 
for three separate analyses.  Periodic analyses of the stored samples help to monitor the 
stability of the compounds in plasma.  The concentrations of the stability samples are 
calculated from the calibration curve constructed with a set of freshly prepared WCSS.  
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Concentrations of all the stability samples analysed on different days are compared to the 
mean of the samples analysed on day 1.  The day 1 analysis took place within 24 h after 
the samples were prepared.  It is recommended that two consecutive assessments be 
carried out on two successive days to determine whether the analyte has become unstable 
due to its storage conditions[155]. 
3.6.2.1 Results for QCH 
 A large volume of QCH was freshly prepared and aliquoted into several portions.  
Three aliquots were analysed in batch # 1.  The resulting data from analysis of these three 
aliquots were labelled as the day 1 analysis, and they are tabulated in the first row of 
Table 3.17.  Half of the remaining aliquots were stored at – 20 oC and the other half were 
stored at – 80 oC. 
In the day 1 analysis, the accuracy data were calculated by comparing the mean 
concentration of the replicates to the nominal concentration of the QC samples.  All 
samples have % accuracy ranging from 90 to 99 %.  The precision data demonstrated that 
the concentrations of the replicates were very close to each other.  The bioanalytical 
validation guidelines generally suggest that the result of the day 1 analysis should not 
deviate from the nominal concentration by more than 5 to 7 %[155].  For this project, we 
have accepted the data to deviate from the nominal concentration by 10 %.
Analysis of QCH samples that have been stored at –20 oC and –80 oC for 10 days 
and 6 months are also shown in Table 3.17.  The precision data that are lower than 5 % 
showed that the replicates have only minor differences from each other.  The accuracy 
data were calculated by comparing the mean concentration of the replicates to the 
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concentration obtained from the day 1 analysis.  The accuracy data are mostly within 15 
% of the nominal concentration.  The result suggests that Thiamet-G and Thiamme-G at a 
high concentration level were stable in the plasma at the corresponding storage conditions.  
Further stability experiments should demonstrate whether Thiampro-G is unstable under 
these conditions since the recorded accuracy data deviated from the concentration of the 
day 1 analysis by more than 15 %. 
Table 3.17. Long-Term Analyte Stability of QCH for Thiamet-G and its Analogues 
1Replicates of QCH was prepared and analysed on day 1.  The other data are for replicates of 
QCH that were stored at -20 oC and - 80 oC for 10 days and 6 months before analysis. 
3.6.2.2 Results for QCL 
In the case of QCL, the data for the day 1 analysis show high accuracy (Table 
3.18).  The precision data demonstrate that the concentrations of the replicates were very 
close to each other.  The mean concentration obtained from the samples of the day 1 
analysis was used for calculating accuracy data for the further long-term stability 
experiments. 
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Analysis of QCL samples that have been stored at –20 oC and –80 oC for 10 days 
and 6 months are also shown in Table 3.18.  The precision data that are lower than 7 % 
demonstrated that the replicates have only minor differences from each other.  The 
accuracy data are mostly within 15 % of the nominal concentration.  The result suggests 
that Thiamme-G at a high concentration level is stable in the plasma under the 
corresponding storage conditions.  Further stability experiments should demonstrate 
whether Thiamet-G and Thiampro-G are unstable under these conditions since some of 
the recorded accuracy data deviated from the concentration of the day 1 analysis by more 
than 15 %. 
Table 3.18. Long-Term Analyte Stability of QCL for Thiamet-G and its Analogues 
1Replicates of QCL were prepared and analysed on day 1.  The other data are for replicates of 
QCL that were stored at -20 oC and - 80 oC for 10 days and 6 months before the analyses. 
3.6.3 Freeze-Thaw Stability 
The stability of the analyte was determined after three freeze - thaw cycles.  Three 
aliquots of QC samples were frozen at their storage temperature for 24 h and thawed at 
room temperature.  Once the samples were completely thawed, the samples were frozen 
again for at least 12 h under the same storage conditions.  The freeze - thaw cycle was 
repeated two more times.  After the last freeze - thaw cycle, the stability samples were 
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analysed using the LC-MS/MS along with a set of samples that had undergone only one 
freeze - thaw cycle. 
3.6.3.1 Results 
Aliquots of QC samples were stored at –20 oC and –80 oC.  Three aliquots of QC 
samples were removed from each of the storage conditions and were thawed at room 
temperature.  Then, these samples were returned back to their original storage conditions.  
This cycle was repeated a total of three times.  On the day of the analysis, three aliquots 
of QC samples that have been thawed only once (1 FT) were extracted and analysed 
along with the samples that had gone through the freeze-thaw cycles three times (3 FT).  
These samples were analysed along with a set of WCSS from batch #2.  
The accuracy data for each type of freeze – thaw samples were calculated by 
comparing the mean concentration of the replicates to the nominal concentration of the 
QC samples.  The accuracy data of close to 100 % suggests that the concentration of the 
replicates were very close to their actual values (Table 3.19).  Variation in precision of 
less than 5 % further suggests that there were minimal differences between replicates. 
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Table 3.19. Freeze-thaw (FT) Stability of QCH for Thiamet-G and its Analogues. 
 
Replicates of QCH were prepared and stored at -20 oC and - 80 oC.  3FT QC samples were 
subjected to three freeze-thaw cycles while the 1FT samples were subjected to only one freeze-
thaw cycle. 
In Table 3.20, the accuracy data of samples that were thawed only once are 
compared with the accuracy data of samples that have gone through the freeze-thaw cycle 
three times.  The difference in percentage is in all cases less than 11 %.  The numerical 
data showed that the compounds in plasma were stable after going through the three 
freeze-thaw cycles. 
Table 3.20. Comparison of the Accuracy Data of QCH for FT Samples. 
Storage  Thiamet-G Thiampro-G Thiamme-G 
-20
 
o
 
C 3.0% 3% 5.7% 
-80
 
o
 
C 1.6% 2% 10% 
Percent values = |% accuracy of 3FT - % accuracy of 1FT| 
 For the stability analyses for QCL, the accuracy data for all the compounds, except 
for Thiampro-G, are high (Table 3.21).  The percent values for all the samples being 
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close to 100 % suggests that the FT samples had minor deviations from the nominal 
concentration that were not problematic. 
Table 3.21. Freeze-thaw (FT) Stability of QCL for Thiamet-G and its Analogues. 
 
Replicates of QCL were prepared and stored at -20 oC and - 80 oC.  QC samples for 3FT were 
subjected to three freeze-thaw cycles while the 1FT samples were subjected to only one freeze-
thaw cycle. 
In Table 3.22, the accuracy data for QCL samples that have undergone three 
freeze-thaw cycles compared with samples that have undergone only one freeze-thaw 
cycle.  The results suggest that Thiamet-G and Thiamme-G were stable in plasma after 
three freeze-thaw cycles at the low concentration.  For Thiampro-G, the FT samples that 
were stored at – 20 oC had accuracy values close to 100 %.  In the FT samples that were 
stored at – 80 oC, 1FT and 3FT had a % accuracy of less than 80 %.  The precision data 
suggest that the measurements of the replicates were very close to each other.  A possible 
reason for the observed result is that Thiampro-G might precipitate out when stored at  
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– 80 oC and then it might take additional time for Thiampro-G to redissolve at room 
temperature.  This is a possibility that will need to be investigated further. 
Table 3.22. Comparison of the Accuracy Data of QCL for FT Samples. 
Storage Thiamet-G Thiampro-G Thiamme-G 
-20 oC 4.4% 2.3% 3.6% 
-80 oC 1.5% 0.4% 1.6% 
Percent values = |% accuracy of 3FT - % accuracy of 1FT| 
3.6.4 Short-term Stability Experiment 
This experiment ensures that the analyte does not degrade during the sample 
cleanup process prior to analyses.  Three aliquots of QC samples were removed from the 
storage conditions, thawed, and then maintained at room temperature for the period of 
time that the samples will be at room temperature during the proposed analytical method.  
The typical time for analysis is between 4 and 24 h.  For this project, 24 h is used to be on 
the safe side since the batch analysis can take 7 h.  After 24 h, another set of stability 
samples was removed from storage and thawed.  When the second set of samples had 
thawed, a WCSS standard was freshly prepared and analysed along together with the two 
sets of samples.  The accuracy data were calculated by comparing the mean concentration 
of the replicates to the nominal concentration of the QC samples.   
Results 
Three aliquots of QCH samples were removed from each of the storage conditions 
and were thawed and then maintained at room temperature for 24 h.  On the day of the 
analysis, three aliquots of QC samples were removed from the storage conditions and 
thawed.  These freshly removed samples (1 FT) were extracted and analysed along with 
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the samples that had been at room temperature for 24 h (ST).  These samples were 
analysed with a set of WCSS from batch #2. 
The data for the short-term stability experiment for QCH are reported in Table 
3.23.  The % accuracy and the precision data are shown to be close to 100 % and below 4 
% respectively.  The % accuracy of these two sets of stability samples should be within 
15 % of the nominal concentration.  The CV of the three replicates should be less than 15 
%[155].  These data indicate the measured concentrations were close to the nominal 
concentrations and measurements of the replicates were in agreement with each other. 
Table 3.23. Stability of QCH for Thiamet-G and its Analogues at Room Temperature for 24 
h. 
 
Replicates of QCH were prepared and stored at -20 oC and - 80 oC.  QC samples for ST were 
thawed and held at room temperature for 24 h while the 1FT samples were thawed and analysed 
immediately afterward. 
In Table 3.24, accuracy data of the samples that have thawed right away are 
compared with the samples that were at room temperature for 24 h.  The difference in 
percentage is less than 7 % suggesting that the compounds in plasma were stable after 
sitting at room temperature for 24 h. 
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Table 3.24. Comparison of the Accuracy Data of QCH for Short-term Stability Samples. 
Storage Thiamet-G Thiampro-G Thiamme-G 
- 20
 
oC 2.0% 2% 7% 
- 80
 
oC 1.2% 3% 7% 
Percent values = |% accuracy of ST - % accuracy of 1FT| 
Aliquots of QCL samples were removed from the storage conditions, were thawed 
and maintained at 24 h, and labelled as ST.  After 24 h, aliquots of freshly removed 
samples (1 FT) were extracted along with the ST samples that had been at room 
temperature for 24 h.  These samples were analysed as batch # 4. 
The short-term stability data for QCL are reported in Table 3.25.  For samples that 
were stored at -20 oC, the accuracy data for both the ST and 1 FT samples are close to 
100 %, which suggests that the reported data have only minor deviations from the 
nominal concentration.  The calculated CV values that are less than 5% indicating that 
the concentrations of the replicates were in agreement with each other.  The data shows 
that the compounds were stable in plasma for 24 h at room temperature.  The only 
exception was the samples containing Thiampro-G that was stored at – 80 oC. 
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Table 3.25. Stability of QCL for Thiamet-G and its Analogues at Room Temperature for 24 
h. 
 
Replicates of QCL were prepared and stored at -20 oC and - 80 oC.  QC samples for ST were 
thawed at room temperature for 24 h while the 1FT samples were thawed and analysed right 
away. 
In the case of Thiampro-G, the FT samples stored at – 80 oC are shown to have low 
accuracy.  The samples that underwent both one and three freeze thaw cycles were 
observed to have the same variation.  However, the ST samples that were stored at – 80 
oC still maintained high accuracy.  This could be because, when thawing a sample stored 
at – 80 oC, Thiampro-G needs more time to be redissolved at room temperature.  This 
idea will need to be tested in the future.  See Table 3.26 for the comparison between the 
accuracy data of 1 FT and ST samples. 
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Table 3.26. Comparison of the Accuracy Data of QCL for Short-term Stability Samples. 
Storage Thiamet-G Thiampro-G Thiamme-G 
- 20
 
oC 3.3% 3.0% 3.7% 
- 80
 
oC 6% 21% 2.0% 
Percent values = |% accuracy of ST - % accuracy of 1FT| 
3.6.5 Post-Preparative Stability 
There are two types of post-preparative stability experiments, on-instrument and 
extraction stability.  For the on-instrument experiment, QCstability samples analysed at the 
beginning of the run were compared against QCstability samples analysed in between or at 
the end of the run[155].  For the extraction stability experiment, the stored QCstability 
samples are compared with replicates of QCstability samples that are prepared fresh.  This 
evaluation is not part of the routine validation process[155].  For this project, only the on-
instrument stability experiment was performed.   
3.6.5.1 Results 
 Replicates of extracted QC samples were pooled together and aliquoted into six 
portions.  They are referred to as the QCstability samples, and two concentration levels were 
prepared, a low concentration QCLstability and a high concentration QCHstability were 
prepared.  These aliquots of samples were run through out the batch.  The number of 
replicates was six.  Since they were pooled together after the extraction process, the 
resulting data should yield a low CV.  There were pooled together to eliminate the 
differences in concentrations during sample preparation. 
 In the longest on-instrument stability experiment, the time of the analysis between 
the first and the last QCstability samples was 79 h.  The accuracy data were close to 100 % 
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(Table 3.27).  The precision data were less than 8 %.  All three compounds were 
therefore stable in the autosampler at 10 oC for 79 h. 
Table 3.27. On-Instrument Stability of QCstability for Thiamet-G and its Analogues for 27 h. 
 
3.7 Sensitivity 
 Sensitivity is the assessment of the lowest concentration that can be measured 
using the method with acceptable accuracy and precision[152].  For this method, the 
LOQ is set at 0.5 ng / mL.   
3.7.1 Results 
Six replicates of QC samples at the concentration of LOQ were prepared.  They 
were injected into the system one after another.  The accuracy and precision data are 
reported in Table 3.28.  The accuracy data for all three analytes are within 85 to 115 % 
whereas the precision data are lower than 5 %.  The data support the fact that method is 
able to detect the lowest concentration at 0.5 ng / mL.   
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Table 3.28. Sensitivity Data for Thiamet-G and its Analogues. 
 
Expected 
Conc. 
(ng / mL) 
Mean 
(ng / mL) SD CV % Accy 
Thiamet-G 0.506 0.47 0.02 4% 92.5% 
Thiampro-G 0.497 0.432 0.008 2% 86.9% 
Thiamme-G 0.502 0.44 0.01 3% 86.7% 
3.8 Analyses of PK Samples 
After completing of the validation procedure, the PK samples for Thiamet-G were 
analysed using the same protocol.  Three rats were treated by with100 mg / kg of 
Thiamet-G were fed into three rats by oral gavage.  Aliquots of rat plasma were collected 
from the animals throughout a time period extending up to 24 h.  These samples were 
prepared as described above and analysed by LC-MS/MS.  Two separate analyses were 
carried out for each sample.  The mean concentrations and standard deviation obtained 
for each time point are tabulated in Table 3.29. 
From the experimental results, we could determine the maximum concentration of 
Thiamet-G that can be absorbed into the bloodstream, Cmax, and the time point for Cmax.  
As seen in table, Cmax and tmax are determined to be 370 ± 20 ng / mL and 2 h 
respectively.   
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Table 3.29. Concentration of Thiamet-G in the Pharmacokinetic Samples 
 
 The total amount of compound that is absorbed into the body system can be 
determined by plotting the average concentrations of Thiamet-G in Table 3.29 against the 
range of time points for collecting the plasma samples.  The result, which is a typical 
pharmacokinetic graph, is shown in Figure 3.4.  The area under the curve (AUC) 
represents the average amount of Thiamet-G absorbed by the rats.  The AUC was 2263 
ng / mL by oral administration.  In the future, additional information, such as the 
bioavailability, can be determined by using this data along with a pharmacokinetic study 
using intravenous administration.   
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Figure 3.4. The Total Amount of Thiamet-G that was Absorbed by Rats. 
Concentrations of Thiamet-G were plotted against the time points of collection.  The 
AUC was 2263 ng / mL. 
 PK compartment models are often used to describe how a compound behaves in a 
biological system after administration.  The behaviour of Thiamet-G in rat can be 
examined by plotting the log of concentrations of Thiamet-G versus time points.  In the 
logarithmic graph of Figure 3.5, it exhibits an absorption phase, a distribution phase and 
an elimination phase are all observed.  In oral administration as compared to IV injection, 
the compound in the blood is slower to reach Cmax because of the absorptive processes of 
the GI tract[94].  Since the experiment was performed using oral gavage, these phases are 
not distinctive in the graph.  Nevertheless, most of the points lie on the trendline.  The 
shape of the graph resembles the curve expected for a one compartment model (Figure 
1.12 B).  The actual determination of the type of compartment model should be 
determined by administration via the intravenous route. 
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Figure 3.5. An Apparent One Compartment Model is Exemplified in the Log of 
Concentrations of Thiamet-G versus Time Graph. 
The behaviour of Thiamet-G in the body of rat can be determined by compartment 
modeling.  In an one compartment model, the body is considered as one unit.  Once 
the compound reaches the body system, the compound immediately distributes 
throughout the body and maintain steady state between tissues.  The black line is 
the actual data and the red line is the trendline. 
The elimination rate constant, k, can be determined by plotting the natural log of the 
concentrations of Thiamet-G in the elimination phase versus time.  The graph is shown in 
Figure 3.6.  A minimum of three points are required for determining k[91].  A linear 
relationship was drawn between concentration and time with a coefficient of regression 
of 0.998.  The plot supports the fact that the compound is eliminated from the body by a 
first order kinetic process.  The apparent k can be estimated from the negative slope of 
the line representing the elimination phase of the graph (Figure 3.6).  Hence, the apparent 
k is 0.201 ± 0.009.  Using equation 14, the apparent half life, t1/2, can be determined as 
well that is the time it takes for the initial concentration of the compound in the plasma to 
decrease to 50 %.   
t1/2 = 0.693 / k (14) 
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In this study, t1/2 is 4.977 ± 0.222 h.  The t1/2 suggests that Thiamet-G indeed partitions 
between the plasma and the tissues in the body and it is well absorbed by the body 
system.   
 
Figure 3.6. The Apparent Elimination Rate Constant can be Determined from the Natural 
Log of Concentrations of Thiamet-G versus Time Graph. 
k is equal to the negative slope of the plot.  t1/2 can be determined once k is known. k 
and t1/2 are 0.201 ± 0.009 and 5.0 ± 0.2 h respectively. 
3.9 Conclusion 
We have developed a LC-MS/MS method for supporting the pharmacokinetic 
analyses for Thiamet-G, Thiampro-G, and Thiamme-G.  During method development, 
samples were prepared by spiking compounds in rat plasma that mimicked the make up 
of the actual pharmacokinetic plasma samples.  Thiambu-G acted as the internal standard.  
The method utilized the Hypercarb offline cartridge as the sample extraction tool and the 
ZIC-HILIC column as the stationary phase.  The instrumental settings for the 
bioanalytical method are summarised in Table 3.30. 
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Table 3.30. Summary of Validated Instrumental Settings 
LC Ultimate 3000 HPLC system (Dionex Corporation, Bannockburn, USA 
MS 4000 QTRAP mass spectrometer (Applied Biosystems Life Technologies Corporation, Foster City, USA) 
Column 
Merck SeQuant ZIC-HILIC column (Umeå, Sweden) (5 µm, 2.1 
x 100 mm ID), was protected by a guard column (5 µm, 2.1 x 20 
mm ID). 
Separation conditions 
Step 1) 0 - 10 min, 300 µL / mL, 84 % B, Step 2) 10.5 – 13 min, 
600 µL / mL, 30 % B, Step 3) 13.5 – 16 min, 600 µL / mL, 84 % 
B, Step 4) 16.5 - 18 min, 300 µL / mL, 84 % B (A = 0.5 % FA + 
5 % ACN + H2O, B = 0.1 % FA + ACN). 
Dwell time 200.00 µsec 
CUR 30.00 psi 
ISP 4500.00 V 
TEM 200.00 oC 
GS1 20.00 psi 
GS2 20.00 psi 
DP 56.00 V 
CAD 7.00 psi 
EP 8.00 V 
CE 31.00 eV 
CXP 10.00 V 
We have successfully validated the method specifically for supporting the 
pharmacokinetic analyses for Thiamet-G, Thiampro-G, and Thiamme-G.  The method 
has been proven to be linear, specific, accurate, precise, sensitive, with good recovery, 
and not affected by matrix effect.  The compounds were found to be generally stable with 
some exceptions at their storage conditions, - 20 oC and -80 oC.  The experimental LOD 
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was determined to be 0.05 ng / mL for all three compounds.  Precision and accuracy were 
maintained at the LOQ, 0.05 ng / mL.  The linear dynamic range ranged from 0.05 to 
1000 ng / mL.   
As shown in Section 3.8, the method proved useful for analysis of the actual 
pharmacokinetic samples.  The study was carried out by feeding Thiamet-G to rats by 
oral gavage.  Thiamet-G was found to be absorbed with a Cmax of 370 ± 20 ng / mL and a 
tmax of 2 h.  The AUC was 2263 ng / mL.  From the analysis, the apparent k and t1/2 were 
determined to be 0.201 ± 0.009 and 5.0 ± 0.2 h respectively.  We were conclusively able 
to demonstrate that the method was capable of quantifying the analytes in rat plasma 
from pharmacokinetic studies. 
3.10 Future Plans 
PK samples for other compounds and samples that were collected from 
intravenous administration will be analysed using the same protocol.  The method can be 
expanded to analyse other plasma types and tissues.  It should be possible to make 
improvements to the current sample extraction method and the chromatographic 
conditions.  For example, the manual extraction process can be adapted to an automatic 
format, which will help to shorten the time required to perform the overall analysis.   
3.11 Methods for Validation 
Chemicals and reagents.  HPLC grade acetonitrile was purchased from 
Caledon Laboratories Ltd.  LC-MS grade or HPLC grade water was purchased from 
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Mallinckrodt Baker, Inc, while reagent grade formic acid was purchased from Fluka, 
Sigma-Aldrich.  Reagent grade glacial acetic acid was purchased from Anachemia.   
Control rat plasma was obtained from the animal facility of Valley Biochemical, Inc. 
(Winchester, USA). 
Instrumentation.  The 4000 QTRAP LC-MS/MS system consisted of the 4000 
QTRAP mass spectrometer interfaced with an Ultimate 3000 HPLC system.  The HPLC 
system was composed of a binary LC pump, a vacuum degasser, a temperature controlled 
autosampler and a thermostated column compartment set at 40 oC.  The control software 
for data acquisition was Analyst version 1.4.2, Dionex Chromatography Mass 
Spectrometry Link software version 2.0.0.2315 and Chromeleon version 6.80 SP2.  The 
analytical column for the analysis, Merck SeQuant ZIC-HILIC column (5 µm, 2.1 x 100 
mm ID), was protected by a guard column (5 µm, 2.1 x 20 mm ID).  The mobile phase, 
0.1 % FA + 85 % ACN / H2O, was pumped initially at a flow rate of 300 µL / min.  A 
gradient method was setup for the run as tabulated in Table 3.30. 
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Table 3.31. LC Gradient Program Gradient Method for the ZIC-HILIC Column. 
Time (min) % B Flow Rate (µL) 
0 84 300 
10 84 300 
10.5 30 600 
13 30 600 
13.5 84 600 
16 84 600 
16.5 84 300 
18 84 300 
Mobile phase A was 0.1 % FA + 5 % ACN + H2O and mobile phase B is 0.1 % FA + ACN.   
Preparation of Standards.  One stock solution, Stockmixed, containing Thiamet-
G, Thiampro-G, and Thiamme-G (conc = 100000 ng / mL), was prepared by dissolving 
10 ± 0.1 mg of each standard in water and making the volume up to 100 mL in a 
volumetric flask.  The stock solution of internal standard, StockIS (conc = 10000 ng / 
mL), was prepared by dissolving 1 ± 0.1 mg of Thiambu-G in water and making the 
volume up to 100 mL in a volumetric flask.  The stock solutions were stored at 4 oC.  The 
actual weights of compounds for preparing the stocks solutions and the procedures for 
preparing the Calibration Standards (CS) are described in Appendix Section A2. 
Preparation of Working Calibration Standard Solutions (WCSS) 
11 µL of each calibration standard solution (CS) and 11 µL of a 100 ng / mL 
internal standard solution were transferred into a centrifuge tube.  In addition, two 
portions of 11 µL of the control rat plasma and 110 µL of water were added into each 
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tube to give a final total volume of 154 µL.  After the tubes were capped and vortexed for 
30 sec, they were centrifuged at 10000 rpm for 1 min at room temperature. 
Equilibration of the Cartridges 
1 mL Hypercarb cartridges were loaded onto the vacuum manifold holder, which 
was placed on top of a reversible manifold lid.  When a vacuum was applied to the 
assembly, the liquid solutions present inside the cartridges were drawn into the waste 
container.  The steps for equilibration of the cartridges were as follows: a) 1 mL of 0.5 M 
ammonium hydroxide, b) 2 x 1 mL of HPLC grade water, c) 30% acetic acid, d) 1 mL of 
HPLC grade water, e) 1 mL of 70% ACN / H2O (premixed earlier), f) 5 x 1 mL of HPLC 
grade water 
During the equilibration process, the solutions present in the cartridges were kept 
no lower than the top edge of the manifold holder, which was located immediately above 
the bed level of the cartridge.  Effort was made to avoid trapping air bubbles inside the 
column bed.  The vacuum pressure reading was maintained so that it was no higher than 
7 mm Hg.  The next equilibration solution was loaded when the level of the previous 
solution present in the cartridge has just reached the top edge of the holder.  Just prior to 
loading the next solution, the vacuum was released. 
Application of the Samples 
140 µL of the sample was individually loaded onto the 1 mL Hypercarb SPE cartridge 
using an adjustable pipette.  The vacuum pressure was maintained below mm Hg until the 
sample had entered into the cartridge bed.   
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Washes 
Five washes each being 720 µL in volume of water were applied into the cartridges.  The 
cartridges were dried completely after both the fourth and fifth wash.  When drying the 
cartridges, a vacuum was drawn through the assembly for 30 sec at 8 mm Hg.  
Elution 
Two portions of 180 µL of a 70% ACN / H2O solution (premixed earlier) were 
applied into the cartridge.  The collection tubes were placed underneath the reversible 
manifold lid, so the eluted fractions were collected.  In between the two elution 
processes, the cartridges were dried completely at 8 mm Hg.  When initially passing the 
eluent into the cartridges, the vacuum reading was kept at 2 mm Hg.  The two eluted 
fractions were pooled into one collection tube.  The eluent was dried down completely 
under vacuum at 55°C. 
Preparation of the Test Article 
100 µL of a premixed 70% acetonitrile/water solution was transferred into 
collection tubes to reconstitute the samples.  The tubes were capped and vortexed for 30 
sec.  After 5 min of sonication, the tubes were centrifuged at 10000 rpm for 6 min at 
room temperature.  Hence, the WCSS are five times more dilute than the CS.  7 µL of 
each sample were transferred into separate HPLC vials containing inserts.  All samples 
were capped.  One set of samples were used for LC–MS/MS analysis and other samples 
were stored either in the 4°C refrigerator or in the -20°C freezer. 
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Preparation of the QC Samples 
Three QC stocks for compounds with high (QCH = 800 ng / mL), medium (QCM = 
400 ng / mL), and low (QCL = 1 ng / mL) concentrations of analytes were prepared from 
the Stockmixed.  Please see Appendix Section A2 for the procedure used to prepare these 
QC spiking stocks.  These QC stocks were added separately into six aliquots of plasma.  
Eventually, six replicates of QC samples for three different concentration levels were 
prepared.  11 µL of a QC stock solution and 11 µL of 100 ng / mL internal standard 
solution were transferred into a centrifuge tube.  In addition, two portions of 11 µL of the 
control rat plasma and 110 µL of water were added into each tube, total volume of 154 
µL.  After the tubes were capped and vortexed for 30 sec, they were centrifuged at 10000 
rpm for 1 min at room temperature.  140 µL of the QC sample was loaded onto a 
Hypercarb cartridge for sample cleanup.  The procedure for sample cleanup was the same 
as the sample cleanup for the WCSS samples as described above. 
Preparation of the QCstability Samples 
Six QC samples containing analytes at the same concentration underwent the 
sample extraction processes.  These samples were pooled together and aliquoted into six 
portions of QCstability samples.  These six stability samples should have identical 
concentrations because the possible causes of deviation have been eliminated. 
Analytical Procedure.  4 µL of sample was injected by the autosampler into the 
4000 QTRAP LC-MS/MS system.  With the HPLC pump pumping the mobile phase, the 
4 µL of the sample was delivered into the turbo ion spray ion source.  During acquisition, 
the MRM transitions were set according to Table 2.2 and the dwell time was set as 
200.00 msec.  The resolution of Q1 and Q3 was set to be 1 unit mass resolution.  With 
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positive ionisation mode set in the acquisition method, the other parameters were CUR 
(30.00 psi), ISP (4500.00 V), TEM (200.00 oC), GS1 (20.00 psi), GS2 (20.00 psi), DP 
(56.00 V), CAD (7.00 psi), EP (8.00 V), CE (31.00 eV), and CXP (10.00 V).
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APPENDICES 
Appendix A1 PK Parameters 
Volume of distribution (Vd): Vd represents the apparent volume of plasma needed to 
dissolve the compound so that the resulting concentration would give the concentration of 
compound in plasma[98].  In the equation below, Cp is the drug concentration in plasma, 
X is the amount of compound and t is the time[98]. 
Vd(t) = X / Cp(t) (15) 
 For a bolus injection, the initial plasma concentration, Cp(0), is equal to the dose 
divided by the Vd[91]. 
Cpt = Cp(0) x exp (- kt) (16) 
Equation 14 above describes the plasma concentration when the compound content in the 
plasma undergoes exponential decay[98].  When the equation is converted into the linear 
form, the equation becomes 
ln Cpt = ln Cp(0) – kt, (17) 
where k is the elimination rate constant and the y intercept is ln Cp(0)[98].   
Half-life: Half life is the time needed to reduce the plasma concentration of the 
compound to half of its original concentration[91].  The equation for defining half-life is  
t1/2 = 0.693 / k (14) 
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Bioavailability (F): Bioavailability refers to the fraction of the dose which gets into the 
circulatory system[94].  This parameter strongly depends on the rate of absorption at the 
site of administration[94].  By the intravenous route, 100 % of the dose is considered to 
be in the bloodstream[94].  A common way to determine the bioavailability of the other 
routes is by comparing the area under the curve (AUC) obtained from the intravenous 
route and the other route[91].   
Bioavailability = AUCother route / AUCIV (18) 
Salt factor (S): 
Salt factor, S is the active form of the compound as a salt or an ester.  If there is a 
compound with a salt factor of 0.8, it indicates 1 gram of the salt form of the compound is 
equal to 800 mg of the active compound[98]. 
Area under the Curve (AUC): AUC is found by plotting the concentration of plasma 
against a period of time[91]. 
Clearance (CL):  In general, clearance is a theoretical term, which relates the rates of 
elimination to the compound concentration in plasma at the site of measurement[91]. 
CL = Elimination rate of drug from the entire body / concentration 
From the physiological perspective, CL is the apparent volume of plasma present in the 
system, cleared of the compound per unit time by metabolic and elimination 
processes[91].  In multicompartmental models, the volume of distribution at steady state 
can be related to clearance by the equation 6[94].   
CLtotal = k x Vd (19) 
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Mathematically, CL is the elimination rate constant in which a portion of drug is 
constantly lost from the Vd as described in equation 6 above.  However, in most cases, 
the clearance and the volume of distribution are assumed to be independent of each 
other[94]. 
Steady State Concentration (CpSS):  A steady state is observed when multiple dosing is 
applied at a regular dosing interval, Т.  The condition is reached when the amount of 
compound applied to a body system is equivalent to the amount of compound that is 
eliminated from the system within the same time period.  By the route of intravenous 
infusion, steady state is also observable when the compound concentration in the plasma 
increases with time until it remains constant. 
Rate of compound administration = (S x F x D) / Т (20) 
Rate of compound elimination = CL x CpSS (21) 
When the two rates are equivalent, the following formula is useful for estimating 
the CpSS: 
CpSS = (S x F x D) / (CL x
 
Т) (22) 
As a result, one could use equation 9 to calculate CpSS[98]. 
Loading Dose (LD): The dose administered at the beginning of a treatment to reach the 
desired compound concentration in the body system[98]. 
The LD can be estimated by equation 10 assuming CpSS is the desired 
concentration to be reached. 
LD = Vd x CpSS (23) 
  
128 
Since LD is increasing exponentially inside the body system, the above equation is 
modified into: 
Cp = LD x exp(-kt) / Vd (24) [98] 
Maintenance dose: A dose that is used to offset the amount of compound that is being 
eliminated from the body.  The dose is administered by intravenous infusion[98]. 
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Appendix A2 Supplementary Data for the Validated Method 
In Table 1A, the weights of the analogues used for making the StockIS, the stock 
of each compound, and Stockmixed solutions are tabulated.  The procedure for preparing 
these stock solutions is described in the Method of Validation (See Section 3.7).  
Stockmixed was prepared by mixing samples of Thiamet-G, Thiampro-G, and Thiamme-G 
in one vial.  StockIS was prepared with Thiambu-G. 
Table 1A. Actual Weights of Each Analogue. 
 
Analogue Weight (ng) 
1 Thiamet-G 1.01220 x 107 
2 Thiampro-G 0.99446 x 107 
3 Thiamme-G 1.00440 x 107 
4 Thiambu-G (IS) 0.10180 x 107 
The six calibration standard solutions (CS) ranging from 2.5 to 5000 ng / mL 
were prepared from the Stockmixed according to Figure 1A.  The three different 
concentration levels of QC stock solutions at different concentrations (QCL = 62.5 ng / 
mL, QCM = 25000 ng / mL, and QCH = 50000 ng / mL) were also prepared from the 
stock solution.  
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Figure 1A. Dilution Scheme for Calibration standards. 
The dilution factors are indicated in the square brackets. 
The weights of Thiamet-G, Thiampro-G, and Thiamme-G in the CSSs samples 
are reported in Table 2A.  The weights of these compounds in the QC spiking stocks are 
reported in Table 3A.   
For preparing the internal standard, 5 mL of stockIS was added into a 100 mL 
volumetric flask.  The flask was made up to volume with water.  2 mL of the water 
mixture was transferred into a 10 mL volumetric flask, and it was made up to the volume 
with water.  The concentration of the prepared internal standard was 102 ng / mL. 
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Table 2A. Calibration Standard Solutions (CSSs). 
No. [Stock
1] 
(ng / mL) 
Volume 
transferred 
from 
[stock] 
(mL) 
Final 
volume 
(mL) 
Final 
[Thiamet-G] 
(ng / mL) 
Final 
[Thiampro-G] 
(ng / mL) 
Final 
[Thiamme-G] 
(ng / mL) 
Std 1 1.000 x 105 5.00 100.0 5.06 x 103 4.97 x 103 5.02 x 103 
Std 2 5.00 x 103 5.00 10.0 2.53 x 103 2.49 x 103 2.51 x 103 
Std 3 2.50 x 103 2.00 10.0 506 497 502 
Std 4 250 2.00 10.0 50.6 49.7 50.2 
Std 5 125 2.00 50.00 5.06 4.97 5.02 
Std 6 5.00 5.00 10.0 2.53 2.49 2.51 
1Stock concentration is the approximate concentration of each analogue present with the stock 
solution.  For example, for std 1 it is approximately 1.012 x 105 ng / mL of Thiamet-G, 0.9945 x 
105 ng / mL of Thiampro-G, and 1.004 x 105 ng / mL of Thiamme-G. 
Table 32A. QC Stocks. 
 
[Stock1] 
(ng / mL) 
Volume 
transferred 
from 
[stock] 
(mL) 
Final 
volume 
(mL) 
Final 
[Thiamet-G] 
(ng / mL) 
Final 
[Thiampro-G] 
(ng / mL) 
Final 
[Thiamme-G] 
(ng / mL) 
QCH 1.000 x 105 5.00 10.0 5.06 x 104 4.97 x 104 5.02 x 104 
QCM 5.00 x 104 5.00 10.0 2.53 x 104 2.49 x 104 2.51 x 104 
QCL 125 5.00 10.0 63.3 62.2 62.8 
1Stock concentration is the approximate concentration of each analogue present in the stock 
solution.  For example, for the stock solution for preparing the QCH stock it is approximately 1.012 
x 105 ng / mL of Thiamet-G, 0.9945 x 105 ng / mL of Thiampro-G, and 1.004 x 105 ng / mL of 
Thiamme-G. 
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Appendix A3 Supplementary Experiments on Different Types 
of Stationary Phases 
As discussed in Section 2.3.2 and 2.4.2, the data obtained using other columns are 
shown in this section. 
A3.1 Reverse Phase Columns 
A3.11 Phenomenex Synergi 2.5 µm Fusion-RP 100 Å with Guard Column  
The Synergi Fusion column uses a polar embedded C18 resin with suitable 
operating pH conditions ranging from 1.5 to 10.  The timerecommended elution on the 
Synergi Fusion column was 1.86 min.  In chromatogram (A) shown in Figure 2A, none of 
the analytes were efficiently retained when using water as the mobile phase, and co-
elution was observed for Thiampro-G and Thiambu-G.  In chromatogram (B), only 
Thiambu-G was retained efficiently when using 5 % ACN / H2O as the mobile phase.  
The ability for the column to retain these polar compounds under these conditions was 
poor.  Other chromatographic conditions have been tested for this column, but none of 
the conditions demonstrated that the Synergi Fusion column was capable of retaining and 
separating the analogues (data not shown). 
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Figure 2A. Attempted Separation and Analysis of the Analogues Using a Synergi Fusion 
Column. 
(Column: 3 x 50 mm; guard: 3 x 4 mm, flow rate: 200 µL / min, CVempty: 382 µL, 
Timerecommended: 1.86 min, sample: a mixed compound standard solution dissolved in 
water, elution with: 100 % H2O for chromatogram (A) and 5% ACN / H2O for 
chromatogram (B)). 
 The exocyclic nitrogen of the inhibitors have a pKa of 8.0[74].  At physiological 
pH or under acidic conditions, Thiamet-G and its analogues are in their protonated states.  
To favour deprotonation of the analytes, the pH of the mobile phase has to be above 
8[74].  When compounds are not in their ionised states, they become less polar and are 
likely to be more easily retained on reverse phase columns.  Nevertheless, use of an 
aqueous solution containing 100 % 10 mM CH3COONH4 at pH 8.3 as the mobile phase, 
illustrated in Figure 3A, did not improve the retention of the compounds and only 
Thiambu-G was retained on the column.  The effect of partially deprotonating the 
analogues was poor and the separation was even worse than when using the 
chromatographic conditions outlined for the data described in Figure 3A.   
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Figure 3A. Attempted Separation of the Analogues on the Synergi Fusion Column Using 
an Aqueous Mobile Phase, pH 8.3. 
The analysis was performed using an API 2000 LC-MS/MS system, and 100 % 10 
mM CH3COONH4, pH 8.3 was used as the mobile phase.  The sample is a mixed 
compound standard solution dissolved in water.  Only Thiambu-G was retained.  
The resolution of the analogues was poor, and peak tailing was observed.   
A3.12 Agilent Zorbax Eclipse XDB 
The Zorbax Eclipse column is a normal C18 column with operating pH conditions 
ranging from 2 to 9.  In chromatogram (A) shown in Figure A4, all analytes were retained 
except for Thiamme-G.  It took more than 8 min for Thiampro-G and Thiambu-G to elute 
from the column.  In chromatogram (B), only Thiambu-G was fully retained.  The 
separation shown in Figure 4A indicated that this column was not ideal for retaining all 
these analogues.  The column was tested previously with the usual concentration of the 
analytes used in these studies (1400 ng / mL) but detection of the analogues was very 
poor when using the API 2000 LC-MS/MS.  Hence, the concentration of analytes used in 
the LC-MS analyses reported in Figure 4A was increased to 2 mg / mL in order to 
determine the performance of the column.  The use of this column was not further 
pursued. 
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Figure 4A. Attempted Use of Zorbax Eclipse XDB Column for Separation of the Analytes.   
The analysis was performed using an API 2000 LC-MS/MS system.  (Column: 4.6 x 
150 mm; flow rate: 1 mL / min, CVempty: 2.49 mL, Timerecommended: 2.43 min, sample: a 
mixed compound standard solution dissolved in water, elution with: 100 % 10 mM 
CH3COONH4 at pH 8.3 for chromatogram (A) and 5% ACN / 10 mM CH3COONH4 at 
pH 8.3 for chromatogram (B)) 
A3.2 PGC Column 
A3.2.1 Thermo Scientific Hypercarb Column, 3µm, 200 Å 
The Hypercarb column is a porous graphite column (PGC).  When the 
hydrophobicity of the analytes increases, they are retained longer on a reverse phase 
column. Analytes behave similarly when using a Hypercarb column.  As shown in Figure 
5A, all four analytes were retained on the column, and they were well separated from 
each other.  Thiamme-G, being the most polar compound, was eluted first while 
Thiambu-G, being the least polar compound, was retained on the stationary phase for the 
longest time.  All four analogues have tall and narrow peak shapes.  The only concern 
was that background signals matching those for the MRM used for monitoring Thiambu-
G continued to increase after the elution of Thiambu-G.  The MS parameters were not 
optimized for this column because of the apparent instability of the column, which is 
discussed below. 
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Figure 5A. The PGC Column was able to Retain all Four Analytes. 
Analytes were separated with the PGC column.  In this figure, only the first seven 
min of the chromatogram are shown.  (Column: 3 x 50 mm; guard: 3 x 4 mm, flow 
rate: 600 µL / min, CVempty: 353 µL, Timerecommended: 0.57 min, sample: a mixed 
compound standard solution dissolved in water, separation conditions: Step 1) 0 
min, 600 µL / mL, 0 % B, Step 2) 5 min, 600 µL / mL, 21.1 % B, Step 3) 5.1 – 7.1 
min, 600 µL / mL, 94.7 % B, Step 4) 7.2 – 20.1 min, 600 µL / mL, 0 % B (A = 0.5 % 
FA + 5 % ACN + H2O, B = 0.1 % FA + ACN)) 
Stability of the Hypercarb Column 
A sample that was treated with plasma was injected into the analytical system 
connected to the Hypercarb column.  The sample cleanup procedure used was 
ultrafiltration.  A control sample, acting as a positive control, was also prepared by 
replacing the plasma with water.  A standard solution was also prepared by dissolving the 
four analogues into water.   
These three samples were injected into the system to measure the repeatability of 
the retention times of the analytes.  Aliquots of each sample were consecutively injected 
(n = 5) into the autosampler for the LC-MS/MS analysis.  Five aliquots of standard were 
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analysed first, then followed by five aliquots of the control samples.  Lastly, five aliquots 
of plasma samples were analysed.  The peak area responses and retention times of the 
analyses were computed in a statistical manner and are reported in Table 4A and Table 
5A.   
Before analysing the control and plasma samples, a standard solution was run to 
determine the stability of the system.  Five injections were made with the last four 
injections showing consistency in peak area responses and retention times.  As tabulated 
in Table 4A, the % RSD of the peak area counts and retention times were in all cases less 
than 5 % and 2 % respectively.   
Table 4A. Analyses of a Standard Solution. 
Peak Area RT 
Analyte Average 
(cps) SD 
% RSD 
(n = 4) 
Average 
(min) SD 
% RSD 
(n = 4) 
Thiambu-G 8.0 x 104 3 x 103 4 3.02 0.02 1 
Thiampro-G 6.9 x 104 2 x 103 2 2.10 0.02 1 
Thiamet-G 5.8 x 104 2 x 103 3 1.50 0.03 2 
Thiamme-G 4.4 x 104 1 x 103 3 0.98 0.02 2 
A total of five injections of the standard solution were made.  The data obtained by the first 
injection of the standard was ignored due to the significant differences in peak area responses 
and retention times when compared with the other four injections, which suggested the column 
was likely not appropriately equilibrated. 
As mentioned in Section 2.4.1, the desired % RSD for the peak area counts is less 
than 10 %, and the desired % RSD for the RT is less than 2 %.  For the control and 
plasma samples, the % RSD for both the peak area responses and the retention times are 
higher than 10 % and 2 % respectively (Table 5A).  The data suggest that the retention 
times became unstable after the introduction of the ultrafiltrated samples.  Statistical 
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analyses confirmed that the retention times of Thiamet-G and its analogues were 
inconsistent.  In summary, the Hypercarb column in combination with ultrafiltration was 
a poor candidate for column selection and further studies using this column were 
discontinued.  In addition, the time required to equilibrate the column (30 column 
volumes) was generally unsuitable for further method development. 
Table 5A. Analyses of the Ultrafiltrated Samples. 
Peak Area RT 
Types of 
Samples 
Average 
(cps) SD 
% RSD 
(n = 5) 
Average 
(min) SD 
% RSD 
(n = 5) 
Thiambu-G 
Control 8.7 x 104 1 x 104 1 x 101 3.2 0.1 3 
Plasma 6.4 x 104 2 x 104 2 x 101 3.20 0.09 3 
Thiampro-G 
Control 9 x 104 1 x 104 1 x 101 2.26 0.09 4 
Plasma 1.00 x 105 7 x 103 7 2.24 0.08 3 
Thiamet-G 
Control 7.8 x 104 8 x 103 1 x 101 1.66 0.10 6 
Plasma 8.9 x 104 7 x 103 8 1.63 0.08 5 
Thiamme-G 
Control 6.2 x 104 8 x 103 1 x 101 1.11 0.08 7 
Plasma 6.8 x 104 5 x 103 8 1.10 0.06 6 
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Appendix A4 Supplementary Results of using Different 
Sample Cleanup Procedures 
As discussed in Table 2.11, the data obtained with the various clean up methods 
are reported in this section. 
A4.1 Deproteinisation by Protein Precipitation  
A4.1.1 Deproteinisation by Protein Precipitation (TSKgel column) 
A4.1.1.1 MeOH as the Precipitant 
 In the chromatograms shown in Figure 6A, MeOH was used to precipitate 
proteins that were present in the plasma sample.  The mobile phase and the test article 
contained 80 % ACN and 90 % MeOH respectively.  Since MeOH and ACN have 
polarity indexes of 5.1 and 5.8, respectively[156], ACN is slightly more polar than 
MeOH[156].  Chromatograms (A) and (B) showed a striking difference in the peak 
shapes for all the analytes.  Due to the interaction between the more polar mobile phase 
and the MeOH in the test article, it was hard to explain the differences observed in the 
chromatograms.  Thus, the organic solvent in the test article should match with the 
organic solvent in the mobile phase to produce interpretable results, yet this was not the 
case.  It is possible the analytes interact better than intended with MeOH through 
hydrogen bonding.  In any event, MeOH was abandoned as a potential precipitant. 
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Figure 6A. Attempted Separation of the Analytes Using MeOH as a Precipitant for Sample 
Clean up.   
Supernatants that were collected after protein precipitation were separated with the 
TSKgel column and analysed using the MS.  Analysis of the control and the plasma 
samples are reported in chromatogram (A) and (B) respectively.   
A4.1.1.2 ACN as the Precipitant (TSKgel Column) 
In the chromatograms illustrated in Figure 7A, ACN was used to precipitate 
proteins that were present in the samples.  In chromatogram (A), Gaussian peak shapes 
was observed for the analytes in the control sample.  In chromatogram (B), suppression 
that was caused by matrix ions was seen for the peaks arising from Thiamet-G and 
Thiamme-G.   
 
Figure 7A. Attempted Separation of the Analytes using ACN as a Precipitant for Sample 
Clean up. 
Supernatants, collected after precipitation, were analysed using a TSKgel column 
and analysed with the MS.  Analysis of the chromatograms of the control and the 
plasma samples are shown in (A) and (B) respectively.   
By comparing the retention times of the analyte in the two chromatograms, one can see 
that the retention time of Thiamme-G has shifted by 8 % (Figure 7A).  This result 
suggests that ions present in the plasma might interfere with the analytes and cause 
deviations in the elution time.  Severe suppression was observed for Thiamet-G and 
Thiamme-G.  In Table 6A, the suppression of analogues caused by the matrix ions is 
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reported in a percent ratio, the % matrix suppression.  The deformation of the peak 
shapes in the plasma sample is also summarised in the last column. 
Table 6A. Comparison of the Peak Characteristics from the Chromatograms Shown in 
Figure 7A. 
Analyte 
Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak Shape of 
the Plasma 
Sample 
Thiamet-G 1.92 x 106 *4.40 x 105 22.9 % Heavily 
suppressed 
Thiambu-G 2.05 x 106 1.99 x 106 97.1 % N/A 
Thiampro-G 2.06 x 106 1.24 x 106 60.2 % Sharpened 
Thiamme-G 1.54 x 106 *7.24 x 105 47.0 % Slight 
suppression 
% Matrix suppression = peak area of (plasma /control) x 100 %. 
* = manual integration was used to integrate the peak area counts. 
Q1 Scan Analyses 
Many peaks were observed in the Q1 chromatogram of the plasma sample, but 
these ions were not observable during analysis of the control sample.  The response for 
both Thiamet-G and Thiampro-G was impaired by elution along with the species giving 
rise to this same cluster of peaks, with 430.8 m/z as the representative peak.  The cluster 
as shown in Figure 8A chromatogram (A) extended from 100 m/z all the way to 2400 
m/z.  Many isotopic peaks were observed as shown in chromatogram (B).  Another 
cluster of peaks, with a representative peak at 431.1 m/z, had a pattern showing a 
repeating difference of 68 Da (chromatogram not shown).  These clusters of ions likely 
suppressed ionisation of Thiamme-G.   
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These data support the fact that there were indeed matrix ions causing the 
suppression observed for all the analytes, except for Thiambu-G.  Hence, protein 
precipitation alone was not capable of efficiently removing interfering matrix ions. 
 
Figure 8A. Ion Clusters that Appear to Interfere with Ionisation of Thiamet-G and 
Thiampro-G. 
Chromatogram (A) shows the pattern of an interfering cluster with 430.8 m/z as the 
representative peak.  Chromatogram (B) was the expanded version of 432.9 m/z.  
(Sample: plasma sample collected after protein precipitation, Scan type: Q1 scan). 
A4.1.2 Deproteinisation by Protein Precipitation (ZIC-HILIC column) 
A4.1.2.1 ACN as the Precipitant (Initial Experiment) 
The protein precipitated samples, using ACN as the precipitant, were analysed 
using a ZIC-HILIC column.  In Figure 9A chromatogram (A), Gaussian peak shapes 
were observed for all analytes in the control sample.  In chromatogram (B), suppression 
caused by matrix ions was seen for the peaks corresponding to Thiamet-G and Thiamme-
G.   
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Figure 9A. Attempted Separation of the Analytes using ACN as a Precipitant for Sample 
Clean up. 
Analytes were separated using a ZIC-HILIC column and analysed using the MS.  
The control and the plasma samples are reported in chromatogram (A) and (B) 
respectively.   
As reported for the % matrix suppression in Table 7A, suppression was found for 
Thiampro-G and Thiamme-G, with Thiamme-G being suppressed heavily.  Enhancement 
of ionisation was observed for Thiambu-G.  The retention times of all analytes were 
shifted earlier, with Thiamme-G shifted the most. 
Table 7A. Peak Characteristics of the Analogues from the Chromatograms Shown in 
Figure 9A. 
Peak Area 
Analyte Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak Shape of 
the Plasma 
Sample 
Thiamet-G 1.55 x 106 1.70 x 106 110 % Sharpened 
Thiambu-G 1.59 x 106 2.28 x 106 143 % Sharpened 
Thiampro-G 1.62 x 106 1.03 x 106 63.6% Suppressed 
Thiamme-G 1.36 x 106 6.63 x 105 48.8% Sharpened 
% Matrix suppression = peak area of (plasma /control) x 100 %. 
The analysis was carried out when the column was used for a brief period of time. 
Q1 Scan Analysis 
The same matrix ions as reported in Section A4.1.2, were observed in the plasma 
sample when the sample was analysed using a ZIC-HILIC column.  Thiamme-G was 
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found to co-elute with the clusters of ions having a representative 430.8 m/z.  Some new 
matrix ions were detected when the analysis was performed on the TSKgel column due to 
the different elution time of these matrix ions and the compounds.  The matrix ions, such 
as those having 524.4 and 496.5 m/z, were found to co-elute with Thiambu-G and 
Thiamme-G.  Based on a literature search, these ions could be phospholipids[157].  The 
protein precipitation experiment was repeated in Section A 4.1.2.2 
A 4.1.2.2 ACN as the Precipitant (Repeated Experiment) 
Samples prepared using the same procedure as used for the samples analysed in 
Figure 9A were injected into the autosampler for LC-MS/MS analysis equipped with a 
ZIC-HILIC column.  In the experiment the column had been conditioned and this enabled 
a comparison of the effect of this conditioning on performance of this clean up method.  
In chromatogram (A) of Figure 10A, Gaussian peak shape was observed for the analytes 
in the control sample.  Based on the % matrix suppression reported in Table 8A, 
Thiambu-G and Thiamme-G were found to be suppressed, with minor suppression 
observed for Thiamme-G.   
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Figure 10A. Another Attempt of Separating the Analytes using ACN as a Precipitant for 
Sample Clean up, Using a Conditioned ZIC-HILIC Column 
The control and the plasma samples are reported in chromatogram (A) and (B) 
respectively.   
Table 8A. Peak Characteristics of the Analogues in the Chromatograms Shown in Figure 
10A (after Partial Conditioning of a ZIC-HILIC Column). 
Analyte 
Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak Shape of 
the Plasma 
Sample 
Thiamet-G 1.91 x 106 2.15 x 106 113 % Sharpened 
Thiambu-G 2.08 x 106 1.26 x 106 60.6 % Sharpened 
Thiampro-G 2.03 x 106 2.09 x 106 103 % Suppressed 
Thiamme-G 1.53 x 106 1.35 x 105 88.2 % Sharpened 
% Matrix suppression = peak area of (plasma / control) x 100 % 
The analysis was carried out with the column in use for awhile. 
Behaviour of the ZIC-HILIC Column  
 There were some noticeable differences in the behaviour of the ZIC-HILIC 
column prior to conditioning (as illustrated in Figure 9A) and when it had been 
conditioned by extended use (as illustrated in Figure 10A).  In Figure 9A, the control 
sample was analysed, followed by analysis of nine samples before analysis of the plasma 
sample.  The nine samples analysed were the SS and plasma samples.  All the analytes in 
chromatogram (B) of Figure 9A eluted earlier than in chromatogram (A).  In the case of 
the chromatograms reported in Figure 10A, the control and plasma samples were 
analysed almost one after the other and after extensive conditioning of the column.  The 
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retention times of the same analytes in both chromatograms were similar.  It seems that 
when using the ZIC-column, the retention time of the analytes would shift depending on 
whether the column was conditioned.  Suppression observed in the plasma sample, 
reported in chromatogram (B) of Figure 10A, was not as severe as in the case of the 
corresponding sample reported in Figure 9A.  Severe suppression was only observable 
when the column was first being used, further suggesting that conditioning of the column 
was important. 
A4.2 Altering the Mobile Phase 
 Changing the mobile phase is a possible way to alter the elution times of the 
matrix ions and the analytes and therefore to perhaps eliminate matrix suppression.  In 
this experiment, the samples for the analysis were the protein precipitated samples using 
methanol as the precipitant.  These samples were separated using a TSKgel column and 
analysed using the MS.  The mobile phase was changed from 80 % ACN to 100 % 
MeOH.  This could also be beneficial for samples obtained using MeOH as a precipitant 
because the mobile phase and solvent containing the analyte would be similar. 
A4.2.1 MeOH as the Mobile Phase 
 The MRM chromatogram (A) of Figure 11A suggests that there was no 
interaction between the analytes and the stationary phase. With final composition of the 
sample being less polar than the mobile phase, the analytes eluted out without being 
retained on the column.  The possible reason was that MeOH in the mobile phase 
interacted with the hydroxyl groups of the ions to obstruct with the binding of the 
analytes to the stationary phase. 
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Figure 11A. Attempted Separation of the Analytes using the TSKgel column with MeOH as 
the Mobile Phase.   
In chromatogram (A) of Figure 11A, a standard solution that was dissolved in 90 % 
MeOH / H2O was injected into the system with 0.1% FA + 80% MeOH / H2O as the 
mobile phase.  In chromatograms (B) and (C), the control (B) and the plasma (B) 
samples were prepared with 90 % MeOH / H2O, and the mobile phase was 0.1% FA 
+ MeOH. 
As discussed in Section 2.3.3.1, the Trecommended for the TSKgel column is 2.45 
min.  In chromatogram (A), none of the analytes was retained.  In chromatogram (B), two 
of the analytes, Thiamet-G and Thiamme-G were retained while Thiampro-G was 
partially retained.  This chromatogram shows that the matrix alters the retention time of 
the analytes.  Presumably by altering the interaction between the eluent and the analytes 
or by affecting the stationary phase.  This data also indicate that the eluent might interact 
with the matrix ions, or the matrix ions might have formed a complex with the ions.  For 
either reason, the separation of the analytes has changed making this an inappropriate 
approach.  A similar observation was made when the precipitant of the samples was 
changed to ACN (data were not shown). 
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Summary of the Q1 Scan Analysis 
With the mobile phase composed of MeOH, the elution of the matrix ions in the 
plasma sample changed in comparison to using ACN in the mobile phase.  The 430.8 m/z 
cluster, which happened to interfere with Thiamet-G and Thiampro-G, was found to elute 
at the beginning of the run.  The other cluster, with 431.1 m/z as the representative peak, 
eluted at 2.154 min.  This set of ions have mass differences of 68 Da cluster was 
suppressed by the 430.8 m/z cluster, and its elution was also hastened when MeOH was 
present in the eluent.  Another matrix ion having 132.3 m/z was also apparent at the 
beginning of the run.  These matrix ions tended to elute at the middle or at the end of the 
run when ACN was used in the mobile phase.  A similar observation was made for the 
matrix ions when the precipitated samples were analysed using a ZIC-HILIC column 
(data not shown).  Since some matrix ions co-eluted with the analytes, it was crucial to 
try other sample preparation procedures before doing any further analysis on the MS. 
A4.2.2 ACN as the Mobile Phase 
In Figure 12A, 99.9 % of ACN was used as the mobile phase.  No analyte eluted 
during the run due to the absence of water in the mobile phase.  None of the analytes 
eluted in both the MRM chromatograms of the control and plasma samples (only the 
plasma sample was shown in Figure 12A.)  In the Q1 scan analysis, no other matrix ions 
were found, except for 118.2 m/z (data not shown).  This finding suggests that most of 
the matrix ions are polar.  The elution of the unretained analytes with 99.9 % MeOH as 
the mobile phase (A 4.3.1) supported the fact that MeOH interacts with the analogues. 
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Figure 12A. Attempted Separation of the Analytes using the TSKgel column with ACN as 
the Mobile Phase.  
Plasma sample with final composition of 90 % ACN / H2O was injected into TSKgel 
column and analysed in MS.  The mobile phase was 0.1 % FA + ACN.  A minimal 
amount of Thiamet-G eluted during the run. 
A4.3 Deproteinisation by Ultrafiltration  
A4.3.1 Deproteinisation by Ultrafiltration (TSKgel column) 
 Since protein precipitation as the sample preparation procedure resulted in test 
article that still had high levels of interference, it was important to try other 
deproteinisation processes.  Removal of protein by using a size exclusion filter is a 
common process which traps proteins in the filter while obtaining the small compounds 
in the filtrate. 
Samples were analysed using ultrafiltration.  In chromatogram (A) of Figure 13A, 
Gaussian peak shapes were observed for the analytes.  For the plasma sample, as 
illustrated in chromatogram (B), severe suppression was observed for both Thiamet-G 
and Thiamme-G.  Differences in retention times between the control and plasma samples 
were noted for Thiamet-G and Thiamme-G. 
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Figure 13A. Attempted Separation of the Ultrafiltrated Analytes. 
Samples were cleaned up using ultrafiltration and the final solvent composition was 
90 % ACN / H2O.  Analytes were separated using a TSKgel column and analysed by 
LC-MS/MS.  The mobile phase was 0.1 % FA + 80 % ACN / H2O.  Data for the 
control and the plasma samples are reported in chromatogram (A) and (B) 
respectively.   
As indicated by the % matrix suppression shown in Table 9A, the ionisation of all the 
compounds was affected by the matrix of the plasma sample, except for Thiampro-G.   
Table 9A. Peak Characteristics of the Analogues of the Chromatograms in Figure 13A. 
Peak Area 
Analyte Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak Shape 
of the 
Plasma 
Sample 
Thiamet-G 1.20 x 106 *4.19 x 105 34.9 % Suppressed Severely 
Thiambu-G 1.46 x 106 1.25 x 106 85.6 % 
Lower 
Intensity 
than 
Thiampro-G 
Thiampro-G 1.45 x 106 1.42E x 106 97.9 % Slightly Sharpened 
Thiamme-G 8.93 x 105 *4.75 x 105 53.2 % 
Severely 
Suppressed  
% Matrix suppression = peak area of (plasma /control) x 100 % 
* = manual integration was used to integrate the peak area counts 
Summary of the Q1 Scan Analysis 
 Based on the analysis on the Q1 mass spectra, the major matrix ions likely 
contributing to suppression of Thiamet-G and Thiamme-G were the 430.8 m/z cluster and 
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431.1 m/z cluster respectively.  Other major matrix ions had 118.2, 132.3, and 162.3 m/z.  
Thus, the matrix affected the ionisation of some analytes, and the process of 
ultrafiltration alone was not capable of removing these matrix ions.  The use of 
ultrafiltration for clean and TSKgel column for analysis was therefore inappropriate. 
A4.3.2 Deproteinisation by Ultrafiltration (ZIC-HILIC column) 
 As shown in Figure 14A, samples were cleaned up by passing through ultrafilters 
before analysis using the LC-MS/MS.  The chromatographic conditions were modified to 
include a wash cycle to remove matrix ions that were possibly present in the column after 
eluting the targeted analytes.  Earlier data in Section A4.2.1, confirmed that samples did 
not have stable retention times when separated using a ZIC-HILIC column.  Removal of 
the matrix ions that were left behind in the column could prevent the interference of these 
matrix ions with analytes present in the next injected sample.  An online wash cycle was 
therefore incorporated into the LC program. 
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Figure 14A. Attempted Separation of the Ultrafiltrated Analytes Using an Online Wash 
Cycle. 
Samples analysed in chromatogram (A) and (B) were cleaned up with ultrafilters and 
analysed by LC-MS/MS.  The final sample composition was 90 % ACN / H2O and 
analytes were separated using a ZIC-HILIC column.  The mobile phase was 0.1 % 
FA + 85 % ACN / H2O.  Data for the control and the plasma samples are reported in 
chromatogram (A) and (B) respectively.   
 In chromatogram (A) of Figure 14A, Gaussian peak shapes were observed for all 
the analytes.  In chromatogram (B), suppression caused by matrix ions was seen for 
Thiamme-G.  The % matrix suppression of Thiamme-G (in Table 10A) was calculated to 
be less than 40 %.  This suggests that some substance co-eluted with this analyte and 
caused serious ion suppression despite the online wash cycle.  The difference in the 
retention times of Thiamme-G between control and plasma samples indicated that there 
was need for further sample cleanup.  It was not known why the percent peak area for 
Thiambu-G and Thiamet-G were so high, but the % matrix suppression for Thiampro-G 
was reasonable. 
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Table 10A. Peak Characteristics of the Analogues in the Chromatograms of Figure 14A. 
Peak Area 
Analyte Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Deformation in 
Peak Shape of the 
Plasma Sample 
Thiamet-G 5.32 x 105 7.32E x 105 138 % Enhanced 
Thiambu-G 5.82 x 105 7.42 x 105 127 % Enhanced 
Thiampro-G 5.72 x 105 6.23 x 105 109 % N / A 
Thiamme-G 3.79 x 105 *1.30 x 105 34.3 % Severe Suppression 
% Matrix suppression = peak area of (plasma /control) x 100 % 
* = manual integration was used to integrate the peak area counts 
Q1 Scan Analysis 
Interestingly, in the Q1 scan analysis, ion clusters having representative ions with 
430.8 m/z and 431.1 m/z were not detected during the elution time frame of all the 
analytes (data not shown).  The substance that co-eluted with Thiamme-G cannot be 
detected using the Q1 scan analysis.  The results demonstrate that under these 
chromatographic conditions involving a wash cycle, some of the matrix ions were 
removed from the column prior to the injection of the next sample.  Overall, however, 
this sample clean up method still was inappropriate for further development. 
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Stability of Retention Times when Using a ZIC-HILIC Column 
 As shown in Table 11A, the % RSD of the retention times of standard, control, 
and plasma samples are summarised.  With the incorporation of a wash cycle in the run, 
the shifting of the retention times of the analytes was reduced.  The % RSD of the 
retention times was generally lower than 2 %.  The low % RSD of the retention times for 
the standard solution indicated that the column was stable.  Because Thiamet-G eluted 
earlier in the plasma sample than in the control sample, it is likely that some matrix ions 
co-elute with it.  Nevertheless, as mentioned above, a better sample preparation process is 
necessary to improve the sample analyses. 
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Table 11A. The % RSD of the RT of SS, the Control, and Plasma Samples. 
Thiambu-G Average 
RT (min) 
% RSD Thiamet-G Average 
RT (min) % RSD 
Control Sample 3.22 0.63 Control Sample 5.84 1.01 
Plasma 
Sample 3.23 0.99 Plasma Sample 5.85 0.96 
*SS 3.21 0.80 *SS 5.83 0.98 
^Sum 3.23 0.83 ^Sum 5.85 0.94 
  
Thiampro-G 
Average 
RT (min) % RSD Thiamme-G 
Average 
RT (min) % RSD 
Control Sample 4.20 0.73 Control Sample 8.72 1.35 
Plasma 
Sample 4.20 0.93 Plasma Sample 7.58 1.21 
*SS 4.19 0.96 *SS 8.71 1.01 
^Sum 4.20 0.80 ^Sum 8.15 7.37 
Two sets of control and plasma samples were prepared, and they were injected into the MS 
twice.   
*SS = during the run, SS was run after the analyses of every three samples.  The % RSD of the 
standard was also calculated. 
^Sum = the sum of the % RSD of the RT of the control samples and the plasma samples was 
also calculated. 
A4.4 Protein Precipitation + LLE 
A4.4.1 Ultrafiltration + LLE (TSKgel column) 
 A different approach was attempted using ultrafiltration and liquid-liquid 
extraction.  After the samples were cleaned up by ultrafiltration, the collected filtrates 
were extracted with DCM and the aqueous phase was analysed.  In chromatogram (A) of 
Figure 15A, Gaussian shapes were observed for the analytes present in a control sample 
of analogues lacking plasma.  In chromatogram (B), when matrix ions were present, 
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distortion in peak shape was observed for Thiamet-G and Thiamme-G.  In Table 12A, 
missing peak area counts are observable for Thiamet-G and Thiamme-G.  This sample 
cleanup process did not improve the ionisation of the compound ions. 
 
Figure 15A. Analysis of Samples of Analytes that were Cleaned up by Ultrafiltration and 
LLE Using the TSKgel column. 
Samples were passed through ultrafilters and the collected filtrates were extracted 
with DCM.  The final solvent composition was 90 % ACN / H2O.  The mobile phase 
was 0.1 % FA + 80 % ACN / H2O.  Upon centrifugation, the supernatants were 
injected into the autosampler for MS analysis.  Chromatogram (A) and (B) of the 
above figure are the control and the plasma samples respectively. 
Table 12A. Peak Characteristics of the Analogues of the Chromatograms in Figure 15A. 
Peak Area 
Analyte Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak Shape of 
the Plasma 
Sample 
Thiamet-G 1.07 x 106 *3.78 x 105 35.3 % 
Suppressed 
Severely 
Thiambu-G 1.37 x 106 1.15 x 106 83.9 % 
Lower Intensity 
than Thiampro-
G 
Thiampro-G 1.34 x 106 1.29 x 106 96.3 % N / A 
Thiamme-G 7.83 x 105 4.79 x 105 61.2 % Sharpened 
% Matrix suppression = peak area of (plasma /control) x 100 % 
* = manual integration was used to integrate the peak area counts 
A4.4.2 Ultrafiltration + LLE (ZIC-HILIC) 
In this experiment, samples were cleaned up by ultrafiltration.  Half of the filtrate 
of each sample was saved for analysis, and half of the filtrate was extracted with DCM.  
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In chromatogram (A) of Figure 16A, Gaussian peak shapes are observed for the analytes.  
In chromatogram (B), when matrix ions were present, no distortion in peak shape was 
observed.   
 
Figure 16A. Attempted Separation of the Analytes that were Cleaned up by Ultrafiltration 
and LLE Using the ZIC-HILIC Column. 
Samples were passed through ultrafilters and the collected filtrates were extracted 
with DCM.  The final solvent composition was 90 % ACN / H2O.  The mobile phase 
was 0.1 % FA + 85 % ACN / H2O.  Upon centrifugation, the collected water portions 
were separated with the ZIC-HILIC column and were analysed in the MS. 
However, the peak area counts for Thiamet-G and Thiamme-G were higher when 
compared to the corresponding peaks observed during analysis of the control sample.  
The comparison is reported in Table 13A.  A stable retention time was observed for all 
the analytes. 
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Table 13A. Peak Characteristics of the Analogues of the Chromatograms in Figure 16A. 
Peak Area 
Analyte Control 
Sample 
(cps) 
Plasma 
Sample 
(cps) 
% Matrix 
suppression 
Peak 
Shape of 
the Plasma 
Sample 
Thiamet-G 3.96 x 105 5.06 x 105 128 % 
Higher in 
Intensity 
Thiambu-G 4.16 x 105 4.18 x 105 101 % N/A 
Thiampro-G 4.05 x 105 4.70 x 105 116 % 
Higher in 
Intensity 
Thiamme-G 3.54 x 105 5.65 x 105 160 % 
Higher in 
Intensity 
In Table 14A, the % recovery data are reported for both for the samples that have 
passed through the ultrafilters followed by extraction with DCM (Table a) and the 
samples that have just passed through the ultrafilters (Table b).  By using the same 
standard solution for comparison, one can observe that the peak area counts obtained for 
the control and plasma samples were lower when the extraction process was carried out 
using DCM.  Compounds are likely lost during the extraction process making this process 
inappropriate for further development. 
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Table 14A. Comparison of Response for the Analogues in the Standard Solution, the 
Control, and the Plasma Samples. 
a) % Recovery for Samples (Ultrafiltration + LLE) 
Peak Area (cps) % Recoverycontrol % Recoveryplasma 
Analyte 
Standard Control Sample 
Plasma 
Sample 
Control Sample / 
standard 
Plasma Sample / 
standard 
Thiambu-G 6.04 x 105 4.16 x 105 4.18 x 105 68.9 % 69.2 % 
Thiampro-G 6.20 x 105 4.05 x 105 4.70 x 105 64.8 % 75.8 % 
Thiamet-G 6.58 x 105 3.96 x 105 5.06 x 105 60.2 % 76.9 % 
Thiamme-G 6.56 x 105 3.54 x 105 5.65 x 105 54.0 % 86.1 % 
b) % Recovery for Samples (Ultrafiltration) 
Peak Area (cps) % Recoverycontrol % Recoveryplasma 
Analyte 
Standard Control Sample 
Plasma 
Sample 
Control Sample / 
Standard 
Plasma Sample / 
Standard 
Thiambu-G 5.59E+05 5.28 x 105 5.27 x 105 94.5 % 94.3 % 
Thiampro-G 5.68E+05 5.19 x 105 6.00 x 105 91.4 % 106 % 
Thiamet-G 5.75E+05 4.99 x 105 6.27 x 105 86.8 % 109 % 
Thiamme-G 5.48E+05 4.46 x 105 7.19 x 105 81.4 % 131 % 
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Appendix A5 Supplementary Results of using Further Sample 
Preparation Procedures in Conjunction with Different Columns 
A5.1 Ultrafiltration + Zip tipC18 
From a plasma sample that was cleaned up by ultrafiltration the collected filtrate 
was divided into two portions.  One portion was directly injected onto the analytical 
system for the LC-MS/MS analysis, and the other portion was further cleaned up using 
the C18 ziptip.  Chromatogram (A) in Figure 17A was produced by analysing the filtrate 
that was obtained by using only ultrafiltration.  For chromatogram (B), the samples were 
analysed using the portion of the filtrate that was further cleaned up using a ziptip. 
The two resulting samples have the same final solvent composition, and the 
analogues have the same final concentrations.  Comparing the two chromatograms side 
by side, one can easily observe that the less polar compounds, Thiambu-G, Thiampro-G, 
and Thiampro-G, are much less intense in chromatogram (B).  The purpose of cleaning 
the filtrate with ziptip was to remove the possible hydrophobic interferences present in 
the samples.  The results have demonstrated there was a poor recovery of the analytes 
after this treatment and this approach was not pursued further. 
 
 
  
161 
 
Figure 17A. Analysis of Zip tip Cartridge Clean up of Analyte Samples. 
The final sample composition was 90 % ACN / H2O and analytes were separated 
using a ZIC-HILIC column.  The mobile phase was 0.1 % FA + 85 % ACN / H2O.   
In chromatogram (A), the plasma sample was cleaned up by passing it through an 
ultrafilter.  In chromatogram (B), the filtrate obtained from the ultrafilter was further 
cleaned up by ziptip. 
A5.2 Protein Precipitation Followed by the Sigma Hybrid SPE 
 A set of control and plasma samples underwent protein precipitation using ACN 
and half of the supernatants from both the control and plasma samples were analysed by 
LC-MS/MS analyses using a ZIC-HILIC column.  The supernatant of the control sample 
was labeled as B1 in Table 15A whereas the supernatant of the plasma sample was 
labeled as B3.  The remainder of each supernatant was passed through Sigma Hybrid SPE 
cartridges.  This SPE cartridge is reported to be able to remove phospholipids from 
plasma samples[157].  The supernatant from the control and the plasma samples that 
were cleaned up by the SPE cartridges were labeled as B1 (II) and B3 (II), respectively. 
 The peak area responses observed for the protein precipitated samples, and the 
samples that were cleaned up with the SPE Hybrid SPE cartridges, are reported in Table 
15A.  In Table 16A, a comparison of these peak area responses are made.   
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Table 15A. Analyte Response of Protein Precipitated Samples versus the SPE Hybrid SPE 
Cartridges. 
Peak Area (cps) 
Analyte 
Control Sample 
(B1) 
Plasma Sample 
(B3) 
Control Sample 
(B1 II) 
Plasma Sample 
(B3 II) 
Thiambu-G 5.26 x 105 6.62 x 105 6.06 x 105 4.44 x 105 
Thiampro-G 5.06 x 105 7.58 x 105 4.99 x 105 4.34 x 105 
Thiamet-G 4.87 x 105 7.54 x 105 4.66 x 105 3.99 x 105 
Thiamme-G 4.50 x 105 6.89 x 105 6.42 x 105 7.02 x 105 
In the first column of Table 16A, B1 was compared with B3 by dividing the peak 
area counts of B3 by B1.  The reported percentages provide insight into the % matrix 
effect.  These percentages, which were far from 100 %, suggest that ionisation 
enhancement is occurring as a result of the clean up procedure or, alternatively the high 
viscosity of the plasma sample caused some sampling variation in this experiment.  
Comparison between B1 (II) and B1 yields % recovery, which is a calculation of the 
efficiency of the sample extraction process.  These samples were not treated with plasma 
before the sample extraction process.  The % recovery for all the compounds were nearly 
100 %, except for Thiamme-G.  The high % recovery for Thiamme-G suggests that there 
might some leaching materials from the cartridge, which shares the same MRM transition 
as Thiamme-G.  It is possible the high % matrix effects are caused by leaching of 
materials when matrix is present and these might have similar MRM transitions.  Another 
way to calculate % recovery is to compare B3 (II) with B3.  The recoveries of the 
analogues were low.  In the last column, B3 (II) was compared with B1 (II).  By dividing 
the peak area responses of B3 (II) with the peak area responses of B1 (II) the % matrix 
effect was evaluated.  The reported percentages suggest that the ionisation of the 
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analogues was poor.  In summary, the concentrations of the analogues were high when 
using Hybrid SPE cartridges as a sample clean up tool.  This effect discouraged us from 
pursuing this approach further. 
Table 16A. The % Matrix Effect and % Recovery. 
Analyte B3 vs B1 B1 (II) vs B1 B3 (II) vs B3 B3 (II) vs B1 (II) 
Thiambu-G 126% 115% 67.1% 73.3% 
Thiampro-G 150% 98.6% 57.3% 87.0% 
Thiamet-G 155% 95.7% 52.9% 85.6% 
Thiamme-G 153% 143% 102% 109% 
A5.3 Protein Precipitation Followed by Captiva Cartridge Clean up 
 A different SPE method was attempted in combination with protein precipitation.   
A set of control and plasma samples was cleaned up using Captiva Cartridge after going 
through the process of protein precipitation.  A standard solution composed of 10.5 ng / 
mL was also prepared to act as a reference standard for analysing the extraction 
efficiency and the matrix suppression effect for the plasma sample.  In Table 17A, the 
peak area responses of the analogues for all three samples are tabulated.   
Table 17A. Peak Area Responses for the Analytes. 
Peak Area 
Analyte Control Sample 
(cps) 
Plasma Sample 
(cps) Standard (cps) 
Thiambu-G 1.52 x 105 1.48 x 105 1.71 x 105 
Thiampro-G 1.62 x 105 1.60 x 105 1.81 x 105 
Thiamet-G 1.53 x 105 1.55 x 105 1.78 x 105 
Thiamme-G 1.20 x 105 5.85 x 104 1.59 x 105 
  
164 
 The % recovery and % matrix suppression are calculated and reported in Table 
18A.  The recoveries of the analytes in the control sample are higher than 80 % with 
Thiamme-G being the exception.  For the case of the plasma sample, the recoveries of the 
analogues are similar to the control samples except with Thiamme-G which is only 37 %.  
The % matrix suppression is close to 100 % for Thiamet-G, Thiampro-G, and Thiambu-
G.  For the case of Thiamet-G, the % matrix suppression is reported to be 48.8 %.  The 
result suggests that either the ionisation of Thiamet-G was poor or the cartridge retained 
some of this compound. 
Table 18A. The % Recovery and the % Matrix Suppression of the Captiva Treated 
Samples. 
% Recovery 
Analyte 
Control Sample 
(cps) 
Plasma Sample 
(cps) 
% Matrix 
Suppression 
Thiambu-G 88.9% 86.5% 97.4% 
Thiampro-G 89.5% 88.4% 98.8% 
Thiamet-G 86.0% 87.1% 101% 
Thiamme-G 75.5% 36.8% 48.8% 
When analysing the samples using the Q1 scan, more problems were observed 
when using the captive cartridge as the clean up device.  Phospholipids were observed in 
the plasma sample.  Many other ions of unknown origin and identity were observed to 
elute prior to the analogues.  These observations suggest that the captive cartridge might 
not be compatible with the organic mixture, resulting in the leaching of bulk material 
from the cartridge.  This approach was ultimately abandoned in preference to the 
optimized method that was ultimately established. 
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Appendix A6 Method Section 
A6.1 Method A1: Synergi Fusion Column – 4000 QTRAP (Figure 2A) 
The method was similar to the generic method for the 4000 QTRAP LC/MS 
system (See Section 2.5.2) with the following changes:   
Instrumentation.  The analytical column for the analysis, Phenomenex Synergi 
Fusion-RP (2.5 µm, 50 x 3 mm ID), was protected by a guard column (Phenomenex 
Security Guard cartridge, 4 x 3 mm ID).  The mobile phase, 0.1% FA + H2O, was 
pumped at a flow rate of 200 µL / min for chromatogram (A) illustrated in Figure 1A.  
The mobile phase for generating chromatogram (B) was 0.1% FA + 5% ACN + H2O.   
Preparation of Standards.  Stock solutions for Thiamet-G, Thiambu-G, 
Thiampro-G, and Thiamme-G (conc. = 70000 ng / mL)* were prepared separately in 
water, 30 µL from each stock solution was added to water to yield mixed compound 
standard solution D (210 ng / mL), which was stored in an HPLC vial at 4 oC until 
required. 
Analytical Procedure.  3 µL of standard solution D was injected by the 
autosampler of the LC–MS/MS system.  With the HPLC pump pumping the mobile 
phase, the sample was delivered into the turbo ion spray ion source.  In the acquisition 
method, the MRM transitions were set according to Table 2.2, and the dwell time was set 
as 200.00 µsec.  The resolution for Q1 was set at 1 unit mass resolution and Q3 was set to 
be low mass resolution.  A positive ionisation mode was set in the acquisition method, 
the other parameters were CUR (30.00 psi), ISP (4500.00 V), TEM (150.00 oC), GS1 
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(20.00 psi), GS2 (20.00 psi), DP (50.00 eV), CAD (7.00 psi), EP (6.00 V), CE (32.00 V), 
and CXP (10.00 V). 
*The stock concentration is approximately (70000 ng / mL of each analogue).  
Throughout the methods, the stock concentration is given as approximate for the ease of 
discussion. 
A6.2 Method A2: Synergi Fusion Column – API 2000 (Figure 3A) 
The method was similar to the generic method for the API 2000 LC-MS/MS 
system (See Section 2.5.2) with the following changes:   
Chemicals and reagents.  Reagent grade glacial acetic acid was purchased 
from Anachemia.   
Instrumentation.  The analytical column was same as the one used in Method A 
1 (See Section A6.1).  The mobile phase, 10 mM CH3COONH4 adjusted to pH 8.3 with 
concentrated acetic acid, was pumped at a flow rate of 200 µL / min for analysis of the 
samples; the MRM chromatogram is shown in Figure 3A. 
Preparation of Standards.  20 µL of standard solution D, prepared as described 
in Method A1 (See Section A6.1), was injected by the autosampler of the LC-MS/MS 
system.  With the HPLC pump pumping the mobile phase, the sample was delivered into 
the turbo ion spray ion source.  The software initiated acquisition prior to the injection of 
solution D.  For the acquisition method, the MRM transitions were set according to Table 
2.2 and the dwell time was set as 200.00 µsec.  The resolution of Q1 and Q3 was set to be 
1 unit mass resolution.  A positive ionisation mode was set in the acquisition method, the 
other parameters were CUR (25.00 psi), ISP (5000.00 V), TEM (100.00 oC), GS1 (20.00 
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psi), GS2 (40.00 psi), CAD (7.00 psi), DP (31.09 V), FP (200.00 V), EP (9.00 V), CE 
(30.00 eV), and CXP (25.00 V). 
A6.3 Method A3: Zorbax Eclipse XDB Column – API 2000 (Figure 4A) 
The method was similar to Method A 2 (Section A6.2) with the following 
changes:   
 Instrumentation.  The analytical column used for the analysis was an Agilent 
Zorbax Eclipse XDB (5 µm, 4.6 x 150 mm).  The mobile phase, 10 mM CH3COONH4, 
pH 8.3, was pumped at a flow rate of 1 mL / min to obtain the data shown in the MRM 
chromatogram in Figure 4A (A).  For the data shown in the MRM chromatogram 
illustrated in Figure 4A (B), the same flow rate was used, but the mobile phase was 5 % 
ACN / 95 % 10 mM CH3COONH4, pH 8.3. 
Preparation of Standards.  2.0 mg of each analogue was weighed out 
separately using a 4 decimal place analytical balance (Mettler-Toledo International Inc.) 
and transferred into a 2 mL HPLC vial.  1 mL of water was pipetted into the vial.  The 
vial was vortexed until the sample dissolved.  This sample, standard solution E, was 
roughly 2 mg/mL, and it was not used for exact quantitative purposes.  The vial was 
stored at 4 oC until required. 
Analytical Procedure.  1 µL of solution E was injected by the autosampler of the 
API 2000 LC-MS/MS system. 
A6.4 Method A4: Hypercarb column – 4000 QTRAP (Figure 5A) 
The method was similar to the generic method used when using a ZIC-HILIC 
column for LC-MS/MS analysis (See Section 2.5.4) with the following changes:   
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Instrumentation.  The analytical column for the analysis was a Thermo 
Scientific Hypercarb Column (3µm, 3 x 50 mm).  The LC gradient program is reported in 
Table 19A. 
Table 19A. LC Gradient Program for Hypercarb Column. 
RT (min) Flow (µL / 
min) %B 
0 600 0 
0 600 0 
5 600 21.1 
5.1 600 94.7 
7.1 600 94.7 
7.2 600 0 
20.1 600 0 
Solvent A: 0.1% FA + 5% ACN + H2O, Solvent B: 0.1% FA + ACN 
Preparation of Standards.  Stock solutions for Thiamet-G, Thiambu-G, 
Thiampro-G, and Thiamme-G (conc. = 70000 ng / mL) were prepared separately in 
water.  200 µL from each stock solution were added to a 10 mL volumetric flask and 
made to 10 µL by adding water to yield mixed compound standard solution H (200 mM 
NH4HCO2, pH 4, conc. = 1400 ng / mL), which was stored at 4 oC.  Mixed compound 
standard solution I (final conc. = 10 ng / mL) was prepared by adding 10 µL from 
standard solution H into a 2 mL standard HPLC vial containing 1390 µL of water and 
was stored at 4 oC until required.   
Analytical Procedure.  10 µL of standard solution I was injected by the 
autosampler of the LC-MS/MS system. 
  
169 
A6.5 Method A5: MeOH as the Protein Precipitant Using the TSKgel Column 
(Figure 6A) 
The method was similar to the generic method for TSKgel-MS-analysis (See 
Section 2.5.3) with the following changes:   
Chemicals and reagents.  HPLC grade MeOH was purchased from Caledon 
Laboratories Ltd.  Control rat plasma was obtained from the animal facility of Simon 
Fraser University (Burnaby, BC, Canada). 
Preparation of Samples.  The plasma sample was prepared by transferring 10 
µL of solution A (conc. = 1400 ng / mL), as prepared according to Method 1 (See Section 
2.5.1), into a centrifuge tube.  20 µL of the rat plasma and 10 µL of water were added to 
the tube.  After vortexing the tube for 30 sec, the tube was centrifuged at 5000 rpm for 1 
min at room temperature.  360 µL of MeOH was added as a precipitant, and the tube was 
vortexed for 10 to 30 sec.  The tube was centrifuged at 10000 rpm for 5 min at room 
temperature.  160 µL of the supernatant was transferred into a HPLC vial with insert and 
the HPLC vial was capped prior to LC-MS/MS analysis.  An extra sample was prepared 
by pipetting the remaining supernatant into a HPLC vial and this was stored at -20°C.  
The control sample was prepared the same way, except that the rat plasma was replaced 
with water.  A blank sample was also prepared using the same sample preparation 
procedure as the plasma sample, except that solution A was replaced with water. 
Duplicate sets of samples were prepared for both the control, blank, and plasma 
samples.  The final sample composition of the control and plasma samples was 90 % 
MeOH in H2O, and the final concentration of the samples was 35 ng / mL. 
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Analytical Procedure.  10 µL of the plasma sample was injected by the 
autosampler for the LC-MS/MS system after the analysis of the control sample has 
finished.  The 10 µL control sample was analysed first, followed by seven samples, the 
SS and plasma samples, and only then the plasma sample. 
A6.6 Method A6: ACN as the Protein Precipitant Using the TSKgel Column 
(Figure 7A) 
The method was similar to Method A5 (See Section A6.5) with the following 
changes:   
Preparation of Samples.  Instead of MeOH, ACN was used as the precipitant.  
As a result, the final sample composition of the control and plasma samples was 90 % 
ACN in H2O, and the final concentration of the samples was 35 ng / mL. 
Analytical Procedure.  The control sample was analysed first, followed by three 
samples, SS and blank samples, and only then the plasma sample.  Only one set of the 
duplicate samples were analysed. 
A6.7 Method A7: Q1 Scan Analyses using the TSKgel Column (Figure 8A) 
The method was similar to Method A6 (See Section A6.6) with the following 
changes:   
Analytical Procedure.  Instead of using the MRM scan mode, Q1 scan analysis 
was used.  The scanning range used was from 100.00 amu to 1000.00 amu.  The dwell 
time was 3.00 sec.  The resolution of Q1 was one mass unit, and the step size was 0.3 
amu.  The set parameters were the same, except that setting of the CUR, CAD, and CXP 
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were not required for this scan mode.  The control sample was analysed first, followed by 
two samples, SS and plasma blank, and only then the plasma sample. 
A6.8 Method A8: ACN as the Protein Precipitant Using the ZIC-HILIC 
Column (Figure 9A) 
The method was similar to the generic method for ZIC-HILIC-MS-analysis (see 
Section 2.5.4) with the following changes:   
Preparation of Samples.  The samples were the same samples that were 
prepared as described in Method A6 (See Section A6.6). 
Analytical Procedure.  The control sample was analysed first, followed by nine 
samples, SS and blank samples, and only then the plasma sample.  Only one set of the 
duplicate samples was analysed.  10 µL of samples were injected by the autosampler. 
A6.9 Method A8b: Q1 Scan Analyses using the ZIC-HILIC Column 
The method was similar to Method A7 (See Section A6.7) with the following 
changes: 
Preparation of Samples.  The samples were the same samples prepared as 
described in Method A6 (See Section A6.6). 
Analytical Procedure.  The control sample was analysed first, followed by six 
samples, SS and blank samples, and only then the plasma sample. 
A6.10 Method A9: ACN as the Protein Precipitant with the ZIC-HILIC 
Column (Figure 10A) 
The method was similar to Method A8 (See Section A6.8) with the following 
changes:   
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Analytical Procedure.  The control sample was analysed first, followed by a 
plasma blank, and then the plasma sample. 
A6.11 Method A10: MeOH as Part of the Mobile Phase (Figure 11A) 
The method was similar to Method A5 (See Section A6.5) with the following 
changes:   
Preparation of Samples.  Mixed standard solution K (conc. = 10 ng / mL) was 
prepared by transferring 10 µL from mixed standard solution J (conc. = 1400 ng / mL, 
water) into a standard 2 mL HPLC vial.  To this vial, 1260 µL of MeOH and 130 µL of 
H2O were added to yield solution X with a final solvent composition of 90 % MeOH / 
H2O.  Standard solution X was stored at 4 oC prior until required.  Samples used to obtain 
chromatograms (B) and (C) of Figure 10 A were the same samples as chromatograms (A) 
and (B) in Figure 6A, respectively. 
Analytical Procedure.  4 µL of the solution X was injected by the autosampler 
for analysis while 10 µL was injected for both the control and the plasma samples.  The 
control sample was analysed first, followed by six samples, SS and blank samples, and 
only then the plasma sample.  Solution X was analysed in a different batch as the control 
and the plasma samples.  A duplicate set of samples were also analysed.   
A6.12 Method A10b: Q1 Scan Analyses using MeOH as Part of the Mobile 
Phase 
The method was the same as described in Method A7 (See Section A6.7).  
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A6.13 Method A11: 99.9 % ACN as the Mobile Phase (Figure 12A) 
The method was similar to the generic method for TSKgel-MS-analysis column 
(See Section 2.5.3) with the following changes:   
Instrumentation.  The mobile phase was 0.1 % FA + 99.9 % ACN. 
Preparation of Samples.  The plasma sample was the same sample that was 
prepared as described in Method A6 (See Section A6.6).  10 µL of the sample was 
injected by the autosampler. 
A6.14 Method A12: Ultrafiltration Using the TSKgel Column (Figure 13A) 
The method was similar to the generic method for TSKgel-MS-analysis column 
(See Section 2.5.3) with the following changes:   
Chemicals and reagents.  Control rat plasma was obtained from the animal 
facility of Simon Fraser University (Burnaby, BC, Canada). 
Preparation of Samples.  The plasma sample was prepared by transferring 20 
µL of solution A (conc. = 1400 ng / mL), as prepared according to Method 1 (See Section 
2.5.1), into a centrifuge tube.  20 µL of the rat plasma and 40 µL of water were added to 
the tube.  After vortexing the tube for 30 sec, the tube was centrifuged at 5000 rpm for 1 
min at room temperature.  The mixture was transferred into an Ultrafree-MC 
5000NMWL (Sigma-Aldrich, USA), which is an ultrafiltration device having a 5000 Da 
cut off size.  The ultrafilter was centrifuged at 12000 x g until a minimal amount of 
residue was left (45 minutes).  28 µL of the filtrate was taken from the tube and spiked 
into 252 µL of ACN.  The final sample composition of the control and plasma samples 
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was 90 % ACN / H2O, and the final concentration of the samples was estimated to be 20 
ng / mL. 
140 µL supernatant was transferred into a HPLC vial with an insert.  The HPLC 
vial was capped and then used for the LC-MS/MS analysis.  An extra sample was 
prepared by pipetting the rest of the diluted filtrate into a HPLC vial and this was stored 
at -20 °C.  The control sample was prepared the same way, except that the rat plasma was 
replaced with water.  A blank sample was also prepared using the same sample 
preparation procedure of the plasma sample, except that solution A was replaced with 
water. 
Analytical Procedure.  10 µL of the plasma sample was injected by the 
autosampler into the LC-MS/MS system after analysis of the 10 µL of the control sample 
had finished.  A plasma blank was analysed in between the control and the plasma 
analyte samples in order to minimize RT deviations. 
A6.15 Method A12b: Q1 Scan Analysis (TSKgel Column) 
The method was similar to Method A7 (See Section A6.7) with the following 
changes:   
Preparation of Samples.  The samples were the same samples that were 
prepared in Method A12 (See Section A6.14). 
A6.16 Method A13: Ultrafiltration Using the ZIC-HILIC Column (Figure 14A) 
The method was similar to Method A8 (See Section A6.8) with the following 
changes:   
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Instrumentation.  A gradient method was established for the run as tabulated in 
Table 20A. 
Table 20A. LC Gradient Program Gradient Method for the ZIC-HILIC Column. 
Time (min) % B Flow Rate (µL / min) 
0 84 300 
10.5 84 300 
10.8 50 800 
12.8 84 800 
16.8 84 800 
17.1 84 400 
18.1 84 400 
Mobile phase A was 0.1 % FA + 5 % ACN + H2O and mobile phase B is 0.1 % FA + ACN.   
Preparation of Samples.  The procedure for the preparation was similar to 
method A11 (See Section A6.13), except that the ultrafilter was replaced with Microcon 
Ym-3 (Sigma-Aldrich, USA), which has a cutoff size of 3000 Da.  The speed for 
centrifugation was 12000 x g.  Instead of using water, 200 mM NH4HCO2, pH 4 (buffer 
A) was used to prepare the samples.  A 10 ng / mL standard, solution M, was also 
prepared by spiking 10 µL of standard solution L (conc. = 1400 ng / mL, 92 % buffer A / 
H2O) into a mixture of solvent comprised of 1260 µL of ACN and 130 µL of buffer A.   
Analytical Procedure.  Two sets of samples were prepared separately and 
analysed using the LC-MS/MS.  The control sample was analysed first, followed by a 
blank sample, and then the plasma sample.  Solution M was run after every three 
samples.   
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A6.17 Method A13b: Q1 Scan Analysis 
The method was similar to Method A8b (See Section A6.9) with the following 
changes:   
Instrumentation.  The setup of the system was same as Method A 13 (See 
Section A6.16). 
Preparation of Samples.  The samples were the same samples that were 
prepared as described in Method A13 (See Section A6.16). 
A6.18 Method A14: Ultrafiltration + LLE Using the TSKgel Column (Figure 
15A) 
The method was similar to Method A12 (See Section A6.14) with the following 
changes:   
Preparation of Samples.  The plasma sample was prepared as described in 
Method A12 (See Section A6.14).  The mixture was transferred into the Ultrafree-MC 
5000NMWL.  The ultrafilter was centrifuged at 12000 x g until a minimal amount of 
residue was left.  30 µL of water was added into the ultrafilter and centrifugation was 
continued until a minimal amount of residue was left.  This process of recentrifugation 
was repeated one more time by adding a further 30 µL of water into the ultrafilter.  14 µL 
of the filtrate was taken from the tube and spiked into 126 µL of ACN.  The prepared 
solution was the plasma sample that was cleaned up by ultrafiltration (process # 1).  70 
µL was added to 400 µL of DCM to perform LLE.  The mixture was vortexed for 5 min.  
The tube was centrifuged at 10000 x g.  14 µL of the supernatant was spiked into 126 µL 
of ACN.  The resulting solution was the plasma sample that had been cleaned up using a 
combination of ultrafiltration and LLE (process # 2) 
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The control and a blank sample for both process # 1 and # 2 were also prepared, 
except that the rat plasma was replaced with water and solution A was replaced with 
water.  The final sample composition of the control and plasma samples was 90 % ACN 
in H2O, and the final concentration of the analogues was 20 ng / mL each. 
A6.19 Method A15: Ultrafiltration + LLE Using the ZIC-HILIC Column (Figure 
16A) 
The method was similar to Method A13 (See Section A6.16) with the following 
changes:   
Preparation of Samples.  The samples were the same samples that were 
prepared in Method A14 (See Section A6.18). 
A6.20 Method A16: Ultrafiltration + Ziptip Using the ZIC-HILIC Column 
(Figure 17A) 
 The method was similar to Method A15 (See Section A6.19) with the following 
changes: 
Preparation of Samples.  30 µL of the filtrate that were obtained after 
ultrafiltration as described in Method A 14 (See Section A6.18) was transferred into a 
centrifuge tube.  A ziptipc18 was equilibrated with 50 % ACN / H2O three times.  The 
ziptip was then equilibrated with 0.1 % FA + H2O.  The filtrate was pipetted up and down 
slowly ten times through the ziptip.  The ziptip was then cleaned three times with a 
solution of 0.1 % FA + H2O.  The compounds that were bound onto the ziptip were 
eluted by the eluting solution composed of 30 µL of 0.1 % FA + 80 % ACN.  The elution 
was performed by pipetting the eluting solution up and down through the ziptip.  The 
eluant was dried down completely under vacuum at 35 °C.  30 µL of H2O was transferred 
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into the collection tube to reconstitute the sample.  The tube was capped and vortexed for 
30 sec.  Followed by 5 min of sonication, the tube was centrifuged at 10000 rpm for 5 
min at room temperature.  14 µL of the water mixture was spiked into 126 µL of ACN.  
The resulting solution was the plasma sample that had been cleaned up using a 
combination of ultrafiltration and ziptip.   
The control and a blank sample were also prepared the same way except that the 
rat plasma was replaced with water and solution A was replaced with water.  The final 
sample composition of the control and plasma samples was 90 % ACN into H2O, and the 
final concentration of the analogues was 20 ng / mL each. 
A6.21 Method A17: Hybrid SPE Cartridge Using the ZIC-HILIC Column 
(Table 15A and 16A) 
 The method was similar to Method A9 (See Section A6.10) with the following 
changes: 
Preparation of Samples.  6 µL of mixed standard solution J (water as solvent, 
conc. = 1400 ng / mL) was added into a centrifuge tube.  12 µL of plasma and 182 µL of 
water were also added into the tube.  The tube was centrifuged at 5000 rpm for 1 min at 
room temperature.  600 µL of ACN that had been acidified by addition of 10 µL of FA 
was added into the tube.  After vortexing the tube for 2 min, it was centrifuged at 14000 x 
g for 20 min at room temperature.  Half of the supernatant was saved for LC-MS/MS 
analyses.  The other half of the supernatant was added onto a Hybrid SPE cartridge.  
Vacuum was applied to the cartridge (10 to 15 mm Hg).  The liquid that was collected 
from the outlet of the cartridge was used for analysis.  A standard solution was also 
prepared by spiking 3 µL of solution J into a mixture composed of 97 µL of water and 
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300 µL of ACN.  A control and a blank sample were also prepared the same way except 
that the rat plasma was replaced with water and solution J was replaced with water 
respectively.  The final sample composition of the control and plasma samples was 75 % 
ACN in H2O, and the final concentration of the analogues was 10.5 ng / mL each. 
A6.22 Method A18: Captiva Cartridge Using the ZIC-HILIC Column (Table 
17A and 18A) 
 The method was similar to Method A9 (See Section A6.10) with the following 
changes:   
Instrumentation.  The run time was extended from 10 min to 20 min. 
Preparation of Samples.  600 µL of ACN was added into a centrifuge tube, 
Tube A.  1 µL of FA was spiked into ACN.  6 µL of mixed standard solution H (200 mM 
NH4HCO2, pH 4, conc. = 1400 ng / mL), 12 µL of plasma, and 182 µL of water were 
premixed together in another centrifuge tube, Tube B.  The resulting plasma mixture was 
vortexed for 30 sec and then centrifuged at 5000 rpm for 1 min at room temperature.  The 
plasma mixture supernatant was spiked into the mixture in Tube A.  Upon vortexing the 
tube for 2 min, the tube was centrifuged at 14000 x g for 20 min at room temperature.  
Half of the supernatant was dried down under vacuum at room temperature and it was 
redissolved in 10 % 200 mM NH4HCO2, pH 4 in 90 % ACN.   
The other half of the supernatant was added to the Captiva cartridge.  Vacuum 
was applied to the cartridge (5 mm Hg).  The liquid that was collected from the outlet of 
the cartridge was used for analysis.  A standard solution was also prepared by spiking 3 
µL of solution J into a mixture composed of 97 µL of water and 300 µL of ACN.  The 
control and a blank sample were also prepared the same way, except that the rat plasma 
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was replaced with water and solution J was replaced with water, respectively.  The final 
sample composition of the control and plasma samples was 75 % ACN in H2O, and the 
final concentration of the analogues was 10.5 ng / mL each. 
Analytical Procedure.  4 µL of the plasma sample was injected by the 
autosampler into the LC-MS/MS system after the analysis of the control sample 
(injection volume = 4 µL) has finished.  The plasma blank was analysed in between the 
control and the plasma samples.  The standard solution, 4 µL injection volume, was 
analysed before the control sample and after the plasma sample. 
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